Unnamed: 0,title,date,stock,sentiment
1075248.0,"Friday's Market Minute: Nasdaq's Top Performers: TSLA, REGN, PYPL",2020-06-05 09:29:00-04:00,REGN,positive
1075249.0,Regeneron CEO To Join Meg Tirrell On Special CNBC COVID-19 Program At 7 p.m. EDT,2020-06-05 09:23:00-04:00,REGN,positive
1075250.0,Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics,2020-06-03 17:53:00-04:00,REGN,neutral
1075251.0,"Regeneron Shares Quiet Following Headline US PTO Upheld A Fifth Patent From Kymab Covering Human Antibodies, Rejected Request By Regeneron",2020-06-03 08:41:00-04:00,REGN,negative
1075252.0,"The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study",2020-06-03 07:39:00-04:00,REGN,negative
1075253.0,"Sanofi's CEO On Cancer Research, Coronavirus Vaccine Progress",2020-06-02 16:51:00-04:00,REGN,negative
1075254.0,Inovio Analyst Watches Coronavirus Play 'From The Sidelines',2020-06-02 11:31:00-04:00,REGN,positive
1075255.0,"Regeneron And Intellia Therapeutics Expand Collaboration To Develop CRISPR/Cas9-Based Treatments; Intellia To Receive Upfront Payment Of $70M, And Regeneron Will Make An Additional Equity Investment In Intellia Of $30M At $32.42 Per Share",2020-06-01 07:13:00-04:00,REGN,positive
1075256.0,Stocks That Hit 52-Week Highs On Friday,2020-05-29 10:36:00-04:00,REGN,neutral
1075257.0,Sanofi Reports Libtayo Longer-Term Results In Advanced Cutaneous Squamous Cell Carcinoma Presented At ASCO Show Durable Responses,2020-05-29 08:09:00-04:00,REGN,positive
1075258.0,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.",2020-05-28 12:33:00-04:00,REGN,positive
1075259.0,"CFRA Maintains Hold on Regeneron Pharmaceuticals, Lowers Price Target to $549",2020-05-27 13:55:00-04:00,REGN,negative
1075260.0,"SVB Leerink Reiterates Outperform on Regeneron Pharmaceuticals, Raises Price Target to $625",2020-05-27 07:28:00-04:00,REGN,neutral
1075261.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,REGN,positive
1075262.0,11.8M Share Secondary Offering of Regeneron Common Stock Held by Sanofi Priced $515/Share,2020-05-27 05:50:00-04:00,REGN,positive
1075263.0,Sanofi: FDA approves DupixentÂ® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis,2020-05-26 11:40:00-04:00,REGN,positive
1075264.0,"Benzinga's Top Upgrades, Downgrades For May 26, 2020",2020-05-26 09:42:00-04:00,REGN,positive
1075265.0,"Wells Fargo Upgrades Regeneron Pharmaceuticals to Overweight, Announces $734 Price Target",2020-05-26 06:16:00-04:00,REGN,negative
1075266.0,Sanofi Currently Holds ~20.6% of Regeneron's Capital,2020-05-25 12:54:00-04:00,REGN,neutral
1075267.0,Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5B Stock Repurchase,2020-05-25 12:45:00-04:00,REGN,neutral
1075268.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2020-05-24 14:40:00-04:00,REGN,neutral
1075269.0,Short Sellers Challenge Sorrento's Announcement Of 100% Coronavirus Inhibition: 'Manipulative At The Worst Time',2020-05-20 13:04:00-04:00,REGN,negative
1075270.0,"Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.",2020-05-20 11:19:00-04:00,REGN,positive
1075271.0,Clinical Research and Development Efforts Booming in Midst of COVID-19 Health Crisis,2020-05-20 09:51:00-04:00,REGN,negative
1075272.0,Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market,2020-05-20 08:33:00-04:00,REGN,negative
1075273.0,Moderna Short Sellers Take $450M Hit Following Coronavirus Vaccine Data,2020-05-19 12:09:00-04:00,REGN,neutral
1075274.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,REGN,positive
1075275.0,Stocks That Hit 52-Week Highs On Monday,2020-05-18 10:44:00-04:00,REGN,neutral
1075276.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,REGN,positive
1075277.0,Regeneron Highlights Upcoming Presentations At ASCO,2020-05-13 17:23:00-04:00,REGN,neutral
1075278.0,Regeneron And Colorado Center For Personalized Medicine Announce Human Genetics Research Collaboration,2020-05-11 07:18:00-04:00,REGN,neutral
1075279.0,"Baird Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target of $510",2020-05-06 12:05:00-04:00,REGN,neutral
1075280.0,"BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $525",2020-05-06 11:40:00-04:00,REGN,neutral
1075281.0,Regeneron shares are trading lower. Not currently seeing company-specific news.,2020-05-06 10:10:00-04:00,REGN,neutral
1075282.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $555",2020-05-06 09:11:00-04:00,REGN,neutral
1075283.0,"Credit Suisse Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $605",2020-05-06 08:56:00-04:00,REGN,positive
1075284.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,REGN,positive
1075285.0,10 Biggest Price Target Changes For Wednesday,2020-05-06 08:25:00-04:00,REGN,neutral
1075286.0,"SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $622",2020-05-06 06:51:00-04:00,REGN,neutral
1075287.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-05 10:48:00-04:00,REGN,neutral
1075288.0,Regeneron CEO Sees Possibility An Antibody Cocktail Therapy Could Be Available To Treat Coronavirus By End Of Summer Or Fall,2020-05-05 10:47:00-04:00,REGN,positive
1075289.0,From Conference Call:  Regeneron EO Says Encouraged by Rebound in Demand for Drugs in Recent Weeks Amid Covid-19 Outbreak,2020-05-05 08:52:00-04:00,REGN,positive
1075290.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,REGN,positive
1075291.0,Regeneron Pharmaceuticals shares are trading higher after the company announced its Libtayo PD-1 inhibitor showed clinically meaningful and durable responses in second-line advanced basal cell carcinoma. The company also reported better-than-expected Q1 EPS results.,2020-05-05 07:24:00-04:00,REGN,positive
1075292.0,"Regeneron Pharmaceuticals Q1 Adj. EPS $6.600 Beats $6.200 Estimate, Sales $1.830B Miss $1.850B Estimate",2020-05-05 06:32:00-04:00,REGN,negative
1075293.0,Regeneron and Sanofi Announce Libtayo Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma,2020-05-05 05:30:00-04:00,REGN,positive
1075294.0,"Earnings Scheduled For May 5, 2020",2020-05-05 04:53:00-04:00,REGN,neutral
1075295.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,2020-05-03 09:25:00-04:00,REGN,neutral
1075296.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,REGN,neutral
1075297.0,"Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $575",2020-04-28 12:50:00-04:00,REGN,neutral
1075298.0,10 Biggest Price Target Changes For Tuesday,2020-04-28 08:10:00-04:00,REGN,neutral
1075299.0,"Citigroup Downgrades Regeneron Pharmaceuticals to Neutral, Raises Price Target to $575",2020-04-28 07:00:00-04:00,REGN,neutral
1075300.0,Why Regeneron's Stock Is Trading Lower Today,2020-04-27 10:51:00-04:00,REGN,negative
1075301.0,Regeneron shares are trading lower. The company's trial of arthritis drug Kevzara with Sanofi showed potential for treating the sickest coronavirus patients but showed less benefit in patients with less-advanced disease.,2020-04-27 09:49:00-04:00,REGN,positive
1075302.0,Regeneron's Phase 3 Trial of Libtayo as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival,2020-04-27 07:04:00-04:00,REGN,neutral
1075303.0,Sanofi and Regeneron Say its Phase 2/3 Adaptive-Designed Trial of Kevzara in Hospitalized Coronavirus Patients Met its Primary Endpoint,2020-04-27 07:01:00-04:00,REGN,neutral
1075304.0,"7 Best-Performing Stocks Of 2020: Buy, Sell Or Hold?",2020-04-26 18:05:00-04:00,REGN,neutral
1075305.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,REGN,negative
1075306.0,Shares of several healthcare companies are trading higher. Movement appears market-related as equities gain amid a rebound in oil prices.,2020-04-23 11:27:00-04:00,REGN,positive
1075307.0,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.",2020-04-21 11:35:00-04:00,REGN,negative
1075308.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,REGN,positive
1075309.0,Stocks That Hit 52-Week Highs On Friday,2020-04-17 10:19:00-04:00,REGN,neutral
1075310.0,"Benzinga's Top Upgrades, Downgrades For April 17, 2020",2020-04-17 09:31:00-04:00,REGN,positive
1075311.0,Regeneron Pharmaceuticals shares are trading higher after Benchmark upgraded the stock from Hold to Buy.,2020-04-17 08:50:00-04:00,REGN,positive
1075312.0,"The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement",2020-04-17 07:35:00-04:00,REGN,positive
1075313.0,Benchmark Upgrades Regeneron Pharmaceuticals to Buy,2020-04-17 06:22:00-04:00,REGN,neutral
1075314.0,"Regeneron Shares Tick Higher Following Co. Tweet 'COVID19 program update: We have moved our top SARS-CoV-2-neutralizing antibodies into preclinical-,  clinical-scale cell production lines, remain on track to have supply available for studies in Jun.'",2020-04-16 15:38:00-04:00,REGN,positive
1075315.0,Regeneron Pharmaceuticals shares are trading higher after the company announced the FDA has accepted for priority review a biologics license application for REGN-EB3 to treat Ebola.,2020-04-16 10:43:00-04:00,REGN,positive
1075316.0,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",2020-04-16 08:09:00-04:00,REGN,neutral
1075317.0,"Regeneron Reports FDA Accepted For Priority Review New Biologics License Application For REGN-EB3, A Triple Antibody Cocktail Treatment For Ebola; FDA Target Action Date Set For Oct. 25, 2020",2020-04-16 07:03:00-04:00,REGN,positive
1075318.0,Every Member Of Trump's 'Great American Economic Revival' Industry Groups,2020-04-15 13:09:00-04:00,REGN,positive
1075319.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $409",2020-04-15 10:53:00-04:00,REGN,negative
1075320.0,Stocks That Hit 52-Week Highs On Wednesday,2020-04-15 10:48:00-04:00,REGN,neutral
1075321.0,"JP Morgan Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $429",2020-04-15 10:38:00-04:00,REGN,positive
1075322.0,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US",2020-04-15 08:03:00-04:00,REGN,neutral
1075323.0,Stocks That Hit 52-Week Highs On Tuesday,2020-04-14 10:31:00-04:00,REGN,neutral
1075324.0,"The Daily Biotech Pulse: Amarin Reports Strong Q1 Vascepa Sales, BeiGene Aces Late-Stage Lung Cancer Study, Glaxo, Sanofi Strike COVID-19 Vaccine Partnership",2020-04-14 07:59:00-04:00,REGN,negative
1075325.0,Stocks That Hit 52-Week Highs On Monday,2020-04-13 10:25:00-04:00,REGN,neutral
1075326.0,"Sanofi CEO Talks Coronavirus Vaccine Development, Potential Treatment",2020-04-08 15:07:00-04:00,REGN,neutral
1075327.0,"Benzinga's Top Upgrades, Downgrades For April 8, 2020",2020-04-08 09:35:00-04:00,REGN,positive
1075328.0,Benchmark Initiates Coverage On Regeneron Pharmaceuticals with Hold Rating,2020-04-08 06:35:00-04:00,REGN,neutral
1075329.0,"Regeneron And Zai Lab Announce Regional Strategic Collaboration For REGN1979 (CD20xCD3 Bispecific Antibody); Regeneron To Receive $30M Upfront, Eligible To Receive Up To $160M In Additional Milestones",2020-04-08 06:04:00-04:00,REGN,neutral
1075330.0,"SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $604",2020-04-07 12:27:00-04:00,REGN,neutral
1075331.0,"Jim Cramer, On CNBC's 'Squawk On The Street,' Says He Is More Bullish On Regeneron Than Gilead",2020-04-07 09:38:00-04:00,REGN,neutral
1075332.0,"The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation",2020-04-07 07:55:00-04:00,REGN,negative
1075333.0,"Trump Says Spoke With Pharmaceutical Companies; Says 10 Different Therapeutic Agents Are In Active Trials, Says Will Be 'Fairly Quick Process' And Says A Second Company Was Approved To Start Vaccine Trials",2020-04-06 18:02:00-04:00,REGN,positive
1075334.0,"STAT News Reporter Says CEOs Of Amgen, Genentech, Gilead And Regeneron Were Involved In Call With Trump",2020-04-06 17:06:00-04:00,REGN,neutral
1075335.0,Sanofi Finalizes Praluent Restructuring With Regeneron,2020-04-06 17:01:00-04:00,REGN,neutral
1075336.0,"'There are four main antibody programs underway in U.S. by Lilly, Regeneron, Vir, and Amgen. Regeneron may be furthest along and have the best chance of doing this at the scale required...' -Weekend Tweet From Former FDA Commish Gottlieb",2020-04-06 12:24:00-04:00,REGN,positive
1075337.0,"Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $435",2020-04-06 09:58:00-04:00,REGN,positive
1075338.0,Regeneron's Coronavirus Program May Have Results At End Of April,2020-04-03 13:38:00-04:00,REGN,neutral
1075339.0,"The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO",2020-04-03 07:36:00-04:00,REGN,neutral
1075340.0,Sanofi Reports Dupixent Phase 3 Data Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years,2020-04-03 05:24:00-04:00,REGN,positive
1075342.0,Regeneron Highlights Results From Phase 3 Study Of Evinacumab In Patients With Severe Inherited Form Of High Cholesterol Presented At American College of Cardiology's Annual Scientific Session,2020-03-30 11:56:00-04:00,REGN,negative
1075343.0,Regeneron and Sanofi shares are trading higher after the companies announced the dosing of the first patient in their trial of Kevzara for coronavirus.,2020-03-30 10:10:00-04:00,REGN,positive
1075344.0,Sanofi Reports First Patient Outside U.S. Treated in Global Kevzara Clinical Trial Program for Patients with Severe COVID-19,2020-03-30 05:40:00-04:00,REGN,negative
1075345.0,Ex-FDA Chief Gottlieb Expects Coronavirus Therapeutic Option By Summer,2020-03-29 18:40:00-04:00,REGN,neutral
1075346.0,10 Stocks To Buy With Low Debt And High Liquidity,2020-03-27 08:15:00-04:00,REGN,negative
1075347.0,"Zoom Video, Teladoc Lead The Coronavirus Short Squeeze Candidates",2020-03-25 12:10:00-04:00,REGN,neutral
1075348.0,"Chloroquine, Hydroxychloroquine And Coronavirus: What You Should Know",2020-03-24 17:16:00-04:00,REGN,neutral
1075349.0,"Shares of several healthcare companies are trading higher the Fed announced actions to support the U.S. economy. The Fed will do open-ended treasury, mortgage-backed securities and will buy $375 billion in treasury this week.",2020-03-23 11:07:00-04:00,REGN,positive
1075350.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,REGN,negative
1075351.0,"Trump Mentions Regeneron At Coronavirus Task Force Presser, Discusses Gilead As Near Approval Via FDA, Then Highlights Regeneron Trial",2020-03-19 11:47:00-04:00,REGN,positive
1075352.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,REGN,positive
1075353.0,130 Biggest Movers From Yesterday,2020-03-18 06:06:00-04:00,REGN,neutral
1075354.0,94 Stocks Moving In Tuesday's Mid-Day Session,2020-03-17 12:41:00-04:00,REGN,neutral
1075355.0,"Regeneron Pharmaceuticals shares are trading higher after the company said its coronavirus antibody program could enter the clinics as early as early summer, with the potential to enter human clinical trials by Summer.",2020-03-17 09:13:00-04:00,REGN,positive
1075356.0,Hearing Regeneron CEO Will Be On Jim Cramer's 'Mad Money' Tonight,2020-03-17 08:52:00-04:00,REGN,negative
1075357.0,Regeneron Working To Rush 'Cocktail' COVID-19 Antibody To Clinics At Start Of Summer,2020-03-17 08:50:00-04:00,REGN,neutral
1075358.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,REGN,neutral
1075359.0,Regeneron Announces 'Important Advances' In Coronavirus Antibody Program; Says Plans To 'initiate large-scale manufacturing by mid-April with antibody cocktail therapy' With Potential To Enter Human Clinical Trials By Summer,2020-03-17 07:04:00-04:00,REGN,positive
1075360.0,Coronavirus Downturn Prompts Bitcoiners To Take A Bet On Alternate Markets,2020-03-16 10:11:00-04:00,REGN,neutral
1075361.0,Sanofi And Regeneron Begin Global Kevzara Clinical Trial Program In Patients With 'Severe' Coronavirus,2020-03-16 08:03:00-04:00,REGN,neutral
1075362.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,REGN,positive
1075363.0,Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.,2020-03-12 09:26:00-04:00,REGN,negative
1075364.0,"Argus Research Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $540",2020-03-12 08:15:00-04:00,REGN,neutral
1075365.0,"Oppenheimer Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $525",2020-03-11 08:47:00-04:00,REGN,neutral
1075366.0,"Regeneron, Sanofi To Test Arthritis Drug As Potential Coronavirus Treatment",2020-03-10 16:48:00-04:00,REGN,neutral
1075367.0,"The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study",2020-03-06 08:49:00-05:00,REGN,negative
1075368.0,"The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19",2020-03-05 08:05:00-05:00,REGN,negative
1075369.0,"CFRA Downgrades Regeneron Pharmaceuticals to Hold, Raises Price Target to $487",2020-03-04 12:58:00-05:00,REGN,neutral
1075370.0,Stocks That Hit 52-Week Highs On Wednesday,2020-03-04 10:24:00-05:00,REGN,neutral
1075371.0,Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,2020-03-04 07:48:00-05:00,REGN,positive
1075372.0,How The COVID-19 Outbreak Is Benefiting Biotech Investors,2020-03-02 14:27:00-05:00,REGN,neutral
1075373.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,REGN,neutral
1075374.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-27 10:24:00-05:00,REGN,neutral
1075375.0,28 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-02-27 07:40:00-05:00,REGN,neutral
1075376.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,REGN,positive
1075377.0,"Benzinga's Top Upgrades, Downgrades For February 26, 2020",2020-02-26 10:02:00-05:00,REGN,positive
1075378.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,REGN,negative
1075379.0,"Credit Suisse Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $510",2020-02-26 08:46:00-05:00,REGN,positive
1075380.0,10 Biggest Price Target Changes For Wednesday,2020-02-26 08:45:00-05:00,REGN,neutral
1075381.0,Baird Downgrades Regeneron Pharmaceuticals to Neutral,2020-02-26 05:44:00-05:00,REGN,neutral
1075382.0,"Canaccord Genuity Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $550",2020-02-26 05:31:00-05:00,REGN,neutral
1075383.0,Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug,2020-02-25 11:46:00-05:00,REGN,negative
1075384.0,Regeneron Pharmaceuticals shares are trading higher. Jefferies analysts said recent adverse events arising from competitor Novartis' Beovu will likely minimize competitive risk to Regeneron's Eylea franchise.,2020-02-25 10:58:00-05:00,REGN,negative
1075385.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-25 10:15:00-05:00,REGN,neutral
1075386.0,"UPDATE: Jefferies Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $492 As Firm Attributes Optimism Towards 'recent adverse events that have arisen with Novartis' Beovu, which will likely dampen its uptake and minimizes competitive risk.'",2020-02-25 10:03:00-05:00,REGN,positive
1075387.0,10 Biggest Price Target Changes For Tuesday,2020-02-25 08:56:00-05:00,REGN,neutral
1075388.0,"Jefferies Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $492",2020-02-25 07:04:00-05:00,REGN,neutral
1075389.0,Evercore ISI Group Upgrades Regeneron Pharmaceuticals to Outperform,2020-02-25 05:03:00-05:00,REGN,neutral
1075390.0,"Chip Stocks, Apple, Airlines Among Hardest Hit As Stocks Plunge On Coronavirus Spread",2020-02-24 17:21:00-05:00,REGN,neutral
1075391.0,"Regeneron Shares Higher; It Was Earlier Repored The ASRS Announced Reports Of Vasculitis Tied To Beovu, A Drug From Competitor Novartis",2020-02-24 14:16:00-05:00,REGN,positive
1075392.0,"Benzinga's Top Upgrades, Downgrades For February 11, 2020",2020-02-11 09:39:00-05:00,REGN,positive
1075393.0,"Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $430 Price Target",2020-02-11 07:59:00-05:00,REGN,neutral
1075394.0,"Regeneron Announces Positive Two Year EYLEA  Results in Patients with Diabetic Retinopathy at Angiogenesis, Exudation, and Degeneration 2020 Meeting",2020-02-08 17:04:00-05:00,REGN,positive
1075395.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $410",2020-02-07 09:37:00-05:00,REGN,negative
1075396.0,Regeneron Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.,2020-02-06 13:38:00-05:00,REGN,positive
1075397.0,Regeneron Executive Says A Set Of Its Treatments Could Be Available For Testing Or Passionate Use In Coronavirus Patients 'Within Few Months',2020-02-06 08:29:00-05:00,REGN,positive
1075398.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,REGN,negative
1075399.0,"Regeneron Pharmaceuticals Q4 Adj. EPS $7.5 Beats $6.9 Estimate, Sales $2.17B Beat $2.11B Estimate",2020-02-06 06:32:00-05:00,REGN,neutral
1075400.0,"Earnings Scheduled For February 6, 2020",2020-02-06 04:30:00-05:00,REGN,neutral
1075401.0,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,2020-02-05 09:47:00-05:00,REGN,positive
1075402.0,Regeneron Reports Expanded Deal with US Dept. Of Health And Human Services To Develop New Treatments Combating Novel Coronavirus,2020-02-04 09:05:00-05:00,REGN,positive
1075403.0,"Department Of Health & Human Services Says It Is Reviewing A Potential Vaccines, Treatments & Diagnostics From Public, Private SectorsTo Identify Candidates For Coronavirus Detection",2020-02-04 08:51:00-05:00,REGN,neutral
1075404.0,"HHS, Regeneron Collaborate To Develop 2019 nCoV Treatment",2020-02-04 08:29:00-05:00,REGN,neutral
1075405.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,REGN,neutral
1075406.0,Regeneron Pharmaceuticals Earlier Announced It Has Received FDA Approval For Priority Review Dupixent For Children Aged 6 To 11 Years With Moderate-To-Severe Atopic Dermatitis,2020-01-28 08:23:00-05:00,REGN,positive
1075407.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $411",2020-01-17 08:29:00-05:00,REGN,neutral
1075408.0,Regeneron Sees Prelim. US Net Product Sales Of EYLEA Injection ~$4.64B,2020-01-13 09:19:00-05:00,REGN,neutral
1075409.0,"A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations",2020-01-10 08:52:00-05:00,REGN,neutral
1075410.0,Regeneron Highlights Phase 2 Results From Garetosmab Trial: 'Approximately 25% decrease in total bone lesions (both new and existing) driven by nearly 90% reduction in formation of new lesions',2020-01-09 07:01:00-05:00,REGN,neutral
1075411.0,10 Best Performing S&P 500 Stocks Of The Decade,2019-12-31 15:01:00-05:00,REGN,positive
1075412.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,REGN,neutral
1075413.0,"Benzinga's Top Upgrades, Downgrades For December 24, 2019",2019-12-24 10:49:00-05:00,REGN,positive
1075414.0,Raymond James Initiates Coverage On Regeneron Pharmaceuticals with Market Perform Rating,2019-12-24 06:16:00-05:00,REGN,neutral
1075415.0,Quantum Leap Healthcare Collaborative Announces Selection Of Regeneron's Libtayo & REGN3767 For Injection In I-SPY 2 Trial For Breast Cancer,2019-12-18 15:30:00-05:00,REGN,negative
1075416.0,"Benzinga's Top Upgrades, Downgrades For December 16, 2019",2019-12-16 10:10:00-05:00,REGN,positive
1075417.0,Evercore ISI Group Downgrades Regeneron Pharmaceuticals to In-Line,2019-12-16 08:39:00-05:00,REGN,neutral
1075418.0,Intellia Therapeutics Will Modify its Cost and Profit Share with Regeneron for Development of Transthyretin Amyloidosis From 50% to 25%,2019-12-16 07:24:00-05:00,REGN,positive
1075419.0,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 13, 2019: EWU, SRPT, FDX, IHRT, REGN",2019-12-13 08:56:00-05:00,REGN,positive
1075420.0,Credit Suisse Upgrades Regeneron Pharmaceuticals to Outperform,2019-12-13 06:41:00-05:00,REGN,positive
1075421.0,"Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations",2019-12-10 12:28:00-05:00,REGN,positive
1075422.0,25 Stocks Moving in Tuesday's Pre-Market Session,2019-12-10 06:48:00-05:00,REGN,neutral
1075423.0,Hearing Sanofi May Sell Regeneron Stake After Lockup Expires,2019-12-09 16:32:00-05:00,REGN,neutral
1075424.0,Regeneron Announces First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma at ASH 2019,2019-12-08 09:36:00-05:00,REGN,positive
1075425.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,REGN,positive
1075426.0,"Regeneron Reports Topline Phase 2 Data From Pozelimab In Patients With Rare Blood Disorder, Shows Results From Initial 6-Patient Cohort Reduced LDH To Normal Levels At Week 8",2019-12-05 07:07:00-05:00,REGN,negative
1075427.0,Medicines Company Shares Soar On Rumored Buyout Interest From Novartis,2019-11-19 09:50:00-05:00,REGN,positive
1075428.0,"Benzinga's Top Upgrades, Downgrades For November 12, 2019",2019-11-12 09:37:00-05:00,REGN,positive
1075429.0,"SunTrust Robinson Humphrey Initiates Coverage On Regeneron Pharmaceuticals with Hold Rating, Announces $360 Price Target",2019-11-12 06:35:00-05:00,REGN,neutral
1075430.0,UPDATE: Citi On Regeneron Continues 'to remain bullish on Dupixent and see $10B peak sales vs current run-rate of ~$2.5B within 3 years of launch. We are less concerned about the Dupi competition as we think the safety profile of Dupi sets it apart',2019-11-07 13:46:00-05:00,REGN,positive
1075431.0,"UPDATE: Citi Upgrades Regeneron To Buy, Raises Target To $420 As Firm Notes 'We think between Libtayo data next year and continuous Dupi growth, investors will find it easy to stay invested through near-term Eylea competition'",2019-11-07 13:45:00-05:00,REGN,positive
1075432.0,"Benzinga's Top Upgrades, Downgrades For November 7, 2019",2019-11-07 09:32:00-05:00,REGN,positive
1075433.0,"Citigroup Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $420",2019-11-07 06:55:00-05:00,REGN,neutral
1075434.0,UPDATE: Morgan Stanley On Regeneron Also Awaits 'clearer data on Beovu's impact in 4Q',2019-11-06 12:07:00-05:00,REGN,negative
1075435.0,"UPDATE: Morgan Stanley Maintains Equal-Weight On Regeneron, Raises Target To $387 As Firm Notes 'Eylea outperformed and cost control continued in the JV improving profitability. Pipeline updates from NSCLC, bispecifics and C5 were encouraging'",2019-11-06 12:07:00-05:00,REGN,positive
1075436.0,AstraZeneca Named The Most Innovative Global Pharma Company,2019-11-06 11:20:00-05:00,REGN,positive
1075437.0,16 S&P 500 Stocks With The Most Insider Ownership,2019-11-06 11:10:00-05:00,REGN,neutral
1075438.0,"BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $358",2019-11-06 09:49:00-05:00,REGN,neutral
1075439.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $387",2019-11-06 09:08:00-05:00,REGN,neutral
1075440.0,10 Biggest Price Target Changes For Wednesday,2019-11-06 08:32:00-05:00,REGN,neutral
1075441.0,"Regeneron, Vyriad Reports Strategic Deal For Discovery, Development Of New Oncolytic Virus Treatments For Cancer, No Terms Disclosed",2019-11-06 08:26:00-05:00,REGN,negative
1075442.0,"Credit Suisse Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $340",2019-11-06 07:19:00-05:00,REGN,positive
1075443.0,Regeneron Pharmaceuticals Says In Sept. Received A Civil Investigative Demand From The DOJ Pursuant To The Federal False Claims Act,2019-11-05 08:58:00-05:00,REGN,negative
1075444.0,Regeneron Pharmaceuticals shares are trading higher after the company reported Q3 EPS and sales results up from last year. The company also reported a $1 billion buyback.,2019-11-05 07:53:00-05:00,REGN,positive
1075445.0,10 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-11-05 07:33:00-05:00,REGN,neutral
1075446.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,REGN,negative
1075447.0,Regeneron Pharmaceuticals Sees FY19 Sanofi Collaboration Revenue $490M-$510M,2019-11-05 06:34:00-05:00,REGN,neutral
1075448.0,Regeneron Reports $1B Buyback,2019-11-05 06:33:00-05:00,REGN,neutral
1075449.0,"Regeneron Pharmaceuticals Q3 EPS $6.67 Up From $5.87 YoY, Sales $2.048B Up From $1.663B YoY",2019-11-05 06:32:00-05:00,REGN,neutral
1075450.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,REGN,neutral
1075451.0,Regeneron And Sanofi Announce European Commission Approval Of A New Indication For Dupixent In Severe Chronic Rhinosinusitis With Nasal Polyposis,2019-10-29 08:18:00-04:00,REGN,positive
1075452.0,11 Stocks With The Highest Gross Margins,2019-10-28 17:10:00-04:00,REGN,negative
1075453.0,"Bank of America Reinstates Neutral on Regeneron Pharmaceuticals, Announces $325 Price Target",2019-10-17 07:20:00-04:00,REGN,neutral
1075454.0,"Canaccord Genuity Maintains Hold on Regeneron Pharmaceuticals, Lowers Price Target to $320",2019-10-09 08:16:00-04:00,REGN,negative
1075455.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,REGN,neutral
1075456.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,REGN,negative
1075457.0,"Benzinga's Top Upgrades, Downgrades For September 23, 2019",2019-09-23 12:47:00-04:00,REGN,positive
1075458.0,Guggenheim Upgrades Regeneron Pharmaceuticals to Buy,2019-09-23 08:08:00-04:00,REGN,neutral
1075459.0,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,2019-09-20 13:00:00-04:00,REGN,negative
1075460.0,CHMP Recommends Approval Of Regeneron's Dupixent For Severe Chronic Rhinosinusitis With Nasal Polyposis,2019-09-20 06:45:00-04:00,REGN,positive
1075461.0,Biotech Stock On The Radar: Aimmune Awaits Adcom Test,2019-09-10 16:37:00-04:00,REGN,positive
1075462.0,"The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris",2019-09-10 07:36:00-04:00,REGN,neutral
1075463.0,"The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings",2019-08-29 07:38:00-04:00,REGN,negative
1075464.0,Stocks That Hit 52-Week Lows On Wednesday,2019-08-28 11:12:00-04:00,REGN,negative
1075465.0,"The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved",2019-08-28 07:31:00-04:00,REGN,positive
1075466.0,"The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO",2019-08-27 07:29:00-04:00,REGN,positive
1075467.0,"Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster",2019-08-20 17:35:00-04:00,REGN,positive
1075468.0,"Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession.",2019-08-14 11:17:00-04:00,REGN,negative
1075469.0,Regeneron's Drug To Treat Genetic Form Of Bad Cholesterol Aces Late-Stage Trial,2019-08-14 09:33:00-04:00,REGN,negative
1075470.0,"The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering",2019-08-14 07:50:00-04:00,REGN,negative
1075471.0,"Regeneron Announces Phase 3 Trial Of Evinacumab In Patients With Severe, Inherited Form Of High Cholesterol Met Primary Endpoint",2019-08-14 07:06:00-04:00,REGN,negative
1075472.0,Regeneron's Eylea Prefilled Syringe Clears FDA Hurdle,2019-08-13 11:01:00-04:00,REGN,positive
1075473.0,A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Consumer Price Index,2019-08-13 07:29:00-04:00,REGN,negative
1075474.0,Regeneron Pharmaceuticals Receives FDA Approval For EYLEA Injection Prefilled Syringe,2019-08-13 07:06:00-04:00,REGN,positive
1075475.0,Regeneron Pharma Reports Has Been Informed By Study Investigators That Trial Evaluating 4 Therapies For Ebola Stopped Early Because REGN-EB3 Was Superior To ZMapp In Preventing Death,2019-08-12 10:03:00-04:00,REGN,negative
1075476.0,Baird Upgrades Regeneron Pharmaceuticals to Outperform,2019-08-07 09:55:00-04:00,REGN,neutral
1075477.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-06 08:55:00-04:00,REGN,neutral
1075478.0,Regeneron Pharmaceuticals Reports Q2 Earnings Beat,2019-08-06 08:18:00-04:00,REGN,neutral
1075479.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,REGN,positive
1075480.0,"Regeneron Pharmaceuticals Q2 Adj. EPS $6.04 Beats $5.37 Estimate, Sales $1.93B Beat $1.8B Estimate",2019-08-06 06:36:00-04:00,REGN,neutral
1075481.0,"Earnings Scheduled For August 6, 2019",2019-08-06 04:00:00-04:00,REGN,neutral
1075482.0,Sanofi/Regeneron Dupixent Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years With Severe Atopic Dermatitis,2019-08-06 03:32:00-04:00,REGN,positive
1075483.0,Regeneron shares trading lower following news Praluent will be pulled from Germany. A Mizuho analyst said the news has positive implications for Amgen's Repatha and The Medicine Company's Inclisiran,2019-07-11 12:40:00-04:00,REGN,positive
1075484.0,"Mizuho Comments On News Praluent Will Be Pulled From Germany, Sees Positive Implications For Amgen's Repatha, The Medicine Co.'s Inclisiran",2019-07-11 11:46:00-04:00,REGN,positive
1075485.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,REGN,negative
1075486.0,Shares of several healthcare companies in the pharmaceutical space are trading lower after Amneal Pharmaceuticals announced a cost reduction plan in response to the continuing industry challenges. Amneal cut guidance as part of plan.,2019-07-10 11:37:00-04:00,REGN,negative
1075487.0,Regeneron Pharma Reports Libtayo Was Approved For Advanced Cutaneous Squamous Cell Carcinoma In EU,2019-07-01 10:01:00-04:00,REGN,positive
1075488.0,Regeneron Pharma Reports CHMP Recommended Approval Of Dupixent For Moderate To Severe Atopic Dermatitis In Adolescents,2019-06-28 06:59:00-04:00,REGN,positive
1075489.0,Regeneron Pharmaceuticals And Sanofi Announce That The FDA Has Approved Dupixent (Dupilumab) For Use With Other Medicines To Treat Chronic Rhinosinusitis With Nasal Polyposis In Adults Whose Disease Is Not Controlled,2019-06-26 13:33:00-04:00,REGN,positive
1075490.0,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart",2019-06-26 07:19:00-04:00,REGN,neutral
1075491.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-06-22 15:07:00-04:00,REGN,neutral
1075492.0,"The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy",2019-06-21 07:18:00-04:00,REGN,negative
1075493.0,"Sanofi, Regeneron Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma",2019-06-21 04:36:00-04:00,REGN,positive
1075494.0,"UPDATE: Argus Downgrades Regeneron To Hold As Firm Notes Co's 'primary revenue-generating drug, Eylea faces threats from competing products and the expiration of its patents'",2019-06-18 10:35:00-04:00,REGN,negative
1075495.0,Argus Downgrades Regeneron Pharmaceuticals to Hold,2019-06-18 08:12:00-04:00,REGN,neutral
1075496.0,"Regeneron Announces CD20xCD3 Bispecific REGN1979 Shows 'Positive' Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures",2019-06-14 07:01:00-04:00,REGN,negative
1075497.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-06-08 16:09:00-04:00,REGN,neutral
1075498.0,Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates,2019-05-31 13:45:00-04:00,REGN,neutral
1075499.0,Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.,2019-05-31 10:25:00-04:00,REGN,negative
1075500.0,"Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to $340",2019-05-23 10:25:00-04:00,REGN,negative
1075501.0,"Credit Suisse Initiates Coverage On Regeneron Pharmaceuticals, Inc. - Common Stock with Neutral Rating, Announces $336 Price Target",2019-05-21 07:07:00-04:00,REGN,positive
1075502.0,"Regeneron Shares Initiated With Neutral Rating, $336 Price Target By Credit Suisse",2019-05-20 17:04:00-04:00,REGN,positive
1075503.0,"Regeneron, Sanofi Highlight Positive Updated Data For Libtayo In Locally-Advanced, Metastatic Cutaneous Squamous Cell Carcinoma Will Be Shared At 2019 ASCO",2019-05-16 07:11:00-04:00,REGN,positive
1075504.0,"Temasek 13F Shows Liquidated Positions In Antero Resources, Regeneron, Ctrip, Turquoise Hill Resources",2019-05-15 06:57:00-04:00,REGN,neutral
1075505.0,"The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings",2019-05-14 07:42:00-04:00,REGN,positive
1075506.0,Regeneron Pharma Reports FDA Approved EYLEA Injection For Diabetic Retinopathy,2019-05-13 16:29:00-04:00,REGN,positive
1075507.0,FDA Approves Eylea Injection For Diabetic Retinopathy,2019-05-13 14:47:00-04:00,REGN,positive
1075508.0,"Cantor Fitzgerald Maintains Neutral on Regeneron Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to $405",2019-05-13 08:11:00-04:00,REGN,negative
1075509.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-05-11 08:40:00-04:00,REGN,neutral
1075510.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Wed., May 8, 2019",2019-05-08 14:09:00-04:00,REGN,positive
1075511.0,"UBS Maintains Buy on Regeneron Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to $440",2019-05-08 08:47:00-04:00,REGN,negative
1075512.0,"BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to $375",2019-05-08 08:40:00-04:00,REGN,negative
1075513.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to $389",2019-05-08 08:12:00-04:00,REGN,negative
1075514.0,Regeneron Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 EPS and sales.,2019-05-07 09:29:00-04:00,REGN,neutral
1075515.0,"Regeneron, Sanofi Report Dupixent Approved For Severe Asthma By EC",2019-05-07 09:00:00-04:00,REGN,positive
1075516.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,REGN,neutral
1075517.0,"Regeneron Pharmaceuticals Q1 Adj. EPS $4.45 Misses $5.46 Estimate, Sales $1.71B Miss $1.76B Estimate",2019-05-07 06:36:00-04:00,REGN,negative
1075518.0,"10 Stocks To Watch For May 7, 2019",2019-05-07 05:18:00-04:00,REGN,neutral
1075519.0,"Earnings Scheduled For May 7, 2019",2019-05-07 05:03:00-04:00,REGN,neutral
1075520.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-05-04 16:56:00-04:00,REGN,neutral
1075521.0,5 Biotech Stocks With Near-Term Catalysts Ahead,2019-05-02 14:18:00-04:00,REGN,neutral
1075522.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,2019-04-30 13:00:00-04:00,REGN,neutral
1075523.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,REGN,negative
1075524.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-04-27 11:44:00-04:00,REGN,neutral
1075525.0,"Regeneron, Sanofi Report CHMP Issued Positive Opinion For Libtayo",2019-04-26 11:16:00-04:00,REGN,positive
1075526.0,"Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation",2019-04-25 14:23:00-04:00,REGN,positive
1075527.0,Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.,2019-04-18 10:42:00-04:00,REGN,negative
1075528.0,Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.,2019-04-17 10:38:00-04:00,REGN,positive
1075529.0,"Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics",2019-04-08 13:55:00-04:00,REGN,negative
1075530.0,UPDATE: Alnylam Will Be Eligible For Added $200M In Potential Near-Term Milestones,2019-04-08 07:01:00-04:00,REGN,neutral
1075531.0,"UPDATE: Regeneron Will Invest $800M In Alnylam Through Upfront Cash, Equity Investment",2019-04-08 07:01:00-04:00,REGN,neutral
1075532.0,"Alnylam, Regeneron Report Collaboration To Discover, Develop, Commercialize RNAi Therapeutics Focused On Ocular, Central Nervous System Diseases",2019-04-08 07:00:00-04:00,REGN,positive
1075533.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2019-03-29 12:45:00-04:00,REGN,neutral
1075534.0,Regeneron Late Friday Announced Praluent HAs Been approved In European Union,2019-03-18 09:43:00-04:00,REGN,positive
1075535.0,Regeneron Pharmaceuticals Announces Praluent Is Not Approved In EU,2019-03-15 16:02:00-04:00,REGN,negative
1075536.0,Regeneron And Sanofi To Present New Praluent Data At ACC.19,2019-03-13 07:09:00-04:00,REGN,neutral
1075537.0,Regeneron Press Release confirms FDA Approval Of Dupixent For Moderate-To-severe Atopic Dermatitis In Adolescents,2019-03-11 15:45:00-04:00,REGN,positive
1075538.0,Regeneron Pharmaceuticals Supplemental Submission For Dupixent Wins FDA Approval,2019-03-11 15:13:00-04:00,REGN,positive
1075539.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs",2019-03-10 14:32:00-04:00,REGN,neutral
1075540.0,"The Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings",2019-03-08 07:38:00-05:00,REGN,neutral
1075541.0,Sanofi Announces FDA to Undertake Priority Review of Dupixent for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps,2019-03-08 03:54:00-05:00,REGN,negative
1075542.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2019-03-04 11:50:00-05:00,REGN,neutral
1075543.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,REGN,positive
1075544.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,REGN,positive
1075545.0,"Regeneron, Sanofi Issue Press Release Highlighting 'Strongly Disagree' With Verdict To Uphold 3 Of 5 Amgen US Patent Claims Related To PCSK9 Antibodies",2019-02-25 17:23:00-05:00,REGN,neutral
1075546.0,"Jury Finds Amgen's Patents For Repatha Are Valid; Sanofi, Regeneron Have Lost Validity Trial, Conceded Infringement",2019-02-25 15:47:00-05:00,REGN,negative
1075547.0,"Regeneron, Sanofi Highlight Detailed Results From 2 Phase 3 Trials In Adults With Recurring Severe Chronic Rhinosinusits With Nasal Polyps",2019-02-25 12:46:00-05:00,REGN,negative
1075548.0,8 Biggest Price Target Changes For Friday,2019-02-22 09:42:00-05:00,REGN,neutral
1075549.0,"Guggenheim Downgrades Regeneron Pharmaceuticals to Neutral, Lowers Price Target to $425",2019-02-22 08:03:00-05:00,REGN,negative
1075550.0,US And EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies To IL-4 Receptor,2019-02-15 16:44:00-05:00,REGN,neutral
1075551.0,"'*SANOFI, REGENERON WIN IPR CHALLENGE TO AMGEN ANTIBODY PATENT' -Tweets zbiotech",2019-02-14 12:23:00-05:00,REGN,positive
1075552.0,Regeneron and Sanofi Offer Praluentat a New Reduced US List Price,2019-02-11 07:00:00-05:00,REGN,neutral
1075553.0,Regeneron Announces One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium,2019-02-09 19:13:00-05:00,REGN,positive
1075554.0,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering",2019-02-06 08:23:00-05:00,REGN,neutral
1075555.0,Regeneron Pharmaceuticals Sees FY19 Sanofi Collaboration Revenue Of $510M-$560M,2019-02-06 06:40:00-05:00,REGN,neutral
1075556.0,"Regeneron Pharmaceuticals Q4 Adj. EPS $6.84 Beats $5.72 Estimate, Sales $1.93B Beat $1.71B Estimate",2019-02-06 06:39:00-05:00,REGN,neutral
1075557.0,"Earnings Scheduled For February 6, 2019",2019-02-06 04:10:00-05:00,REGN,neutral
1075558.0,Regeneron Pharmaceuticals Q4 Earnings Preview,2019-02-05 14:15:00-05:00,REGN,neutral
1075559.0,Sanofi Says CHMP Recommends Approval Of Praluent To Reduce Cardiovascular Risk In People With Established Atherosclerotic Cardiovascular Disease,2019-02-04 04:14:00-05:00,REGN,positive
1075560.0,"The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs",2019-02-03 10:09:00-05:00,REGN,neutral
1075561.0,"The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of  Titan's Opioid Disorder Treatment Implant",2019-02-01 09:10:00-05:00,REGN,positive
1075562.0,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug",2019-01-18 07:49:00-05:00,REGN,neutral
1075563.0,US Supreme Court Rejects Amgen Bid To Reinstate Patent Verdict Against Sanofi And Regeneron Over Cholesterol Medication,2019-01-07 09:41:00-05:00,REGN,positive
1075564.0,"Sanofi,Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs; Sanofi to Pay Regeneron $462M Plus Up to $120M in Development Costs",2019-01-07 03:52:00-05:00,REGN,negative
1075565.0,Guggenheim Upgrades Regeneron Pharmaceuticals to Buy,2019-01-04 06:42:00-05:00,REGN,neutral
1075566.0,"The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO",2018-12-28 07:29:00-05:00,REGN,neutral
1075567.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,REGN,neutral
1075568.0,Goldman Sachs Upgrades Regeneron Pharmaceuticals to Buy; Added To Its 'Conviction Buy' List,2018-12-14 09:30:00-05:00,REGN,neutral
1075569.0,Ziopharm Oncology Announces Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer,2018-11-12 07:18:00-05:00,REGN,negative
1075570.0,Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer,2018-11-12 07:14:00-05:00,REGN,negative
1075571.0,Sanofi Reports FDA Accepted For Priority Review For Supplemental Biologics License Application For Dupixent In Adolescent Patients 12-17 Years Of Age,2018-11-06 08:03:00-05:00,REGN,positive
1075572.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,REGN,positive
1075573.0,UPDATE: Regeneron Cuts FY18 Sanofi Collaboration Sales From $455M-$485M To $430M-$455M,2018-11-06 06:31:00-05:00,REGN,negative
1075574.0,Regeneron Cuts Guidance,2018-11-06 06:30:00-05:00,REGN,negative
1075575.0,"Regeneron Pharmaceuticals, Inc. Q3 EPS $5.87 Beats $5.18 Estimate, Sales $1.663B Beat $1.64B Estimate",2018-11-06 06:30:00-05:00,REGN,neutral
1075576.0,"Earnings Scheduled For November 6, 2018",2018-11-06 05:31:00-05:00,REGN,neutral
1075577.0,Regeneron Pharmaceuticals Q3 Earnings Preview,2018-11-05 13:19:00-05:00,REGN,neutral
1075578.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,REGN,neutral
1075579.0,"Regeneron Offers an Update on its Complete Response Letter From the FDA, Says Will Resubmit the Prior-Approval Supplement in Early 2019 and Expects a 2019 Launch of the EYLEA Pre-Filled Syringe",2018-10-25 07:59:00-04:00,REGN,neutral
1075580.0,Regeneron's Phase 3 Trial Evaluating EYLEA Met its Primary and Key Secondary Endpoints,2018-10-25 07:58:00-04:00,REGN,neutral
1075581.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2018-10-22 07:21:00-04:00,REGN,neutral
1075582.0,Regeneron Reports FDA Approved Asthma Indication For Dupixent,2018-10-22 07:04:00-04:00,REGN,positive
1075583.0,"Regeneron Highlights 2 Phase 3 Trials Of Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupixent: 'significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery'",2018-10-16 08:04:00-04:00,REGN,neutral
1075584.0,"Sanofi, Regeneron Announce Dupixent Showed Positive Topline Results in Two Phase 3 Trials of Patients With Chronic Rhinosinusitis With Nasal Polyps",2018-10-16 04:02:00-04:00,REGN,positive
1075585.0,Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients,2018-10-15 08:02:00-04:00,REGN,neutral
1075586.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",2018-10-14 13:21:00-04:00,REGN,neutral
1075587.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $412",2018-10-11 09:54:00-04:00,REGN,neutral
1075588.0,"Canaccord Genuity Maintains Hold on Regeneron Pharmaceuticals, Raises Price Target to $410",2018-10-11 07:46:00-04:00,REGN,neutral
1075589.0,"Cantor Fitzgerald Initiates Coverage On Regeneron Pharmaceuticals with Neutral Rating, Announces $415 Price Target",2018-10-01 08:21:00-04:00,REGN,neutral
1075590.0,FDA Approves Regeneron And Sanofi's Libtayo (cemiplimab-rwlc) As First And Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma,2018-09-28 16:40:00-04:00,REGN,positive
1075591.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2018-09-26 16:41:00-04:00,REGN,neutral
1075592.0,"Analyst: Amarin's Vascepa Results Create Unicorn Potential, M&A Opportunity",2018-09-25 12:43:00-04:00,REGN,positive
1075593.0,5 Stocks Primed To Fall Lower In The Coming Days,2018-09-19 17:05:00-04:00,REGN,negative
1075594.0,Regeneron Pharma Reports FDA Will Review EYLEA Injection For Treatment Of Diabetic Retinopathy,2018-09-13 07:02:00-04:00,REGN,neutral
1075595.0,"Sanofi, Regeneron Report FDA Will Review Supplemental Biologics License Application For Praluent For Treatment To Reduce Major Adverse Cardiovascular Events",2018-09-12 08:10:00-04:00,REGN,negative
1075596.0,"Sanofi, Regeneron Announces FDA to Review Supplemental Biologics License Application for Praluent Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events",2018-09-12 04:24:00-04:00,REGN,negative
1075597.0,22 Stocks Moving In Monday's Pre-Market Session,2018-09-10 08:03:00-04:00,REGN,neutral
1075598.0,"The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict",2018-08-24 08:47:00-04:00,REGN,positive
1075599.0,REMINDER: Regeneron Has FDA PDUFA Date Today For Praluent,2018-08-24 05:58:00-04:00,REGN,neutral
1075600.0,"The Week Ahead: Alibaba, More Retail Earnings Take Center Stage",2018-08-20 15:08:00-04:00,REGN,neutral
1075601.0,Regeneron Pharmaceuticals Announces The FDA Approves EYLEA,2018-08-17 07:00:00-04:00,REGN,positive
1075602.0,Teva Pharmaceuticals shares are up 4.4% and Regeneron shares are trading up 2.5% after the companies reported positive results from  a Phase 3 study of fasinumab for osteoarthritis pain.,2018-08-16 12:29:00-04:00,REGN,positive
1075603.0,Regeneron and Teva Announce Phase 3 Fasinumab Met Both Co-Primary Endpoints And All Secondary Endpoints,2018-08-16 07:02:00-04:00,REGN,neutral
1075604.0,"Regeneron Gets a Complete Response Letter From the FDA for EYLEA Due to Ongoing Labeling Discussions, Expects to Receive a Final FDA Action Within 2 Months",2018-08-13 07:03:00-04:00,REGN,neutral
1075605.0,"The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss",2018-08-10 07:38:00-04:00,REGN,negative
1075606.0,REMINDER: Regeneron Has FDA PDUFA Date Saturday Aug. 11th for its sBLA for Eylea in Wet AMD,2018-08-09 15:16:00-04:00,REGN,neutral
1075607.0,Regeneron To Make $100M bluebird bio Investment In Cancer Research Collaboration,2018-08-06 11:02:00-04:00,REGN,negative
1075608.0,Benzinga Pro's 5 Stocks To Watch Today,2018-08-06 08:51:00-04:00,REGN,neutral
1075609.0,"Barclays Maintains Underweight on Regeneron Pharmaceuticals, Raises Price Target to $305",2018-08-06 08:22:00-04:00,REGN,neutral
1075610.0,"bluebird bio and Regeneron Announce Cancer Collaboration, Regeneron to Invest $100M in bluebird Stock at $238.10/Share",2018-08-06 06:35:00-04:00,REGN,negative
1075611.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs",2018-08-05 09:44:00-04:00,REGN,neutral
1075612.0,"Canaccord Genuity Maintains Hold on Regeneron Pharmaceuticals, Raises Price Target to $390",2018-08-03 09:42:00-04:00,REGN,neutral
1075613.0,"Benzinga's Top Upgrades, Downgrades For August 3, 2018",2018-08-03 09:41:00-04:00,REGN,positive
1075614.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $409",2018-08-03 07:23:00-04:00,REGN,neutral
1075615.0,A Peek Into The Markets: US Stock Futures Edge Higher; All Eyes On Jobs Report,2018-08-03 07:11:00-04:00,REGN,neutral
1075616.0,Baird Downgrades Regeneron Pharmaceuticals to Neutral,2018-08-03 06:48:00-04:00,REGN,neutral
1075617.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,REGN,positive
1075618.0,Regeneron Narrows FY18 Guidance For Sanofi Collaboration Sales From $450M-$485M To $455M-$485M,2018-08-02 06:36:00-04:00,REGN,neutral
1075619.0,"Regeneron Pharmaceuticals Q2 EPS $5.45 Beats $4.70 Estimate, Sales $1.608B Beat $1.56B Estimate",2018-08-02 06:35:00-04:00,REGN,neutral
1075620.0,"Earnings Scheduled For August 2, 2018",2018-08-02 04:48:00-04:00,REGN,neutral
1075621.0,Regeneron Pharmaceuticals Earnings Outlook,2018-08-01 15:46:00-04:00,REGN,neutral
1075622.0,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,2018-08-01 07:38:00-04:00,REGN,neutral
1075623.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,REGN,neutral
1075624.0,Intellia Therapeutics 8-K Indicates Co. And Regeneron Agreed To Form Co-Development And Co-Promotion Agreement Consistent With April 2016 Collaboration Deal,2018-07-20 16:46:00-04:00,REGN,positive
1075625.0,"Argus Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $415",2018-07-16 09:21:00-04:00,REGN,neutral
1075626.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $396",2018-07-13 07:54:00-04:00,REGN,neutral
1075627.0,Oppenheimer Upgrades Regeneron Pharmaceuticals to Outperform,2018-06-27 08:18:00-04:00,REGN,neutral
1075628.0,Inovio Reports Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor,2018-06-21 08:02:00-04:00,REGN,negative
1075629.0,Watching Shares of Regeneron After Traders Circulate Unconfirmed Chatter Of Offer From Sanofi,2018-06-20 13:52:00-04:00,REGN,positive
1075630.0,Crispr Therapeutics Falls As Studies Suggest Possible Cancerous Side Effect,2018-06-11 13:58:00-04:00,REGN,neutral
1075631.0,"Intellia Therapeutics Shares Down 10% Over Last 45 Mins. Following STAT News Article On CRISPR Sickle-Cell, Thalassemia Programs 'should not affect the gene-disruption approach Intellia Therapeutics and Regeneron' Use",2018-06-11 11:49:00-04:00,REGN,positive
1075632.0,"Regeneron, Zoetis Report Collaboration To Research Antibody Therapies For Use In Animal Health",2018-06-06 07:03:00-04:00,REGN,neutral
1075633.0,"Regeneron, Sanofi Report New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Results in Advanced Cutaneous Squamous Cell Carcinoma",2018-06-04 14:18:00-04:00,REGN,positive
1075634.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,REGN,negative
1075635.0,"Jim Cramer Shares His Thoughts On Lululemon, Regeneron And More",2018-06-01 07:38:00-04:00,REGN,positive
1075636.0,Regeneron Announces It's Shipping Investigational Ebola Treatment REGN-EB3 To Democratic Republic of the Congo For Use In Current Outbreak,2018-05-31 16:12:00-04:00,REGN,neutral
1075637.0,"Sanofi, Regeneron Announce New England Journal of Medicine Published 2 Positive Phase 3 Trials Showing Dupixent (dupilumab) Improved Moderate-to-Severe Asthma",2018-05-21 14:15:00-04:00,REGN,positive
1075638.0,"Sanofi, Regeneron Announce Dupixent Phase 3 Trial in Adolescents With Inadequately Controlled Moderate-to-severe Atopic Dermatitis Met Primary, Secondary Endpoints",2018-05-16 03:52:00-04:00,REGN,negative
1075639.0,"Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway",2018-05-09 07:48:00-04:00,REGN,neutral
1075640.0,"Stocks That Made New 52-Week Lows Today Include: Colgate-Palmolive, Acuity Brands, International Flavors & Fragrances, Regeneron, Celgene, L Brands, and Dentsply Sirona",2018-05-07 15:53:00-04:00,REGN,negative
1075641.0,Stocks That Made New 52-Week Lows Today Include Regeneron and L Brands,2018-05-04 11:43:00-04:00,REGN,negative
1075642.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $370.00",2018-05-04 10:45:00-04:00,REGN,negative
1075643.0,"BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Lowers Price Target to $361.00",2018-05-04 08:56:00-04:00,REGN,negative
1075644.0,"Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down",2018-05-04 08:16:00-04:00,REGN,neutral
1075645.0,"Jim Cramer Shares His Thoughts On Blackstone, Celgene And More",2018-05-04 07:52:00-04:00,REGN,positive
1075646.0,"Stocks That Made New 52-Week Lows Today Include Colgate-Palmolive, Philip Morris, Regeneron, Corning, Hanesbrands, Bed Bath & Beyond, Pepsi, Coca-Cola, Paccar, Johnson & Johnson, Mallinckrodt, CBS, DISH Network, Goodyear Tire, Chubb, Hershey, and AT&T",2018-05-03 11:31:00-04:00,REGN,negative
1075647.0,Regeneron Pharmaceuticals: Sequencing Its Way to +30% Upside,2018-05-03 09:39:00-04:00,REGN,neutral
1075648.0,"Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss",2018-05-03 08:31:00-04:00,REGN,negative
1075649.0,"Regeneron Pharmaceuticals Q1 EPS $4.67 Beats $4.32 Estimate, Sales $1.511B Beat $1.51B Estimate",2018-05-03 06:32:00-04:00,REGN,neutral
1075650.0,"Earnings Scheduled For May 3, 2018",2018-05-03 05:15:00-04:00,REGN,neutral
1075651.0,Esperion Shares Plunge After Cholesterol-Lowering Drug's Phase 3 Results Stir Safety Concerns,2018-05-02 11:56:00-04:00,REGN,positive
1075652.0,"Stocks That Made New 52-Week Low Today Include: CBS, Goodyear Tire, Vulcan Materials, Regeneron, Hershey, Leggett & Platt, Harley-Davidson, Kraft Heinz, Kellogg, Mallinckrodt, Fortune Brands Home, Comcast, Pepsi, and Acuity Brands",2018-05-01 10:33:00-04:00,REGN,negative
1075653.0,"Benzinga's Top Upgrades, Downgrades For May 1, 2018",2018-05-01 10:12:00-04:00,REGN,positive
1075654.0,Guggenheim Downgrades Regeneron Pharmaceuticals to Neutral,2018-05-01 07:31:00-04:00,REGN,neutral
1075655.0,"Regeneron and Sanofi to Lower the Price of Praluent Injection in Exchange for 'Straightforward, More Affordable' Patient Access for Express Scripts Patients",2018-05-01 07:03:00-04:00,REGN,negative
1075656.0,"Stocks That Made New 52-Week Lows Today Include: Arconic, Mohawk Industries, Comcast, DISH Network, Regeneron, and Skyworks Solutions",2018-04-30 12:19:00-04:00,REGN,neutral
1075657.0,Sanofi Announces FDA to Conduct Priority Review of Cemiplimab as Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma,2018-04-30 03:52:00-04:00,REGN,positive
1075658.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap",2018-04-29 08:11:00-04:00,REGN,neutral
1075659.0,"Stocks That Made New 52-Week Highs Today Include: AES and Macy's; Stocks That Made New 52-Week Lows Today Include: Regeneron Pharma, DISH Network, Comcast, and Charter Communications",2018-04-27 10:56:00-04:00,REGN,negative
1075660.0,"Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'",2018-04-17 11:21:00-04:00,REGN,positive
1075661.0,"Benzinga's Top Upgrades, Downgrades For April 9, 2018",2018-04-09 09:18:00-04:00,REGN,positive
1075662.0,"The Market In 5 Minutes: Deutsche Bank, GM, Trump, WrestleMania And More",2018-04-09 09:00:00-04:00,REGN,neutral
1075663.0,Raymond James Downgrades Regeneron Pharmaceuticals to Market Perform,2018-04-09 07:28:00-04:00,REGN,neutral
1075664.0,"Regeneron, Sanofi Announce EMA to Review DUPIXENT as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma",2018-04-03 04:02:00-04:00,REGN,negative
1075665.0,"Regeneron, Sanofi Announce EMA to Review Cemiplimab as Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma",2018-04-03 04:00:00-04:00,REGN,positive
1075666.0,Regeneron and Alnylam Pharmaceuticals Announce Collaboration for Nonalcoholic Steatohepatitis,2018-03-21 17:06:00-04:00,REGN,neutral
1075667.0,A Peek Into The Markets: U.S. Stock Futures Down; NASDAQ Futures Tumble Over 2%,2018-03-19 07:23:00-04:00,REGN,neutral
1075668.0,Regeneron's EYLEA Meets 24-Week Primary Endpoint In Its Phase 3 PANORAMA Trial,2018-03-19 07:03:00-04:00,REGN,neutral
1075669.0,"Strong Trial Results, Effective Distribution Could Put Regeneron's Praluent 'Back In The Competition'",2018-03-12 13:39:00-04:00,REGN,positive
1075670.0,Meg Tirrell Tweets: Coming up on @SquawkStreet: $REGN CEO Len Schleifer. What do you want to know?,2018-03-12 09:59:00-04:00,REGN,positive
1075671.0,"Regeneron And Sanofi On Saturday Announced Plan To Expand Accessibility And Affordability Of Praluent, Will Offer Reduced Net Price To Payers Willing To Reduce Access Barriers For Highest-Risk Patients",2018-03-12 08:24:00-04:00,REGN,positive
1075672.0,Report: The 10 Most Overpaid S&P 500 CEOs,2018-03-11 15:44:00-04:00,REGN,neutral
1075673.0,"Sanofi, Regeneron Announce ODYSSEY OUTCOMES Trial Met Primary Endpoint",2018-03-10 19:32:00-05:00,REGN,neutral
1075674.0,"ICYMI: Valeant, Overstock And Biotechs",2018-03-05 18:35:00-05:00,REGN,neutral
1075675.0,7 Biotech Stocks With Clinical Trial Outcomes In March,2018-03-05 12:01:00-05:00,REGN,neutral
1075676.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-02 14:12:00-05:00,REGN,neutral
1075677.0,"Regeneron, Sanofi Announce FDA to Review DUPIXENT as Potential Treatment for Moderate-to-Severe Asthma",2018-03-02 04:07:00-05:00,REGN,neutral
1075678.0,"Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges",2018-02-21 11:07:00-05:00,REGN,positive
1075679.0,"Benzinga's Top Upgrades, Downgrades For February 21, 2018",2018-02-21 09:31:00-05:00,REGN,positive
1075680.0,Canaccord Genuity Downgrades Regeneron Pharmaceuticals to Hold,2018-02-21 05:37:00-05:00,REGN,neutral
1075681.0,"Companies That Earlier Made New 52-Wk Highs Include Coty, S&P Global, and Estee Lauder; Those That Made New 52-Wk Lows Include Regeneron Pharma, Vornado Realty, Federal Realty Investment, and Allergan",2018-02-14 12:52:00-05:00,REGN,negative
1075682.0,"BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Lowers price target to $398.00",2018-02-09 12:07:00-05:00,REGN,negative
1075683.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises price target to $415.00",2018-02-09 11:14:00-05:00,REGN,neutral
1075684.0,Analyst: Regeneron Is Undervalued By The Street,2018-02-09 10:46:00-05:00,REGN,neutral
1075685.0,"Benzinga's Top Upgrades, Downgrades For February 9, 2018",2018-02-09 10:17:00-05:00,REGN,positive
1075686.0,"Leerink Swann Maintains Outperform on Regeneron Pharmaceuticals, Lowers price target to $502.00",2018-02-09 10:15:00-05:00,REGN,negative
1075687.0,Baird Upgrades Regeneron Pharmaceuticals to Outperform,2018-02-09 07:16:00-05:00,REGN,neutral
1075688.0,BTIG Research Downgrades Regeneron Pharmaceuticals to Neutral,2018-02-09 06:36:00-05:00,REGN,neutral
1075689.0,"A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Jobless Claims, Fed Speakers",2018-02-08 07:06:00-05:00,REGN,neutral
1075690.0,"Regeneron Reports Q4 Adj. EPS $5.23 vs $4.53 Est., Sales $1.58B vs $1.5B Est.",2018-02-08 06:30:00-05:00,REGN,neutral
1075691.0,"Earnings Scheduled For February 8, 2018",2018-02-08 04:36:00-05:00,REGN,neutral
1075692.0,28 Stocks Moving In Monday's Pre-Market Session,2018-02-05 08:07:00-05:00,REGN,neutral
1075693.0,AbbVie Shares Double In A Year; Leerink Moves To Sidelines,2018-01-29 15:51:00-05:00,REGN,positive
1075694.0,Regeneron Announces Approval of DUPIXENT in Japan for the Treatment of Atopic Dermatitis,2018-01-22 07:14:00-05:00,REGN,positive
1075695.0,"Lightning Round: Jim Cramer Advises His Viewers On Chegg, Floor & Decor, Regeneron, And More",2018-01-12 07:16:00-05:00,REGN,neutral
1075696.0,How To Trade The JPMorgan Healthcare Conference,2018-01-08 13:19:00-05:00,REGN,neutral
1075697.0,"JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma",2018-01-08 09:00:00-05:00,REGN,positive
1075698.0,"Regeneron, Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs From $1B To $1.64B",2018-01-08 07:08:00-05:00,REGN,positive
1075699.0,BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A,2018-01-05 17:31:00-05:00,REGN,positive
1075700.0,"Merus Says the US Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision, This Affirms Merus' Inequitable Conduct Claim Against Regeneron for a Patent",2017-12-27 07:31:00-05:00,REGN,negative
1075701.0,Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration,2017-12-18 03:56:00-05:00,REGN,neutral
1075702.0,"Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More",2017-12-15 07:33:00-05:00,REGN,positive
1075703.0,"Deutsche Bank Initiates Coverage On Regeneron Pharmaceuticals with Hold Rating, Announces $397.00 Price Target",2017-12-13 08:40:00-05:00,REGN,neutral
1075704.0,"Regeneron, Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma",2017-12-13 03:56:00-05:00,REGN,positive
1075705.0,Regeneron Reports FDA Accepted sBLA Filing For 12-Week Dosing Of EYLEA Injection For Patients With Wet AMD,2017-12-11 07:01:00-05:00,REGN,positive
1075706.0,31 Stocks Moving In Thursday's Mid-Day Session,2017-12-07 12:24:00-05:00,REGN,neutral
1075707.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-12-07 08:02:00-05:00,REGN,neutral
1075708.0,"Citi Downgrades Regeneron, Citing 'Underappreciated' Risk",2017-12-01 09:57:00-05:00,REGN,negative
1075709.0,"The Market In 5 Minutes: Tax Bill, Bitcoin, 'Today' Show, And More",2017-12-01 09:15:00-05:00,REGN,neutral
1075710.0,"Benzinga's Top Upgrades, Downgrades For December 1, 2017",2017-12-01 09:11:00-05:00,REGN,positive
1075711.0,Citigroup Downgrades Regeneron Pharmaceuticals to Neutral,2017-12-01 06:18:00-05:00,REGN,neutral
1075712.0,Regeneron to Collaborate with Decibel Therapeutics to Discover and Develop Therapeutics for Hearing Loss and Tinnitus,2017-11-29 07:02:00-05:00,REGN,negative
1075713.0,What's Next For Regeneron After A Therapy Trial Failure?,2017-11-28 13:30:00-05:00,REGN,negative
1075714.0,"Despite Nesvacumab Failure, BTIG Remains Buy Rated On Regeneron Pharmaceuticals As The 2018 Pipeline Could 'Improve Visibility For Future Diversification Of Regeneron's Revenues'",2017-11-28 10:42:00-05:00,REGN,positive
1075715.0,"BTIG Research Maintains Buy on Regeneron Pharmaceuticals, But Lowers Price Target From $520 to $480 On The Heels Of Monday's Announcement That Nesvacumab Didn't Meet Clinical Study Endpoints And Won't Enter Phase 3 Development",2017-11-28 08:51:00-05:00,REGN,negative
1075716.0,Regeneron Announces EYLEA Injection and Nesvacumab Combination Program did Not Provide Sufficient Differentiation to Warrant Phase 3 Development,2017-11-27 04:03:00-05:00,REGN,neutral
1075717.0,34 Stocks Moving In Tuesday's Pre-Market Session,2017-11-14 08:06:00-05:00,REGN,neutral
1075718.0,"BMO Capital Maintains Market Perform on Regeneron Pharmaceuticals, Lowers Price Target to $479.00",2017-11-09 09:43:00-05:00,REGN,negative
1075719.0,"Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $463.00",2017-11-09 07:53:00-05:00,REGN,negative
1075720.0,A Big Biotech ETF Is About To Get Cheaper,2017-11-08 15:28:00-05:00,REGN,neutral
1075721.0,Regeneron Surrenders Most Early Gains After Q3 Beat,2017-11-08 14:29:00-05:00,REGN,positive
1075722.0,Regeneron Reaffirms FY17 EYLEA US Net Product Sales ~10% YoY,2017-11-08 06:36:00-05:00,REGN,neutral
1075723.0,"Regeneron Reports Q3 Adj. EPS $3.99 vs $3.85 Est., Sales $1.501B vs $1.46B Est.",2017-11-08 06:35:00-05:00,REGN,neutral
1075724.0,"Earnings Scheduled For November 8, 2017",2017-11-08 04:11:00-05:00,REGN,neutral
1075725.0,Regeneron Pharmaceuticals Gains A Bull Ahead Of Earnings,2017-11-03 13:52:00-04:00,REGN,positive
1075726.0,"Benzinga's Top Upgrades, Downgrades For November 3, 2017",2017-11-03 09:10:00-04:00,REGN,positive
1075727.0,"The Market In 5 Minutes: Apple, iPhones, And Trump's Twitter",2017-11-03 08:56:00-04:00,REGN,neutral
1075728.0,Baird Upgrades Regeneron Pharmaceuticals to Neutral,2017-11-03 06:55:00-04:00,REGN,neutral
1075729.0,Inovio Initiates Phase 1b/2a Study Of INO-5401 In Combination With Regeneron's PD-1 Inhibitor,2017-11-01 09:19:00-04:00,REGN,negative
1075730.0,"Jim Cramer Gives His Opinion On Southwest Airlines, Regeneron Pharmaceuticals And More",2017-10-31 09:12:00-04:00,REGN,neutral
1075731.0,"Regeneron Reports Results From Phase 3 Study Of Dupilumab In People With Severe Steroid-Dependent Asthma: 'Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function'",2017-10-31 07:23:00-04:00,REGN,negative
1075732.0,The Market In 5 Minutes: Tax Overhaul In Focus As Senate Passes Budget Plan,2017-10-20 09:11:00-04:00,REGN,neutral
1075733.0,"Benzinga's Top Upgrades, Downgrades For October 20, 2017",2017-10-20 09:04:00-04:00,REGN,positive
1075734.0,25 Stocks Moving In Friday's Pre-Market Session,2017-10-20 08:03:00-04:00,REGN,neutral
1075735.0,Barclays Downgrades Regeneron Pharmaceuticals to Underweight,2017-10-20 06:32:00-04:00,REGN,neutral
1075736.0,Sanofi and Regeneron Announce 'Positive' Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis,2017-10-16 08:03:00-04:00,REGN,positive
1075737.0,Amgen 'Disappointed' In Court Decision To Reverse Praluent Sales Ban,2017-10-05 12:40:00-04:00,REGN,negative
1075738.0,Regeneron PR Confirms Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent,2017-10-05 12:31:00-04:00,REGN,neutral
1075739.0,"UPDATE: Amgen Highlights To Benzinga, In Process Of Lifting Ban, U.S. Appeals Court Also Rejected A Main Argument Brought By Sanofi & Regeneron; Co. States 'We look forward to reasserting our rights in court'",2017-10-05 12:16:00-04:00,REGN,negative
1075740.0,"Amgen Responds To U.S. Appeals Court Decision to Reverse District Court Ban On Sales Of Sanofi/Regnereron's Praluent, Tells Benzinga: 'We are disappointed by the Court's action,' Ability To Deliver New Medicines Depends On 'Meaningful patent protection'",2017-10-05 12:16:00-04:00,REGN,negative
1075741.0,"Regeneron Shares Halted Up 1.8% Following Earlier Report Appeals Court Has Thrown Out Ban On Sanofi, Regeneron's Praluent Brought By Amgen",2017-10-05 11:04:00-04:00,REGN,negative
1075742.0,UPDATE: Court Filing Confirms Earlier Rumor Of Sanofi Winning New Trial vs Amgen In Case Over Praluent,2017-10-05 10:12:00-04:00,REGN,positive
1075743.0,Regeneron Shares Halted News Pending,2017-10-05 09:59:00-04:00,REGN,positive
1075744.0,Hearing Sanofi Wins New Trial In Amgen Case Over Praluent,2017-10-05 09:56:00-04:00,REGN,positive
1075745.0,"Regeneron Reports New Partnerships with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens",2017-10-02 07:13:00-04:00,REGN,neutral
1075746.0,"Regeneron, Sanofi Announce Approval of DUPIXENT in EU to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis",2017-09-28 04:32:00-04:00,REGN,positive
1075747.0,"Sanofi, Regeneron Announce Positive Study Results for Dupixent in Patients With Moderate-to-Severe Atopic Dermatitis",2017-09-17 10:00:00-04:00,REGN,positive
1075748.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,REGN,neutral
1075749.0,12 Biggest Mid-Day Losers For Monday,2017-09-11 13:05:00-04:00,REGN,negative
1075750.0,18 Stocks Moving In Monday's Pre-Market Session,2017-09-11 08:27:00-04:00,REGN,neutral
1075751.0,"Regeneron, Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma",2017-09-11 04:09:00-04:00,REGN,positive
1075752.0,"Regeneron, Sanofi Announce FDA Breakthrough Therapy Designation for Cemiplimab (REGN2810) for for Advanced Cutaneous Squamous Cell Carcinoma",2017-09-08 04:53:00-04:00,REGN,positive
1075753.0,"The Pullback In Sanofi Is A Buying Opportunity, Says Argus",2017-09-01 09:54:00-04:00,REGN,positive
1075754.0,"Benzinga's Top Upgrades, Downgrades For August 17, 2017",2017-08-17 09:34:00-04:00,REGN,positive
1075755.0,"Evercore ISI Group Initiates Coverage On Regeneron Pharmaceuticals with Outperform Rating, Announces $605.00 Price Target",2017-08-17 07:31:00-04:00,REGN,neutral
1075756.0,"Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus, Suptavumab Didn't Show Signs Of Efficacy In A Subgrouop Of Patients",2017-08-14 09:07:00-04:00,REGN,neutral
1075757.0,20 Stocks Moving In Monday's Pre-Market Session,2017-08-14 08:09:00-04:00,REGN,neutral
1075758.0,25 Stocks Moving In Monday's Pre-Market Session,2017-08-07 08:06:00-04:00,REGN,neutral
1075759.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-08-03 08:07:00-04:00,REGN,neutral
1075760.0,Regeneron Sees FY17 EYLEA US Net Product Sales Growth ~10% YoY,2017-08-03 06:35:00-04:00,REGN,positive
1075761.0,"Regeneron Reports Q2 Adj. EPS $4.17 vs $3.17 Est., Sales $1.47B vs $1.35B Est.",2017-08-03 06:34:00-04:00,REGN,neutral
1075762.0,"Earnings Scheduled For August 3, 2017",2017-08-03 04:10:00-04:00,REGN,neutral
1075763.0,Expectations For Regeneron No Longer Realistic; Analyst Downgrades,2017-08-01 09:58:00-04:00,REGN,negative
1075764.0,"Benzinga's Top Upgrades, Downgrades For August 1, 2017",2017-08-01 09:30:00-04:00,REGN,positive
1075765.0,The Market In 5 Minutes,2017-08-01 08:59:00-04:00,REGN,neutral
1075766.0,Baird Downgrades Regeneron Pharmaceuticals to Underperform,2017-08-01 06:05:00-04:00,REGN,neutral
1075767.0,Baird Downgrades Regeneron to Underperform from Neutral,2017-08-01 04:22:00-04:00,REGN,neutral
1075768.0,22 Stocks Moving In Monday's Pre-Market Session,2017-07-31 08:39:00-04:00,REGN,neutral
1075769.0,"Regeneron, Sanofi Report Received Positive CHMP Opinion For Dupixent To Treat Adult Patients With Moderate-To-Severe Atopic Dermatitis",2017-07-21 07:30:00-04:00,REGN,positive
1075770.0,Sanofi and Regeneron's Dupixent for Severe Eczema Recommended for Approval by the EU Medicines Agency,2017-07-21 07:22:00-04:00,REGN,positive
1075771.0,"Lightning Round: Jim Cramer Shares His Thoughts On GameStop, Pfizer And More",2017-07-20 07:34:00-04:00,REGN,positive
1075779.0,"Regeneron, Sanofi Announce EU Approval of Kevzara to Treat Adult Patients with Moderately to Severely Active RA",2017-06-27 04:40:00-04:00,REGN,positive
1075780.0,Is It Time To Step To The Sidelines On Regeneron?,2017-06-26 13:27:00-04:00,REGN,neutral
1075781.0,"Benzinga's Top Upgrades, Downgrades For June 26, 2017",2017-06-26 09:21:00-04:00,REGN,positive
1075784.0,Bernstein Downgrades Regeneron Pharmaceuticals to Market Perform,2017-06-26 06:17:00-04:00,REGN,neutral
1075785.0,Mid-Day Market Update: Bed Bath & Beyond Drops Following Disappointing Earnings; Synchronoss Technologies Shares Surge,2017-06-23 12:03:00-04:00,REGN,negative
1075786.0,Mid-Morning Market Update: Markets Mostly Flat; BlackBerry Sales Miss Views,2017-06-23 10:15:00-04:00,REGN,negative
1075790.0,Regeneron Provides Deal Details On Royalty Agreement With Novartis For ACZ885,2017-06-22 09:01:00-04:00,REGN,positive
1075792.0,Raymond James Raises Regeneron Price Target From $475 to $547,2017-06-22 08:07:00-04:00,REGN,neutral
1075797.0,20 Stocks Moving In Tuesday's Pre-Market Session,2017-06-20 08:09:00-04:00,REGN,neutral
1075800.0,"Regeneron Lower Day After 8-K Filing, Increased Competition For Pain Remedy",2017-06-15 15:09:00-04:00,REGN,negative
1075808.0,"Sanofi, Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent in Individuals with Diabetes and Hypercholesterolemia",2017-06-11 15:46:00-04:00,REGN,positive
1075811.0,"Watch Regeneron, AbbVie and OncoSec as FDA Shows Orphan Status Granted",2017-06-08 07:52:00-04:00,REGN,positive
1075812.0,"Sanofi, Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 #ASCO17",2017-06-04 17:43:00-04:00,REGN,positive
1075813.0,Diplomat Pharmacy Announces It Will Dispense Regeneron's KEVZARA,2017-05-25 16:31:00-04:00,REGN,neutral
1075814.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-05-25 08:07:00-04:00,REGN,neutral
1075815.0,"Regeneron Announces Positive Phase 2 Data For ANGPTL3/Evinacumab, Met Primary Endpoint With No Adverse Events Leading To Discontinuation",2017-05-24 17:02:00-04:00,REGN,neutral
1075816.0,"Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected",2017-05-24 11:02:00-04:00,REGN,negative
1075817.0,Regeneron and Sanofi Report FDA Approval of Kevzara for Treatment of Moderately to Severely Active RA in Adult Patients,2017-05-22 17:46:00-04:00,REGN,positive
1075818.0,Regeneron And Sanofi Have A Near-Term FDA Catalyst,2017-05-22 14:08:00-04:00,REGN,neutral
1075819.0,REMINDER: Regneron And Sanofi Have Sarilumab FDA PDUFA Date Today,2017-05-22 08:58:00-04:00,REGN,neutral
1075820.0,Vetr Upgrade's REGN's On Price Growth Following Positive Guidance,2017-05-19 07:28:00-04:00,REGN,positive
1075821.0,Regeneron Reports Immuno-Oncology Clinical Study with SillaJen for Combo Treatment in Kidney Cancer,2017-05-08 08:32:00-04:00,REGN,negative
1075822.0,Regeneron Pharma and Immuno-Oncology Announces Clinical Study Agreement,2017-05-08 07:34:00-04:00,REGN,positive
1075823.0,"The Prospects For CHS-3351, Coherus' Most Underappreciated Asset",2017-05-05 11:17:00-04:00,REGN,positive
1075824.0,"Benzinga's Top Upgrades, Downgrades For May 5, 2017",2017-05-05 09:30:00-04:00,REGN,positive
1075825.0,Canaccord Genuity Upgrades Regeneron Pharmaceuticals to Buy,2017-05-05 07:44:00-04:00,REGN,neutral
1075826.0,Regeneron Reaffirms FY17 EYLEA US Net Product Sales Growth Outlook: Single Digit Percentage Range,2017-05-04 06:39:00-04:00,REGN,positive
1075827.0,"Regeneron Reports Q1 Adj. EPS $2.92 vs $3.07 Est., Sales $1.319B vs $1.3B Est.",2017-05-04 06:39:00-04:00,REGN,neutral
1075828.0,"Regeneron, Sanofi Issue Results of 'Honestly RA,' Show 80% of RA Patients Report Life-Altering Pain Daily or Multiple Times/Week Despite Treatment",2017-05-02 08:32:00-04:00,REGN,negative
1075829.0,"Alimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored",2017-04-30 12:59:00-04:00,REGN,neutral
1075830.0,"Regeneron, Sanofi Report FDA Approval of Once-Monthly Dosing Option for Praluent Injection",2017-04-25 08:02:00-04:00,REGN,positive
1075831.0,"Regeneron, Sanofi Receive Positive CHMP Opinion for Marketing of Kevzara to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis",2017-04-24 04:21:00-04:00,REGN,positive
1075832.0,EMA Recommends Approval Of Sanofi And Regeneron's Kevzara For Rheumatoid Arthritis Treatment,2017-04-21 13:27:00-04:00,REGN,positive
1075833.0,"Barron's Picks And Pans: Drug Stocks, Hanesbrands, Wabtec And More",2017-04-17 08:21:00-04:00,REGN,neutral
1075834.0,Your Cheat Sheet For Q1 Biotech Earnings,2017-04-06 12:47:00-04:00,REGN,negative
1075835.0,Regeneron Reports Evinacumab Received FDA Breakthrough Therapy Designation for HoFH,2017-04-06 07:01:00-04:00,REGN,neutral
1075836.0,"Regeneron, Sanofi To Host Conference Call To Discuss Dupixent FDA Approval Today 4pm ET",2017-03-28 13:51:00-04:00,REGN,positive
1075837.0,Regeneron's Dupixent Passes The FDA Muster; Baird Sees Strong Launch,2017-03-28 12:41:00-04:00,REGN,positive
1075838.0,"Regeneron Shares Resume Trading, Now Up 0.07%",2017-03-28 12:06:00-04:00,REGN,positive
1075839.0,Regeneron Shares to Resume Trade at 12:05 p.m. EDT,2017-03-28 11:43:00-04:00,REGN,positive
1075840.0,Regeneron and Sanofi Announce FDA Approval of DUPIXENT,2017-03-28 11:40:00-04:00,REGN,positive
1075841.0,TheStreet's Adam Feuerstein Tweets '$REGN $SNY Dupixent approved.',2017-03-28 11:35:00-04:00,REGN,neutral
1075842.0,TheStreet's Adam Feuerstein Tweets '$REGN halted. Dupi approval announcement coming.',2017-03-28 11:03:00-04:00,REGN,positive
1075843.0,Baird Analyst Brian Skorney Tweets: $REGN halted. Dupixent PDUFA is tomorrow.,2017-03-28 11:00:00-04:00,REGN,neutral
1075844.0,BZ NOTE: Regeneron Halt Related To FDA PDUFA Decision On Dupixent Tomorrow,2017-03-28 11:00:00-04:00,REGN,positive
1075845.0,Regeneron Pharmaceuticals Halted News Pending,2017-03-28 10:59:00-04:00,REGN,neutral
1075846.0,"Adam Feuerstein Tweets: Tomorow's FDA drug approval decision will be Roche Ocrevus in MS. (Also affecting $BIIB)

Wednesday â $REGN $SNY Dupixent in eczema.",2017-03-27 16:31:00-04:00,REGN,positive
1075847.0,Esperion Therapeutics Rockets 70% Higher After Big Selloff,2017-03-20 14:40:00-04:00,REGN,neutral
1075848.0,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,2017-03-20 09:17:00-04:00,REGN,neutral
1075849.0,Esperion Falls Victim To Amgen's Poor Repatha Results,2017-03-17 11:09:00-04:00,REGN,negative
1075850.0,"Amgen Shares Down 5.6%, Regeneron Shares Down 3%",2017-03-17 09:06:00-04:00,REGN,positive
1075851.0,"Watching Shares of Regeneron, Sanofi Amid Expectation for Amgen News Related to Repatha at 9 a.m. EDT",2017-03-17 08:15:00-04:00,REGN,positive
1075852.0,Your Guide To Patent Play Exposure,2017-03-11 19:34:00-05:00,REGN,positive
1075853.0,Vetr Downgrades Regeneron Off Of Share Rise,2017-03-10 12:35:00-05:00,REGN,positive
1075854.0,"Benzinga's Top Upgrades, Downgrades For March 9, 2017",2017-03-09 09:42:00-05:00,REGN,positive
1075855.0,"UBS Initiates Coverage On Regeneron Pharmaceuticals With Buy, Announces $435 Price Target",2017-03-09 06:17:00-05:00,REGN,neutral
1075856.0,Here's Your March PDUFA Date Preview,2017-03-08 14:59:00-05:00,REGN,neutral
1075857.0,"Regeneron, Sanofi Report Will Present New Phase 3 Praluent Injection Clinical Trial Analyses at ACC.17 Scientific Sessions",2017-03-07 08:03:00-05:00,REGN,neutral
1075858.0,"Regeneron, Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT in Moderate-to-Severe Atopic Dermatitis",2017-03-05 17:51:00-05:00,REGN,positive
1075859.0,Icahn's (Potential) Move Into Biotech,2017-03-04 19:25:00-05:00,REGN,neutral
1075860.0,"Adverum Biotechnologies Reports Regeneron Pharma Extends Research Term Of Partnership, Licensing Deal Through May 2020",2017-03-01 16:53:00-05:00,REGN,positive
1075861.0,The Most Overpaid CEOs In S&P 500 Companies That Largely Underperformed The Market,2017-02-24 09:56:00-05:00,REGN,neutral
1075862.0,"Benzinga's Top Upgrades, Downgrades For February 13, 2017",2017-02-13 09:38:00-05:00,REGN,positive
1075863.0,The Market In 5 Minutes: Hello... Can You Hear Me?,2017-02-13 09:29:00-05:00,REGN,neutral
1075864.0,PiperJaffray Upgrades Regeneron Pharmaceuticals To Overweight,2017-02-13 07:35:00-05:00,REGN,negative
1075865.0,Stay Of Court Injunction A Mild Positive For Regeneron,2017-02-09 12:02:00-05:00,REGN,positive
1075866.0,Q4 2016 Real-Time Call Brief,2017-02-09 11:35:00-05:00,REGN,neutral
1075867.0,"Regeneron Gets 'Encouraging' Judicial Decision, Could Still Lose Appeal",2017-02-09 11:18:00-05:00,REGN,negative
1075868.0,Regeneron Spikes to High of $366.95 on Volume,2017-02-09 09:51:00-05:00,REGN,neutral
1075869.0,Regeneron Says Changes In Pharmaceutical Drug Pricing Will Need Congressional Action,2017-02-09 09:12:00-05:00,REGN,neutral
1075870.0,Regeneron Sees FY17 EYLEA US Net Product Sales Up in the Single-Digit Percentage Range vs 2016,2017-02-09 06:34:00-05:00,REGN,neutral
1075871.0,"Regeneron Reports Q4 Adj. EPS $3.04 vs $3.03 Est., Sales $1.227B vs $1.3B Est.",2017-02-09 06:33:00-05:00,REGN,neutral
1075872.0,"Earnings Scheduled For February 9, 2017",2017-02-09 04:43:00-05:00,REGN,neutral
1075873.0,"Regeneraon and Sanofi PR Confirms Reports Appeals Court Grants Stay of Permanent Injunction for Praluent During Appeals Process, Drug Continues To Be Available To Patients In U.S.",2017-02-08 17:31:00-05:00,REGN,positive
1075874.0,"UPDATE: Court of Appeals in Regeneron, Sanofi, Amgen Case Related to Praluent Issued Order Granting Emergency Motion to Stay Pending Appeal",2017-02-08 16:26:00-05:00,REGN,negative
1075875.0,"Hearing Sanofi, Regeneron Won Order Allow Praluent Sales to Continue",2017-02-08 16:19:00-05:00,REGN,positive
1075876.0,"Regeneron Shares Closed Down 1%, Saw After-Hours Action Ahead of Halt; BZ NOTE: Co. Was Expected to Host Q4 Earnings Conference Call Thurs. Morning Before the Open",2017-02-08 16:16:00-05:00,REGN,positive
1075877.0,Regeneron Shares Halted News Pending,2017-02-08 16:13:00-05:00,REGN,positive
1075878.0,"Regeneron, Sanofi Announce First Approval of Kevzara for Treatment of Moderately to Severely Active RA in Adults by Health Canada",2017-02-01 04:14:00-05:00,REGN,positive
1075879.0,"Form 4 Shows Sanofi Buys 87,298 Shares Of Regeneron Pharmaceutical",2017-01-13 16:20:00-05:00,REGN,positive
1075880.0,Top 10 S&P Stocks Of The Obama Presidency,2017-01-11 10:34:00-05:00,REGN,positive
1075881.0,Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April,2017-01-10 09:06:00-05:00,REGN,positive
1075882.0,"8-K from Regeneron Shows Prelim. US Net Sales of EYLEA Injection $858M in Q4, $3.32B in FY16, Global Sales of EYLEA $5B+ for FY16",2017-01-09 17:26:00-05:00,REGN,neutral
1075883.0,Why The Amgen/Regeneron Patent Saga Is Far From Over,2017-01-09 12:27:00-05:00,REGN,neutral
1075884.0,Legal Experts Weigh In On The Amgen/Regeneron Patent Case,2017-01-09 10:12:00-05:00,REGN,positive
1075885.0,15 Biggest Mid-Day Losers For Friday,2017-01-06 13:04:00-05:00,REGN,negative
1075886.0,Low Odds Court Ruling Against Regeneron Get Reversed On Appeal,2017-01-06 11:48:00-05:00,REGN,negative
1075887.0,Amgen Higher After Favorable Court Ruling,2017-01-06 11:02:00-05:00,REGN,positive
1075888.0,"5 Key Takeaways In Regeneron's Praluent Suit, Steps Forward",2017-01-06 09:04:00-05:00,REGN,neutral
1075889.0,Regeneron Falls As Court Grants Permanent Injunction For Infringement Of Amgen's Repatha Patents,2017-01-06 08:54:00-05:00,REGN,negative
1075890.0,18 Stocks Moving In Friday's Pre-Market Session,2017-01-06 08:25:00-05:00,REGN,neutral
1075891.0,Regeneron Down 7% Following Trade Resumption,2017-01-06 07:17:00-05:00,REGN,neutral
1075892.0,UPDATE: Court Grants Permanent Injunction for Infringement of Amgen's Repatha Patents,2017-01-06 04:37:00-05:00,REGN,negative
1075893.0,Amgen Wins Ban On Sanofi's Sales Of Praluent Cholestrol Drug,2017-01-05 16:46:00-05:00,REGN,neutral
1075894.0,Regeneron Shares Halted News Pending,2017-01-05 16:42:00-05:00,REGN,positive
1075895.0,"Regeneron, Sanofi Shares Indicated Lower, Amgen Shares Higher as Hearing Bid to Overturn Amgen's Win in Cholesterol Drug Patent Case Was Lost",2017-01-03 16:50:00-05:00,REGN,positive
1075896.0,Regeneron Spikes to High of $383.09 on Volume,2017-01-03 12:49:00-05:00,REGN,neutral
1075897.0,Regeneron Eyes A Comeback In 2017,2016-12-27 13:50:00-05:00,REGN,neutral
1075898.0,"BMO Capital Initiates Coverage On Regeneron Pharmaceuticals at Market Perform, Announces $419.00 Target",2016-12-20 07:39:00-05:00,REGN,neutral
1075899.0,Ophthotech Clinical Failure Spurs Massive Layoffs; Stock Rises,2016-12-16 15:56:00-05:00,REGN,negative
1075900.0,Nesvacumab Key Catalyst For Regeneron In 2017; BTIG Upgrades To Buy,2016-12-16 10:23:00-05:00,REGN,neutral
1075901.0,"Benzinga's Top Upgrades, Downgrades For December 16, 2016",2016-12-16 09:02:00-05:00,REGN,positive
1075902.0,"BTIG Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $460.00 Target",2016-12-16 08:06:00-05:00,REGN,neutral
1075903.0,Which Wet AMD Stock Would You Buy Right Now?,2016-12-14 11:30:00-05:00,REGN,neutral
1075904.0,What Fovista's Fail Means For OHR Pharma,2016-12-13 08:22:00-05:00,REGN,negative
1075905.0,18 Biggest Mid-Day Gainers For Monday,2016-12-12 12:45:00-05:00,REGN,neutral
1075906.0,One Way To Look At The Ophthotech-Regeneron Pair Trade,2016-12-12 11:29:00-05:00,REGN,neutral
1075907.0,The Market In 5 Minutes: Oil Gushes Higher,2016-12-12 08:59:00-05:00,REGN,neutral
1075908.0,Immune Pharmaceuticals CEO Talks Company And Its Recent Market Rally,2016-12-12 08:51:00-05:00,REGN,positive
1075909.0,20 Stocks Moving In Monday's Pre-Market Session,2016-12-12 08:28:00-05:00,REGN,neutral
1075910.0,"Chardan Upgrades Regeneron; Cites Fovista Failure, Stock's Recent Underperformance",2016-12-12 08:28:00-05:00,REGN,negative
1075911.0,"Chardan Capital Upgrades Regeneron Pharmaceuticals to Neutral, Raises Target to $350.00",2016-12-12 06:25:00-05:00,REGN,neutral
1075912.0,Biotech Stocks Convalescing After Wednesday's Trump-Inspired Biotech Selloff,2016-12-08 09:53:00-05:00,REGN,neutral
1075913.0,"Regeneron, Sanofi Announce Marketing Authorization Application for Dupixent Accepted for Review by EMA",2016-12-08 04:03:00-05:00,REGN,positive
1075914.0,"Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open",2016-12-07 09:34:00-05:00,REGN,negative
1075915.0,Stifel Remains Buyers Of Ophthotech As Year-End Binary Event Looms,2016-12-02 09:13:00-05:00,REGN,negative
1075916.0,RAPS Organization Editor Zach Brennan Tweets: $REGN CEO: The real reason we're not liked: We've used price increases to cover up the gaps in innovation. That's just a fact.,2016-12-01 16:26:00-05:00,REGN,positive
1075917.0,"Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron",2016-12-01 08:21:00-05:00,REGN,neutral
1075918.0,2 Possible Scenarios For Opthotech,2016-11-30 14:02:00-05:00,REGN,neutral
1075919.0,Vetr Thinks Regeneron Is Looking Healthy,2016-11-21 08:12:00-05:00,REGN,positive
1075920.0,Mid-Morning Market Update: Markets Edge Higher; Wal-Mart Posts Mixed Q3 Results,2016-11-17 09:51:00-05:00,REGN,neutral
1075921.0,"Datamonitor Healthcare Analyst Kevin Shannon Tweets: $REGN evinacumab lowers triglycerides by up to 70% with no serious AEs. However, slight increase in moderate AEs (mostly headaches) #AHA16",2016-11-14 15:58:00-05:00,REGN,negative
1075922.0,"Regeneron Shares Spiking To High Of $452.96, Now Coming Back To $444 Level",2016-11-14 15:48:00-05:00,REGN,positive
1075923.0,"10 Stocks That Rallied Four Days, Then Sold Off On Friday",2016-11-14 06:54:00-05:00,REGN,neutral
1075924.0,"Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%",2016-11-09 09:41:00-05:00,REGN,neutral
1075925.0,A Peek Into The Markets: U.S. Stock Futures Edge Lower; All Eyes On Jobs Report,2016-11-04 07:52:00-04:00,REGN,negative
1075926.0,Regeneron's Q3 Results Mixed Compared To Analyst Estimates,2016-11-04 07:34:00-04:00,REGN,neutral
1075927.0,"Regeneron Pharma Reports Q3 Adj. EPS $3.13 vs $2.71 Est., Sales $1.22B vs $1.29B Est.",2016-11-04 06:31:00-04:00,REGN,neutral
1075928.0,"Earnings Scheduled For November 4, 2016",2016-11-04 04:29:00-04:00,REGN,neutral
1075929.0,"Regeneron Pharma Shares Resume Trade, Now Down 2.5%",2016-10-28 15:05:00-04:00,REGN,positive
1075930.0,Regeneron Shares to Resume Trade at 3:05 p.m. EDT,2016-10-28 14:52:00-04:00,REGN,positive
1075931.0,"BZ NOTE: Regeneron Disclosed In Press Release Earlier That Sanofi Was In Discussions With The FDA Regarding Deficiencies In Its French Facility, The Street's Adam Feuerstein Highlights This In A Recent Tweet",2016-10-28 14:48:00-04:00,REGN,positive
1075932.0,"UPDATE: Sanofi Says Co., Regeneron Remain Committed to Development of Sarilumab",2016-10-28 14:38:00-04:00,REGN,positive
1075933.0,Regeneron And Sanofi Receive Complete Response Letter From FDA; Refers To Certain Deficiencies In Mfg Practice At Sanofi Facility; Satisfactory Resolution Of These Deficiencies Is Required Before The FDA Will Grant Approval For Sarilumab,2016-10-28 14:37:00-04:00,REGN,positive
1075934.0,BZ NOTE: Regeneron Shares Likely Halted Ahead of PDUFA Date for Sanilumab for Treatment of RA,2016-10-28 13:51:00-04:00,REGN,positive
1075935.0,Regeneron Pharma Shares Halted News Pending,2016-10-28 13:48:00-04:00,REGN,positive
1075936.0,"Regeneron Says Advised By Collaborator, Sanofi, That Manufacturing Deficiencies have been Raised by FDA During Inspection of  Sanofi Facility",2016-10-28 06:30:00-04:00,REGN,neutral
1075937.0,"News Of Clinical Hold For Fasinumab Weighs On Regeneron, Teva Shares",2016-10-17 08:09:00-04:00,REGN,positive
1075938.0,Regeneron and Teva Place Phase 2b Study On Chronic Back Pain on Clinical Hold,2016-10-17 07:08:00-04:00,REGN,negative
1075939.0,Deal With Regeneron Means Validation For Ocular Therapeutix,2016-10-13 15:07:00-04:00,REGN,neutral
1075940.0,Mid-Afternoon Market Update: Lindsay Gains Following Q4 Results; Fluidigm Shares Drop,2016-10-13 14:48:00-04:00,REGN,positive
1075941.0,10 Biggest Mid-Day Gainers For Thursday,2016-10-13 12:29:00-04:00,REGN,neutral
1075942.0,Mid-Day Market Update: Ocular Therapeutix Surges Following Collaboration Deal With Regeneron; Flex Pharma Shares Slide,2016-10-13 12:02:00-04:00,REGN,positive
1075943.0,Mid-Morning Market Update: Markets Open Lower; Delta Air Lines Profit Beats Estimates,2016-10-13 10:03:00-04:00,REGN,positive
1075944.0,Ocular Therapeutix Shares Charge Higher Following Collaboration Deal With Regeneron,2016-10-13 09:31:00-04:00,REGN,positive
1075945.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-10-13 08:48:00-04:00,REGN,neutral
1075946.0,UPDATE: Ocular Therapeutix Will Receive  up to $305M in Milestone Payments in Addition to Royalties on Potential Future Net Sales,2016-10-13 07:05:00-04:00,REGN,neutral
1075947.0,"Ocular Therapeutix, Regeneron Report Entering Into of Strategic Collaboration for Developing Sustained Release Formulation of Aflibercept for Treatment of Wet AMD, Other Serious Retinal Diseases",2016-10-13 07:04:00-04:00,REGN,negative
1075948.0,Option Alert: REGN Jan17 450 Calls Sweep: 502 @  ASK  $10.50: 512 traded vs 223 OI:  Earnings 11/2  $394.91 Ref,2016-10-10 14:00:00-04:00,REGN,positive
1075949.0,Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista,2016-10-03 11:57:00-04:00,REGN,negative
1075950.0,"Chardan Rates Regeneron A Sell, Advises Caution",2016-09-30 14:37:00-04:00,REGN,neutral
1075951.0,12 Biggest Mid-Day Losers For Friday,2016-09-30 13:43:00-04:00,REGN,negative
1075952.0,"Traders Currently Passing Around Earlier Pre-Open Comment from Chardan Analyst on Ophthotech, Regeneron: Expectation for 'a limited read-across from the REGN2176-3 data to Fovista's pivotal phase III readout'",2016-09-30 11:47:00-04:00,REGN,negative
1075953.0,Here's Why Ophthotech Is Trading Down On Regeneron's News,2016-09-30 11:45:00-04:00,REGN,neutral
1075954.0,"Spokesperson For Ophthotech Says Company Has, ""No Comment At This Time"" Regarding Stock Selloff In Sympathy To Regeneron's anti-PDGFR Study Fail",2016-09-30 10:55:00-04:00,REGN,negative
1075955.0,The Street's Adam Feuerstein Tweets: $OPHT -10% on $REGN anti-PDGFR study fail.,2016-09-30 07:46:00-04:00,REGN,negative
1075956.0,Adam Feuerstein @adamfeuerstein Tweet: $OPHT -10% on $REGN anti-PDGFR study fail.,2016-09-30 07:46:00-04:00,REGN,negative
1075957.0,Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration,2016-09-30 07:00:00-04:00,REGN,negative
1075958.0,The Drug Price Increase Debate: Separating The Winners From The Losers,2016-09-27 11:23:00-04:00,REGN,positive
1075959.0,"Regeneron, Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by FDA",2016-09-26 04:34:00-04:00,REGN,positive
1075960.0,"Regeneron, Teva Reports Global Collaboration to Develop and Commercialize Fasinumab",2016-09-20 07:01:00-04:00,REGN,neutral
1075961.0,"Regeneron, Sanofi Present Positive Phase 3 Investigational Data for Praluent Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016",2016-08-29 03:55:00-04:00,REGN,positive
1075962.0,"Regeneron Reports Deal with BARD for Manufacturing, Testing of New Antibodies Against MERS Virus",2016-08-22 08:31:00-04:00,REGN,neutral
1075963.0,Q2 Earnings Report Card: Biotech,2016-08-08 13:31:00-04:00,REGN,neutral
1075964.0,Benzinga's Top Downgrades,2016-08-05 09:20:00-04:00,REGN,positive
1075965.0,The Market In 5 Minutes: Blowout Jobs Report Pushes Markets Higher,2016-08-05 08:55:00-04:00,REGN,neutral
1075966.0,Baird Downgrades Regeneron Pharmaceuticals to Neutral,2016-08-05 06:38:00-04:00,REGN,neutral
1075967.0,Thursday Morning's Top Earnings Reports,2016-08-04 09:56:00-04:00,REGN,positive
1075968.0,The Market In 5 Minutes: Bank Of England Cut Interest Rates For The First Time In 7 Years,2016-08-04 08:59:00-04:00,REGN,positive
1075969.0,Regeneron Reaffirms FY16 EYLEA US Product Sales Growth 20-25% YoY,2016-08-04 06:34:00-04:00,REGN,positive
1075970.0,"Regeneron Reports Q2 Adj. EPS $2.82 vs $2.65 Est., Sales $1.213B vs $1.24B Est.",2016-08-04 06:33:00-04:00,REGN,neutral
1075971.0,"Earnings Scheduled For August 4, 2016",2016-08-04 04:03:00-04:00,REGN,neutral
1075972.0,"Regeneron To Post Double-Digit Returns, Vetr Crowd Says",2016-08-03 14:20:00-04:00,REGN,neutral
1075973.0,"Regeneron, Adicet Bio Report Strategic Partnership to Discover and Develop Next-Generation Engineered Immune Cell Therapeutics",2016-08-02 08:32:00-04:00,REGN,positive
1075974.0,"Sanofi, Regeneron Announce EMA Acceptance for Review of Marketing Authorisation Application for Sarilumab",2016-08-01 05:58:00-04:00,REGN,positive
1075975.0,Watch These 10 Huge Put Purchases In Thursday Trade,2016-07-28 02:41:00-04:00,REGN,positive
1075976.0,Option Alert: REGN Aug16 412.5 Puts: 535 @  ASK  $15.20: 552 traded vs 0 OI:  Earnings 8/4 Before Open  $409.86 Ref,2016-07-27 14:25:00-04:00,REGN,positive
1075977.0,Option Alert: REGN Aug16 410 Puts Sweep: 548 @  ASK  $15.60: 558 traded vs 51 OI:  Earnings 8/4 Before Open  $407.06 Ref,2016-07-27 11:13:00-04:00,REGN,positive
1075978.0,Option Alert: REGN Aug16 340 Puts Sweep: 757 @  ASK  $4.60: 769 traded vs 274 OI:  Earnings 8/4 Before Open  $377.53 Ref,2016-07-18 11:37:00-04:00,REGN,positive
1075979.0,"Regeneron, Sanofi Announce Approval of Praluent for Treatment of Hypercholesterolemia in Japan",2016-07-05 03:54:00-04:00,REGN,positive
1075980.0,Regeneron Is 'One Of The Stronger Growers In Biotech',2016-06-29 15:04:00-04:00,REGN,positive
1075981.0,Bernstein Initiates Coverage on Regeneron Pharmaceuticals at Outperform,2016-06-29 07:42:00-04:00,REGN,neutral
1075982.0,Regeneron CEO And CFO Met With Citi: Here Are The Takeaways,2016-06-23 10:37:00-04:00,REGN,neutral
1075983.0,5 Of The Hottest Stocks To Own During The Summer,2016-06-20 17:07:00-04:00,REGN,neutral
1075984.0,Watch These 5 Huge Put Purchases In Monday Trade,2016-06-20 01:57:00-04:00,REGN,positive
1075985.0,Option Alert: REGN Jul16 345 Puts: 949 @  ASK  $8.70: 1003 traded vs 55 OI:  Earnings 8/2  $360.20 Ref,2016-06-17 10:52:00-04:00,REGN,positive
1075986.0,"Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators",2016-06-13 09:37:00-04:00,REGN,negative
1075987.0,"Vetr Crowd: After A Large Decline, Regeneron Could Surge 15.5%",2016-06-10 13:54:00-04:00,REGN,neutral
1075988.0,Bernstein Lists Active Buyers Of Ophthalmology Companies,2016-06-09 14:12:00-04:00,REGN,positive
1075989.0,Regeneron Vol Spike,2016-06-09 10:22:00-04:00,REGN,neutral
1075990.0,"Regeneron, Sanofi Announce that Dupilumab Used with Topical Corticosteroids was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients",2016-06-06 04:12:00-04:00,REGN,positive
1075991.0,Regeneron Rallies Off Favorable Interim Data From Evinacumab Trial,2016-06-01 12:27:00-04:00,REGN,positive
1075992.0,Regeneron Presents Favorable Interim Data From Stage 2 Proof-Of-Concept Trial Of Evinacumab,2016-05-31 12:01:00-04:00,REGN,positive
1075993.0,Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia,2016-05-31 09:03:00-04:00,REGN,positive
1075994.0,CEOs Vs. Hedge Fund Managers: Who Gets Paid Better?,2016-05-26 10:49:00-04:00,REGN,positive
1075995.0,Has A Biotech Recovery Started Yet?,2016-05-17 17:56:00-04:00,REGN,neutral
1075996.0,10 Stocks Moving In Monday's Pre-Market Session,2016-05-16 08:24:00-04:00,REGN,neutral
1075997.0,"Regeneron +7.3% Premarket; Temasek Increases Stake to 126,351 Shares vs 58,289 Previous",2016-05-16 06:40:00-04:00,REGN,positive
1075998.0,"Barron's Picks And Pans: Regeneron, Axalta, Alleghany And More",2016-05-14 18:24:00-04:00,REGN,neutral
1075999.0,"Regeneron Says They've Signed Deals With Other Payers In Addition To Cigna, To Assess Value Of Its Praluent Cholesterol Drug",2016-05-11 12:40:00-04:00,REGN,positive
1076000.0,Regeneron Gains 4% Following Q1 Earnings Release,2016-05-05 08:53:00-04:00,REGN,positive
1076001.0,12 Stocks Moving In Thursday's Pre-Market Session,2016-05-05 08:23:00-04:00,REGN,neutral
1076002.0,"Regeneron Q1 EPS $2.57 vs $2.58 est, Revenue $1.2B vs $1.2B est",2016-05-05 06:43:00-04:00,REGN,neutral
1076003.0,"Earnings Scheduled For May 5, 2016",2016-05-05 04:36:00-04:00,REGN,neutral
1076004.0,"Chardan Views Regeneron Fasinumab Data As Net Negative, Reiterates Sell",2016-05-02 10:04:00-04:00,REGN,negative
1076005.0,"Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain, Showed Significant Improvement In Primary Endpoint & Improvements In Secondary Endpoint",2016-05-02 07:05:00-04:00,REGN,positive
1076006.0,Wells Fargo Downgrades Regeneron Pharmaceuticals to Market Perform,2016-04-20 07:03:00-04:00,REGN,positive
1076007.0,Regeneron and Intellia Therapeutics Collaborate to Discover and Develop CRISPR/Cas Therapeutics,2016-04-11 16:05:00-04:00,REGN,neutral
1076008.0,"Roth Capital Maintains Buy on Regeneron Pharmaceuticals, Lowers PT to $520.00",2016-04-04 08:17:00-04:00,REGN,negative
1076009.0,"Leerink Swann Maintains Outperform on Regeneron Pharmaceuticals, Raises PT to $523.00",2016-04-04 07:43:00-04:00,REGN,neutral
1076010.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-04-01 16:43:00-04:00,REGN,neutral
1076011.0,Mid-Afternoon Market Update: Crude Oil Down 3.5%; Tesla Shares Rise Following Model 3 Launch,2016-04-01 14:32:00-04:00,REGN,negative
1076012.0,Benzinga's Volume Movers,2016-04-01 10:21:00-04:00,REGN,neutral
1076013.0,10 Stocks Moving In Friday's Pre-Market Session,2016-04-01 08:22:00-04:00,REGN,neutral
1076014.0,Regeneron +4% Premarket @ $376; Co Announced Positive Results from Atopic Dermatitis Trials,2016-04-01 07:29:00-04:00,REGN,positive
1076015.0,"Regeneron, Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients",2016-04-01 04:11:00-04:00,REGN,positive
1076016.0,Worst Stocks Of The First Quarter,2016-03-31 13:27:00-04:00,REGN,negative
1076017.0,Regeneron Reports Joint Development with Bayer for Novel Combo Therapy for Eye Diseases,2016-03-24 08:02:00-04:00,REGN,positive
1076018.0,"Cramer Shares His Thoughts On Lockheed Martin, Celgene And Regeneron",2016-03-23 07:06:00-04:00,REGN,positive
1076019.0,"Regeneron, Sanofi Announce Positive Topline Results from Phase 3 Praluent Study in Patients Undergoing LDL Apheresis Therapy",2016-03-23 04:29:00-04:00,REGN,positive
1076020.0,Why Regeneron's Praluent Is Likely To Be Removed From The U.S. Market This Year,2016-03-21 11:08:00-04:00,REGN,neutral
1076021.0,"The Market In 5 Minutes: Thursday, March 17, 2016",2016-03-17 10:40:00-04:00,REGN,neutral
1076022.0,"Goldman Sachs Considers Implications For Regeneron, Amgen, Sanofi Following PCSK9 Ruling",2016-03-17 07:45:00-04:00,REGN,neutral
1076023.0,Chardan Downgrades Regeneron To Sell,2016-03-16 16:12:00-04:00,REGN,neutral
1076024.0,The Plot Thickens At Amgen; Piper Still Overweight,2016-03-16 15:25:00-04:00,REGN,negative
1076025.0,"Jury In Repatha Patent Case Ruled In Favor Of Amgen, Against Regeneron And Sanofi",2016-03-16 15:05:00-04:00,REGN,positive
1076026.0,UPDATE: Chardan Capital Lowers Regeneron Pharmaceuticals PT to $325.00,2016-03-16 14:52:00-04:00,REGN,negative
1076027.0,Chardan Capital Downgrades Regeneron Pharmaceuticals to Sell,2016-03-16 14:52:00-04:00,REGN,neutral
1076028.0,"Piper Jaffray Says Street Downplaying What Regeneron And Sanofi Owe Amgen, May Be Substantially Higher Than Street Expectations Without Treble Damages or Willful Infringement",2016-03-16 14:26:00-04:00,REGN,negative
1076029.0,Amgen Wins Patent Case On Repatha,2016-03-16 14:03:00-04:00,REGN,positive
1076030.0,"Regeneron Shares Resume Trade, Turn Negative, Now Down ~1%",2016-03-16 13:01:00-04:00,REGN,negative
1076031.0,Amgen's Rally Off Positive Verdict In Patent Case Fades,2016-03-16 12:58:00-04:00,REGN,positive
1076032.0,Regeneron to Resume Trading at 1:00 PM ET,2016-03-16 12:44:00-04:00,REGN,neutral
1076033.0,"UPDATE: Regeneron, Sanofi Say Ongoing Litigation Does Not Impact Praluent Injection",2016-03-16 12:32:00-04:00,REGN,negative
1076034.0,"UPDATE: Regeneron, Sanofi Say Jury Verdict Asserted Claims of Two Amgen Patents for Antibodies Targeting PCSK9 as Valid",2016-03-16 12:31:00-04:00,REGN,positive
1076035.0,"Regeneron, Sanofi Issue Release Saying 'Strongly Disagree' with US Jury Verdict in Ongoing Patent Litigation Related to Praluent, Will Appeal",2016-03-16 12:30:00-04:00,REGN,negative
1076036.0,Jefferies Says SNY/REGN Had A Win Today When Judge Robinson Determined SNY/REGN Praluent Infringes And Ruled Co's Are Liable For Damages And Royalties To AMGN,2016-03-16 12:22:00-04:00,REGN,positive
1076037.0,Hearing Judge in Repatha Case Has Said Issue of Defendants' Alleged Infringement Will Not Be Heard by Jury,2016-03-16 12:19:00-04:00,REGN,negative
1076038.0,"Wild Price Action in Amgen Shares Implies Some Trader Confusion on Report of Ruling in Repatha Patent Case; Stock Spiked to High of $147, Came Back Down to Below $144 Shortly After",2016-03-16 12:13:00-04:00,REGN,neutral
1076039.0,"Hearing Federal Judge Has Issued Ruling Against Amgen, Said Co. Has Not Shown Clear, Convincing Evidence Defendant's Invalidity Defenses Were Objectively Baseless",2016-03-16 12:11:00-04:00,REGN,negative
1076040.0,Spike Higher in Amgen Ahead of Verdict for Repatha Patent Case Likely Indicates Loss for Regeneron,2016-03-16 12:06:00-04:00,REGN,negative
1076041.0,"Adam Feuerstein â@adamfeuerstein  Tweet: Jury ruled in favor of $AMGN, against $REGN $SNY in PCSK9 patent case, according to Mark Schoenebaum.",2016-03-16 12:06:00-04:00,REGN,positive
1076042.0,Amgen Spikes to High of $145.30; Hearing Jury Verdict,2016-03-16 12:02:00-04:00,REGN,positive
1076043.0,Regeneron Shares Halted News Pending,2016-03-16 11:45:00-04:00,REGN,positive
1076044.0,Benzinga's Top Initiations,2016-03-15 09:45:00-04:00,REGN,positive
1076045.0,Gabelli & Co Initiates Coverage on Regeneron Pharmaceuticals at Buy,2016-03-15 07:57:00-04:00,REGN,neutral
1076046.0,UPDATE: Hearing Jefferies Has Highlighted Decision by Judge Moving Forward Jury in Regeneron/Sanofi/Amgen Case Would Not Consider One of Three Defense Arguments Proposed as for Invalidiation,2016-03-14 14:46:00-04:00,REGN,negative
1076047.0,Regeneron Shares Pullback Following Cautious Comments from Jefferies,2016-03-14 14:43:00-04:00,REGN,positive
1076048.0,Regeneron  Says Phase 3 Monotherapy Study Met Primary Endpoint Demonstrating That Sarilumab Was Superior To Adalimumab,2016-03-11 04:27:00-05:00,REGN,positive
1076049.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-09 16:30:00-05:00,REGN,neutral
1076050.0,"Brean Capital Assumes Regeneron Pharmaceuticals at Buy, Announces $489.00 PT",2016-03-08 07:00:00-05:00,REGN,neutral
1076051.0,"Brean Capital Says Regeneron Pharma Robust Pipeline Drives Upside, Calls Out Dupilumab As Next Catalyst",2016-03-08 06:55:00-05:00,REGN,positive
1076052.0,Benzinga's Top Initiations,2016-03-03 10:01:00-05:00,REGN,positive
1076053.0,"SunTrust Robinson Humphrey Initiates Coverage on Regeneron Pharmaceuticals at Neutral, Announces $450.00 PT",2016-03-03 05:50:00-05:00,REGN,neutral
1076054.0,Regeneron Genetics Center Publication in New England Journal of Medicine Links ANGPTL4 Inhibition and Risk of Coronary Artery Disease,2016-03-02 17:00:00-05:00,REGN,negative
1076055.0,"First Solar, GameStop, Chipotle Lead List Of March's Best Performers Over Past Decade",2016-02-29 15:59:00-05:00,REGN,positive
1076056.0,"Citi: Buy Celgene, Gilead, Biogen And Regeneron As Biotechs Recover",2016-02-25 08:51:00-05:00,REGN,neutral
1076057.0,Citigroup Initiates Coverage on Regeneron Pharmaceuticals at Buy,2016-02-25 06:49:00-05:00,REGN,neutral
1076058.0,"Prospect Capital, Regeneron Lead List Of Key Insider Trades",2016-02-22 16:57:00-05:00,REGN,positive
1076059.0,Benzinga's Top Upgrades,2016-02-16 08:57:00-05:00,REGN,positive
1076060.0,Chardan Upgrades Regeneron Amid Relative Underperformance To Amgen Shares,2016-02-16 08:33:00-05:00,REGN,positive
1076061.0,"RBC Capital Positive On Regeneron, Expects Share Price Appreciation, Says Atopic Dermatitis Is Blockbuster Indication",2016-02-16 08:19:00-05:00,REGN,positive
1076062.0,Chardan Remains Cautious On REGN In Midst Of Upgrade,2016-02-16 06:11:00-05:00,REGN,negative
1076063.0,"Chardan Capital Upgrades Regeneron Pharmaceuticals to Neutral, Lowers PT to $375.00",2016-02-16 03:57:00-05:00,REGN,negative
1076064.0,Chardan: Sell Regeneron After Sanofi Drops Patent Infringement Bombshell,2016-02-10 09:30:00-05:00,REGN,negative
1076065.0,"JP Morgan Maintains Neutral on Regeneron Pharmaceuticals, Lowers PT to $477.00",2016-02-10 07:28:00-05:00,REGN,positive
1076066.0,Chardan Believes Sanofi/Regeneron Invalidation Of Amgen Patents In Entirety Is Unlikely,2016-02-10 07:21:00-05:00,REGN,neutral
1076067.0,"Morgan Stanley Maintains Equal-weight on Regeneron Pharmaceuticals, Lowers PT to $436.00, Says Dupilumab PhIII Is Next Major Catalyst",2016-02-10 07:12:00-05:00,REGN,negative
1076068.0,"UBS Maintains Buy on Regeneron Pharmaceuticals, Lowers PT to $575.00",2016-02-10 06:36:00-05:00,REGN,negative
1076069.0,"Brean Capital Maintains Buy on Regeneron Pharmaceuticals, Lowers PT to $489.00",2016-02-10 05:25:00-05:00,REGN,negative
1076070.0,"Barclays Maintains Equal-weight on Regeneron Pharmaceuticals, Lowers PT to $425.00",2016-02-10 03:45:00-05:00,REGN,negative
1076071.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-02-09 08:19:00-05:00,REGN,neutral
1076072.0,Regeneron Pharmaceuticals Loses 7% Following Q4 Miss,2016-02-09 08:18:00-05:00,REGN,negative
1076073.0,"Regeneron Q4 EPS $2.83 vs $3.36 est, Revenue $1.16B vs $1.17B est",2016-02-09 06:33:00-05:00,REGN,neutral
1076074.0,"Earnings Scheduled For February 9, 2016",2016-02-09 04:06:00-05:00,REGN,neutral
1076075.0,Leerink Is Back On Board The Biotech Train,2016-02-05 10:32:00-05:00,REGN,neutral
1076076.0,Leerink Swann Initiates Coverage on Regeneron Pharmaceuticals at Outperform,2016-02-05 04:08:00-05:00,REGN,neutral
1076077.0,Canaccord Genuity Downgrades Regeneron Pharmaceuticals to Hold,2016-01-27 07:09:00-05:00,REGN,neutral
1076078.0,Here Are The Most Notable Insider Transactions Hitting The Market,2016-01-26 13:19:00-05:00,REGN,neutral
1076079.0,Benzinga's Top Downgrades,2016-01-25 09:30:00-05:00,REGN,positive
1076080.0,Regeneron Is Now A Sell For Chardan,2016-01-25 08:40:00-05:00,REGN,neutral
1076081.0,"Chardan Capital Downgrades REGN To Sell On Infringement Evidence Related To AMGN's PCSK9 Patentts, Expects Market To Increase Focus on 'Praluent' Patent As Driver Of Share Price",2016-01-25 05:52:00-05:00,REGN,positive
1076082.0,"Chardan Capital Downgrades Regeneron Pharmaceuticals to Sell, Lowers PT to $400.00",2016-01-25 05:50:00-05:00,REGN,negative
1076083.0,Looking To Healthcare ETFs For Earnings Growth,2016-01-21 11:34:00-05:00,REGN,positive
1076084.0,Credit Suisse Bullish On Most Big Pharma Names,2016-01-20 10:34:00-05:00,REGN,positive
1076085.0,"Credit Suisse Initiates REGN At Neutral, Positive On Co's Platform, Shares 'look fairly valued'",2016-01-20 05:40:00-05:00,REGN,positive
1076086.0,"Credit Suisse Initiates Coverage on Regeneron Pharmaceuticals at Neutral, Announces $552.00 PT",2016-01-19 16:17:00-05:00,REGN,positive
1076087.0,Roth Capital Upgrades Regeneron Pharmaceuticals to Buy,2016-01-19 07:46:00-05:00,REGN,neutral
1076088.0,Regeneron Pharma Full Year Eylea Sales over $4B,2016-01-12 06:32:00-05:00,REGN,neutral
1076089.0,"Regeneron, Sanofi Announce FDA Has Accepted For Review BLA For Sarilumab",2016-01-08 10:36:00-05:00,REGN,positive
1076090.0,U.S. Stock Futures Surge After Jobs Data; El-Erian To Discuss Economic Situation,2016-01-08 08:50:00-05:00,REGN,neutral
1076091.0,"Regeneron, Sanofi Announce Sarilumab Biologics License Application Accepted for Review FDA",2016-01-08 04:01:00-05:00,REGN,positive
1076092.0,BTIG Research Initiates Coverage on Regeneron Pharmaceuticals at Neutral,2016-01-07 18:37:00-05:00,REGN,neutral
1076093.0,Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016,2015-12-18 10:52:00-05:00,REGN,neutral
1076094.0,"Regeneron, Sanofi Announce UnitedHealth Group to Provide Preferred Access Praluent Injection",2015-12-11 04:13:00-05:00,REGN,neutral
1076095.0,Wells Fargo Initiates Coverage on Regeneron Pharmaceuticals at Outperform,2015-12-04 07:56:00-05:00,REGN,positive
1076096.0,"Regeneron, Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent Injection Fully Enrolled",2015-11-24 04:21:00-05:00,REGN,neutral
1076097.0,5 Biotechs That Can Win From Ophthalmology Innovation,2015-11-16 13:21:00-05:00,REGN,positive
1076098.0,US Stock Futures Gain Ahead Of Macy's Earnings,2015-11-11 07:55:00-05:00,REGN,positive
1076099.0,"Regeneron, Sanofi Present Positive Results from Pivotal Phase 3 Study of Sarilumab at ACR Annual Meeting",2015-11-08 08:29:00-05:00,REGN,positive
1076100.0,Portfolio Armor's Current Number One Stock: Activision Blizzard,2015-11-06 15:12:00-05:00,REGN,positive
1076101.0,"Sanofi, Regeneron Report Will Present Results from Phase 3 Trials at AHA Sessions '15",2015-11-05 08:07:00-05:00,REGN,neutral
1076102.0,"From Conf Call: Regeneron Q4 US Eylea Sales Might Be Negatively Impacted by Changes in Inventory Levels, Holidays, Possible Bad Weather",2015-11-04 08:58:00-05:00,REGN,negative
1076103.0,From Conf Call: Regeneron Pharmaceuticals Sees Continued Strong Physician Demand For Eylea -Reuters,2015-11-04 08:52:00-05:00,REGN,positive
1076104.0,"Regeneron Pharma Reports Q3 EPS $3.47 Vs Est $3.20, Sales $1.14B Vs Est $1.05B",2015-11-04 06:31:00-05:00,REGN,neutral
1076105.0,"Earnings Scheduled For November 4, 2015",2015-11-04 04:03:00-05:00,REGN,neutral
1076106.0,NY Judge Rules Against Regeneron In Patent Case With Merus,2015-11-02 16:54:00-05:00,REGN,neutral
1076107.0,Regeneron Announces EU Approval of EYLEAÂ® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization,2015-10-30 09:00:00-04:00,REGN,positive
1076108.0,Armored Portfolios: The Hedged Portfolio Method,2015-10-27 13:34:00-04:00,REGN,neutral
1076109.0,Cowen: In Biotech Earnings We Trust,2015-10-19 10:02:00-04:00,REGN,positive
1076110.0,Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives,2015-10-12 09:56:00-04:00,REGN,neutral
1076111.0,"Regeneron Trading Up To $517/Share Up 2.6% Premarket On Eli Lilly Evacetraqib Development Discontinuation, Watch Regenron Partner Sanofi",2015-10-12 08:26:00-04:00,REGN,neutral
1076112.0,Regeneron Downgraded At Morgan Stanley; Better Biotech Peer Plays Elsewhere,2015-10-02 10:24:00-04:00,REGN,positive
1076113.0,Morgan Stanley Downgrades Regeneron Pharmaceuticals to Equal-weight,2015-10-02 08:58:00-04:00,REGN,neutral
1076114.0,Regeneron Reports Partnership with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia; Regeneron To Receive $55M Up Front,2015-10-01 16:06:00-04:00,REGN,negative
1076115.0,"Regeneron, Sanofi Announce Approval of Praluent for Treatment of Hypercholesterolemia in EU",2015-09-28 05:20:00-04:00,REGN,positive
1076116.0,Regeneron and Icahn School of Medicine at Mount Sinai Announce New Antibody Research Agreement,2015-09-24 08:38:00-04:00,REGN,positive
1076117.0,"Regeneron, BARDA Agree To Development Of New Antibody Treatment For Ebola",2015-09-21 08:03:00-04:00,REGN,positive
1076118.0,Regeneron Pharmaceuticals Reboots After UBS Upgrade,2015-09-08 14:37:00-04:00,REGN,neutral
1076119.0,UBS Upgrades Regeneron Pharmaceuticals to Buy,2015-09-07 22:14:00-04:00,REGN,neutral
1076120.0,Regeneron and Sanofi Report New Positive Praluent Phase 3 Data Presented at ESC Congress 2015,2015-09-01 09:01:00-04:00,REGN,positive
1076121.0,"Chardan Downgrades Regeneron Pharmaceuticals, Notes Valuation Concerns",2015-08-31 13:31:00-04:00,REGN,neutral
1076122.0,Benzinga's Top Downgrades,2015-08-31 11:03:00-04:00,REGN,positive
1076123.0,"Chardan Capital Downgrades Regeneron Pharmaceuticals to Neutral, Maintains $565.00 PT",2015-08-31 08:07:00-04:00,REGN,neutral
1076124.0,"In new note to subscribers, CMT Christian Tharp making bet that 15-20% correction is coming",2015-08-21 15:39:00-04:00,REGN,neutral
1076125.0,"The Other Bearish Biotech ETF Is Looking Groovy, Too",2015-08-21 15:24:00-04:00,REGN,neutral
1076126.0,What Are Payors Saying About Managed Care Giants?,2015-08-13 09:31:00-04:00,REGN,positive
1076127.0,The Historical Correlation Between Biotech Stocks And Interest Rates,2015-08-07 14:39:00-04:00,REGN,positive
1076128.0,"Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Raises T to $593.00",2015-08-04 17:27:00-04:00,REGN,negative
1076129.0,"Brean Capital Maintains Buy on Regeneron Pharmaceuticals, Raises PT to $659.00",2015-08-04 15:48:00-04:00,REGN,neutral
1076130.0,Evercore Breaks Down Regeneron's Q2 Report,2015-08-04 15:03:00-04:00,REGN,neutral
1076131.0,Stocks Hitting 52-Week Highs,2015-08-04 10:14:00-04:00,REGN,neutral
1076132.0,Morning Market Gainers,2015-08-04 09:45:00-04:00,REGN,neutral
1076133.0,From Conf Call: Regeneron Sasy Bulk of Eyelea Growth Coming from DME,2015-08-04 09:06:00-04:00,REGN,positive
1076134.0,Benzinga's Top #PreMarket Gainers,2015-08-04 08:08:00-04:00,REGN,positive
1076135.0,"Regeneron Tops Q2 Estimates, Shares Surge",2015-08-04 08:00:00-04:00,REGN,positive
1076136.0,"Regeneron +4% Premarket on Solid Earnings Beat, Upbeat Guidance",2015-08-04 07:26:00-04:00,REGN,positive
1076137.0,Regeneron Raises FY15 EYLEA Sales Growth Outlook from 30-35% Previously to 45-50% YoY,2015-08-04 06:33:00-04:00,REGN,positive
1076138.0,"Regeneron Reports Q2 Adj. EPS $2.89 vs $2.77 Est., Sales $999M vs $887.8M Est.",2015-08-04 06:32:00-04:00,REGN,neutral
1076139.0,"Earnings Scheduled For August 4, 2015",2015-08-04 05:05:00-04:00,REGN,neutral
1076140.0,5 Biotechs With Catalysts Coming This Week,2015-08-03 16:59:00-04:00,REGN,neutral
1076141.0,Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?,2015-07-28 13:57:00-04:00,REGN,positive
1076142.0,US Stock Futures Surge Ahead Of Fed Meeting,2015-07-28 07:02:00-04:00,REGN,neutral
1076143.0,"Regeneron, Sanofi Announce Immuno-Oncology Collaboration",2015-07-28 04:39:00-04:00,REGN,neutral
1076144.0,Regeneron Pharmaceuticals CEO Boasts Recently Approved Cholesterol-Lowering Drug,2015-07-27 16:55:00-04:00,REGN,positive
1076145.0,Regeneron Shares Spiking Lower Following Volatile Trades,2015-07-24 15:42:00-04:00,REGN,neutral
1076147.0,Regeneron Sanofi Release Confirms Approval Of Praluent,2015-07-24 15:19:00-04:00,REGN,positive
1076148.0,Regeneron Halted Pending News,2015-07-24 14:05:00-04:00,REGN,neutral
1076149.0,"Regeneron, Sanofi Announce CHMP Recommends European Approval of Praluent (alirocumab) for the Treatment of Hypercholesterolemia",2015-07-24 07:15:00-04:00,REGN,positive
1076150.0,Benzinga's Top Downgrades,2015-07-09 09:26:00-04:00,REGN,positive
1076151.0,"UBS 'Looking Elsewhere,' Says To Sell Regeneron",2015-07-09 08:55:00-04:00,REGN,neutral
1076152.0,UBS Downgrades Regeneron Pharmaceuticals to Sell,2015-07-09 06:48:00-04:00,REGN,neutral
1076153.0,Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication,2015-06-29 15:07:00-04:00,REGN,neutral
1076154.0,Regeneron Announces EYLEA Injection Approved in Japan for the Treatment of Retinal Vein Occlusion,2015-06-26 04:13:00-04:00,REGN,positive
1076155.0,"Jim Cramer Advises His Viewers On GlaxoSmithKline, American International Group, Caesars And Caesars Acquisition",2015-06-18 07:12:00-04:00,REGN,neutral
1076156.0,The Note Moving Pharma Giants Today,2015-06-17 16:06:00-04:00,REGN,neutral
1076157.0,"Avalanche Biotechnologies Buried By Disappointing Data, Downgrades",2015-06-16 14:35:00-04:00,REGN,negative
1076158.0,"Avalanche Bio Downgraded At William Blair, Firm Says Phase IIb 'A Ways Away'",2015-06-16 07:10:00-04:00,REGN,neutral
1076159.0,JMP Sees A 'Negative Market Tone' In Biotechnology,2015-06-15 13:31:00-04:00,REGN,negative
1076160.0,Why Avalanche Biotechnologies Is Coming Off A Big Day,2015-06-11 09:10:00-04:00,REGN,neutral
1076161.0,Mid-Day Market Update: Sigma Designs Surges On Upbeat Results; Boulder Brands Shares Drop,2015-06-10 13:05:00-04:00,REGN,neutral
1076162.0,Selling The News In Regeneron,2015-06-10 11:59:00-04:00,REGN,neutral
1076163.0,"FDA Panel Clears Product Path For Sanofi, Regeneron Pharmaceuticals",2015-06-10 10:52:00-04:00,REGN,positive
1076164.0,Mid-Morning Market Update: Markets Open Higher; Oxford Industries Beats Q1 Expectations,2015-06-10 10:09:00-04:00,REGN,neutral
1076165.0,Morning Market Losers,2015-06-10 09:45:00-04:00,REGN,negative
1076166.0,Benzinga's Top #PreMarket Losers,2015-06-10 08:17:00-04:00,REGN,negative
1076167.0,Regeneron Shares Now Down 13 After-Hours Following Resumption of Trade; FDA Panel Recommended Approval of Praluent,2015-06-09 19:10:00-04:00,REGN,positive
1076168.0,"FDA Advisory Panel Recommends Approval of Regeneron, Sanofi's Praluent",2015-06-09 16:52:00-04:00,REGN,positive
1076169.0,"Regeneron Gives Statement on Stock Halt, Cites FDA Meeting For Praluent Today",2015-06-09 07:08:00-04:00,REGN,neutral
1076170.0,"Shares of Regeneron Halted, News Pending",2015-06-09 06:57:00-04:00,REGN,positive
1076171.0,Stocks Hitting 52-Week Highs,2015-06-05 10:05:00-04:00,REGN,neutral
1076172.0,"Regeneron, Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with RA",2015-05-21 04:36:00-04:00,REGN,positive
1076173.0,Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma,2015-05-18 12:31:00-04:00,REGN,positive
1076174.0,Credit Suisse: Regeneron Now Worth $550/Share,2015-05-15 13:12:00-04:00,REGN,positive
1076175.0,"Regeneron Q1 EPS $2.88 vs $2.68 est, Revenue $870M vs $825M est",2015-05-07 06:32:00-04:00,REGN,neutral
1076176.0,"Earnings Scheduled For May 7, 2015",2015-05-07 04:41:00-04:00,REGN,neutral
1076177.0,Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks,2015-05-06 17:41:00-04:00,REGN,positive
1076178.0,"Regeneron Earnings: Small Growth Expected, Driven By Eylea",2015-05-06 17:30:00-04:00,REGN,positive
1076179.0,"Credit Suisse Assumes Regeneron Pharmaceuticals at Outperform, Announces $400.00 PT",2015-05-05 17:06:00-04:00,REGN,positive
1076180.0,Regeneron Bounces Higher Off Support,2015-04-22 11:10:00-04:00,REGN,positive
1076181.0,Biotech Bubble Valuations From Sam Islay,2015-04-02 07:13:00-04:00,REGN,neutral
1076182.0,Is It Closing Time At The Biotech Bar?,2015-03-26 13:45:00-04:00,REGN,neutral
1076183.0,UPDATE: Regeneron's EYLEA Receives FDA Approval,2015-03-25 11:04:00-04:00,REGN,positive
1076184.0,Hearing FDA Announces Approval of New Treatment for Diabetic Retinopathy by Regeneron's Eylea,2015-03-25 10:35:00-04:00,REGN,positive
1076185.0,Regeneron Pharmaceuticals Enters Into $750M Senior Unsecured Five-Year Revolving Credit Facility,2015-03-23 06:13:00-04:00,REGN,neutral
1076186.0,CVS Says New Cholesterol Drug Types Could Be Costly,2015-03-20 12:58:00-04:00,REGN,negative
1076187.0,"CORRECTION: Chardan Capital Initiates Coverage on Regeneron Pharmaceuticals at Buy, Announces $560.00 PT",2015-03-20 10:15:00-04:00,REGN,neutral
1076188.0,"Sanofi, Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent Published in NEJM",2015-03-15 18:03:00-04:00,REGN,neutral
1076189.0,"Regeneron, Sanofi Announce Positive 18-Month Results of ODYSSEY LONG TERM Trial with Praluent Published in NEJM",2015-03-15 11:03:00-04:00,REGN,positive
1076190.0,Regeneron Says Goldman Sachs to Reduce Remaining Number of Warrants Held by Up to 13%; Regeneron to Pay Up to $24M for Warrants -DJ,2015-03-05 06:29:00-05:00,REGN,neutral
1076191.0,Regeneron Signs Amended Collaboration Agreement with Sanofi-Aventis; Will No Longer Be Required to Reimburse Sanofi for 50% of Development Expenses,2015-02-27 07:13:00-05:00,REGN,positive
1076192.0,UPDATE: Regeneron's EYLEA Injection Receives EU Approval,2015-02-26 08:42:00-05:00,REGN,positive
1076193.0,Regeneron's EYLEA Injection Receives EU Approval,2015-02-26 08:40:00-05:00,REGN,positive
1076194.0,Benzinga's Top Initiations,2015-02-17 09:23:00-05:00,REGN,positive
1076195.0,Bernstein Initiates Regeneron Pharmaceuticals At Outperform,2015-02-17 08:04:00-05:00,REGN,neutral
1076196.0,"Bernstein Initiates Coverage on Regeneron Pharmaceuticals at Outperform, Announces $475.00 PT",2015-02-17 06:28:00-05:00,REGN,neutral
1076197.0,Regeneron's Expanded Pipeline Not A Concern For Morgan Stanley,2015-02-11 10:26:00-05:00,REGN,neutral
1076198.0,Piper Jaffray Downgrades Regeneron Pharmaceuticals to Neutral,2015-02-10 10:54:00-05:00,REGN,neutral
1076199.0,"UPDATE: Regeneron Pharmaceuticals Posts Downbeat Q4 Earnings, But Sales Top Views",2015-02-10 09:24:00-05:00,REGN,positive
1076200.0,"Regeneron Pharma Reports Q4 EPS $2.79 Vs Est $2.82, Sales $802M Vs Est $781.52M",2015-02-10 06:32:00-05:00,REGN,neutral
1076201.0,"Earnings Scheduled For February 10, 2015",2015-02-10 04:42:00-05:00,REGN,neutral
1076202.0,US Stock Futures Signal Lower Start On Wall Street,2015-01-26 07:14:00-05:00,REGN,negative
1076203.0,"Regeneron, Sanofi Announce Praluent Biologics License Application Accepted for Priority Review by FDA",2015-01-26 04:46:00-05:00,REGN,positive
1076204.0,Regeneron Pharmaceuticals' EYLEA Injection Recommended For Approval By CHMP,2015-01-23 07:33:00-05:00,REGN,positive
1076205.0,The 5 Biggest Biotech Stocks,2015-01-20 16:43:00-05:00,REGN,neutral
1076206.0,Notes From The Street: 'FLASHBACK....Oil Going To $200/Barrel',2015-01-13 08:20:00-05:00,REGN,neutral
1076207.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,REGN,neutral
1076208.0,"Regeneron, Sanofi Report Alirocumab Trials Met Primary Efficacy Endpoints",2015-01-09 05:38:00-05:00,REGN,neutral
1076209.0,J.P Morgan Just Chimed In With Ratings On Biotech Stocks,2015-01-06 16:34:00-05:00,REGN,neutral
1076210.0,UPDATE: Barclays Initiates Coverage On Regeneron,2015-01-06 11:28:00-05:00,REGN,neutral
1076211.0,"CORRECTION: Barclays Initiates Coverage on Regeneron at Equal-weight, Announces $450.00 PT",2015-01-06 08:26:00-05:00,REGN,neutral
1076212.0,"Morgan Stanley Issues Wave Of Pharma & Medical Device Upgrades, Downgrades",2015-01-05 15:57:00-05:00,REGN,neutral
1076213.0,Morgan Stanley Upgrades Regeneron Pharmaceuticals to Overweight,2015-01-05 07:57:00-05:00,REGN,negative
1076214.0,3 Biotech ETFs Rally On Merger News,2014-12-08 17:43:00-05:00,REGN,neutral
1076215.0,A Look At 3 Overbought ETFs,2014-12-02 17:34:00-05:00,REGN,neutral
1076216.0,EYLEA Injection Accepted For Priority Review By FDA For Diabetic Retinopathy In Patients With Diabetic Macular Edema,2014-12-01 07:02:00-05:00,REGN,positive
1076217.0,UPDATE: Bank Of America Reiterates On Regeneron Pharmaceuticals Following Several Positive Catalysts,2014-11-21 10:24:00-05:00,REGN,positive
1076218.0,"Bank of America Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to $462.00",2014-11-21 04:18:00-05:00,REGN,neutral
1076219.0,UPDATE: Brean Capital Reiterates On Regeneron Pharmaceuticals On Increased Confidence,2014-11-20 09:08:00-05:00,REGN,positive
1076220.0,"Regeneron, Sanofi Announce Dupilumab Receives FDA Breakthrough Therapy Designation in Atopic Dermatitis",2014-11-20 05:39:00-05:00,REGN,neutral
1076221.0,"Brean Capital Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to $450.00",2014-11-20 05:26:00-05:00,REGN,neutral
1076222.0,Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol,2014-11-19 08:16:00-05:00,REGN,neutral
1076223.0,US Stock Futures Mostly Flat Ahead Of Housing Data,2014-11-18 07:11:00-05:00,REGN,neutral
1076224.0,Regeneron Announces EYLEA Injection Approved for Treatment of DME in Japan,2014-11-18 05:11:00-05:00,REGN,positive
1076225.0,"Argus Research Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to $450.00",2014-11-11 08:27:00-05:00,REGN,neutral
1076226.0,"Regeneron, Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma",2014-11-11 04:59:00-05:00,REGN,positive
1076227.0,Morning Market Losers ,2014-11-04 09:58:00-05:00,REGN,negative
1076228.0,From Regeneron Conf Call: Company Consulting With Government Agencies to See if Antibody Technologies Can Used to Combat Ebola Virus,2014-11-04 08:44:00-05:00,REGN,negative
1076229.0,Benzinga's Top #PreMarket Losers,2014-11-04 08:14:00-05:00,REGN,negative
1076230.0,"Regeneron Pharmaceuticals, Inc. Reports Q3 EPS of $2.52 vs $2.57 Est; Revenue of $726.0M vs $733.04M Est",2014-11-04 06:30:00-05:00,REGN,neutral
1076231.0,"Earnings Scheduled For November 4, 2014",2014-11-04 05:31:00-05:00,REGN,neutral
1076232.0,"UPDATE: Regeneron, Sanofi Report Commencement of Phase 3 Study Of Dupilumab In Patients With AD",2014-10-20 07:06:00-04:00,REGN,neutral
1076233.0,"Regeneron, Sanofi Report Commencement of Phase 3 Study of Dupilumab in Patients with AD",2014-10-20 07:04:00-04:00,REGN,neutral
1076234.0,TGIF As Markets Rally; S&P 500 Posts Longest Weekly Loss Streak Since 2011,2014-10-17 16:43:00-04:00,REGN,positive
1076235.0,Benzinga's Volume Movers,2014-10-17 10:45:00-04:00,REGN,neutral
1076236.0,"Amgen Reports Filing of Suit Against Sanofi, Regeneron for Patent Infrigement, Seeking Injunction Related to PCSK9 Inhibitor",2014-10-17 09:01:00-04:00,REGN,negative
1076237.0,"UPDATE: Regeneron Shows Significant Improvement in BCVA, Primary Endpoint for Both Bevacizumab, Ranibizumab",2014-10-17 07:07:00-04:00,REGN,positive
1076238.0,EYLEA Injection Demonstrates Significantly Greater Gains In Visual Acuity than Both Bevacizumab And Ranibizumab In NIH-Sponsored Diabetic Macular Edema Study,2014-10-17 07:01:00-04:00,REGN,positive
1076239.0,"Regeneron Genetics Center Fully Operational, Announces New Collaborations And Key Appointments ",2014-10-16 08:34:00-04:00,REGN,neutral
1076240.0,Regeneron's EYLEA (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) ,2014-10-06 16:59:00-04:00,REGN,positive
1076241.0,"Guggenheim Securities Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Buy , Announces $432.00 PT",2014-10-02 06:08:00-04:00,REGN,positive
1076242.0,Regeneron Announces EYLEA Injection Approved for Treatment of Patients with Myopic Choroidal Neovascularization in Japan ,2014-09-22 05:08:00-04:00,REGN,positive
1076243.0,UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Inc Following DME Doc Event,2014-09-18 10:51:00-04:00,REGN,neutral
1076244.0,"Deutsche Bank Is Bullish On Gilead Sciences, Inc. And Other Biotech Stocks",2014-09-16 08:19:00-04:00,REGN,neutral
1076245.0,"Regeneron Reports EYLEA Injection Received FDA Breakthrough Therapy Designation, SBLA Expected to Be Submitted by Year End",2014-09-16 07:02:00-04:00,REGN,neutral
1076246.0,"Brean Capital Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to $390.00",2014-09-02 16:11:00-04:00,REGN,neutral
1076247.0,UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Ahead Of Conference Call,2014-09-02 09:36:00-04:00,REGN,neutral
1076248.0,"Regeneron, Sanofi Announce Four Pivotal Alirocumab Trials All Met Primary Efficacy Eendpoint",2014-08-31 08:01:00-04:00,REGN,neutral
1076249.0,Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments,2014-08-11 16:46:00-04:00,REGN,positive
1076250.0,Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower,2014-08-05 16:46:00-04:00,REGN,negative
1076251.0,Deutsche Bank Raises Regeneron's Price Target To $425,2014-08-05 15:30:00-04:00,REGN,neutral
1076252.0,"Deutsche Bank Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to $425.00",2014-08-05 12:24:00-04:00,REGN,neutral
1076253.0,UPDATE: Regeneron Posts Upbeat Q2 Results,2014-08-05 07:03:00-04:00,REGN,neutral
1076254.0,"Regeneron Pharmaceuticals, Inc. Reports Q2 EPS of $2.47 vs $2.28 Est; Revenue of $666.0M vs $647.61M Est",2014-08-05 06:31:00-04:00,REGN,neutral
1076255.0,"Earnings Scheduled For August 5, 2014 ",2014-08-05 05:34:00-04:00,REGN,neutral
1076256.0,"Amended 13D Filing from Sanofi on Regeneron Shows Co. Has Confirmed 22.5% Stake in REGN as of Jul. 30th, Planning to Buy 30% Stake This Year and Next",2014-07-31 17:18:00-04:00,REGN,neutral
1076257.0,Regeneron And Sanofi To Use Priority Review Voucher For FDA Submission,2014-07-30 16:02:00-04:00,REGN,neutral
1076258.0,Regenero and Sanofi Announces Positive Top Line Results For Alirocumab Phase 3 Trials,2014-07-30 08:05:00-04:00,REGN,positive
1076259.0,Sanofi And Regeneron Report Positive Top-Line Results From Nine Phase 3 Trials Of Alirocumab In People With Hypercholesterolemia,2014-07-30 08:03:00-04:00,REGN,positive
1076260.0,UPDATE: Regeneron Shares Now at $316 After-Hours Following FDA Approval of Eylea Injection for DME,2014-07-29 19:02:00-04:00,REGN,positive
1076261.0,Regeneron Resumes Trading,2014-07-29 19:00:00-04:00,REGN,neutral
1076262.0,PREVIEW: Regeneron to Resume Trading at 7:00 PM ET,2014-07-29 18:38:00-04:00,REGN,neutral
1076263.0,Regeneron Announces EYLEA Injection Has Received FDA Approval for Treatment of DME,2014-07-29 18:33:00-04:00,REGN,positive
1076264.0,Shares of Regeneron Pharma Halted News Pending,2014-07-29 17:40:00-04:00,REGN,positive
1076265.0,"Argus Research Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Buy",2014-07-21 08:38:00-04:00,REGN,neutral
1076266.0,Regeneron Announces Two-Year Results from Phase 3 VIVID-DME Trial Of EYLEA Injection for Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision,2014-07-18 06:02:00-04:00,REGN,positive
1076267.0,UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following Good Results Of Drug Study,2014-07-10 10:03:00-04:00,REGN,positive
1076268.0,Benzinga's Top #PreMarket Gainers,2014-07-10 08:09:00-04:00,REGN,positive
1076269.0,"UPDATE: Regeneron, Sanofi Offer Positive Results from Phase 2b Study of Dupilum, All Doses Met Primary Endpoint",2014-07-09 17:02:00-04:00,REGN,positive
1076270.0,"Regeneron, Sanofi Offer Positive Results from Phase 2b Study of Dupilum, All Doses Met Primary Endpoint",2014-07-09 17:00:00-04:00,REGN,positive
1076271.0,"Regeneron Pharmaceuticals Shareholder Sanofi Buys 356,700 Shares @$312.37/Share -Form 4",2014-07-08 17:45:00-04:00,REGN,positive
1076272.0,Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector,2014-07-03 12:26:00-04:00,REGN,neutral
1076273.0,Amended 13D from Sanofi on Regeneron Pharma Shows Firm to Raise Ownership Stake from 20.44% as of May 19th to 22.5%,2014-07-01 07:59:00-04:00,REGN,neutral
1076274.0,US Stock Futures Drop Ahead Of Consumer Sentiment Report,2014-06-27 07:41:00-04:00,REGN,negative
1076275.0,EYLEA Injection Recommended For Approval Regarding Treatment Of Visual Impairment Due To Diabetic Macular Edema In The European Union,2014-06-27 07:18:00-04:00,REGN,positive
1076276.0,Regeneron Shares Fall Following BMO's Note Of Roche Preference,2014-06-20 12:14:00-04:00,REGN,positive
1076277.0,"Watch Shares of Regeneron Right Now as CNBC Just Highlighted Earlier Negative Note from BMO, Suggested Eylea Patients Switching to Avastin",2014-06-20 11:15:00-04:00,REGN,negative
1076278.0,Judge Denies Merus BV's Motion to Dismiss Regeneron's Patent Infringement Suit -Reuters,2014-06-19 10:09:00-04:00,REGN,negative
1076279.0,"US Stock Futures Edge Higher Ahead Of Jobless Claims, Retail Sales Data",2014-06-12 07:28:00-04:00,REGN,neutral
1076280.0,Sanofi and Regeneron Announce Sarilumab Met All Three Co-Primary Endpoints,2014-06-12 05:44:00-04:00,REGN,neutral
1076281.0,US Stock Futures Tumble; World Bank Lowers Global Growth Outlook,2014-06-11 07:31:00-04:00,REGN,positive
1076282.0,EYLEA Injection Submitted for EU Marketing Authorization for Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion,2014-06-11 05:26:00-04:00,REGN,neutral
1076283.0,"Surges In Biotech Short Interest (INCY, PCYC, REGN)",2014-05-11 16:35:00-04:00,REGN,positive
1076284.0,Regeneron Pharmaceuticals Reports Q1 Adjusted EPS of $2.26 vs $2.20 Est; Revenue of $625.70M vs $609.04M Est,2014-05-08 06:32:00-04:00,REGN,neutral
1076285.0,"Regeneron, Avalanche Announces Development Deal for Gene Therapy for Ophthalmology, Avalanche Will Get Upfront Payment, Contingent Payments of Up to $640M",2014-05-05 08:30:00-04:00,REGN,neutral
1076286.0,RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis,2014-04-24 16:31:00-04:00,REGN,neutral
1076287.0,Market Wrap For April 16: Markets Hold On To Gains On Positive Yellen Comments And Economic Data,2014-04-16 16:50:00-04:00,REGN,positive
1076288.0,UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals on Expected Continued Pipeline Success,2014-04-16 10:00:00-04:00,REGN,positive
1076289.0,Benzinga's Top Initiations,2014-04-16 08:21:00-04:00,REGN,positive
1076290.0,"Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Buy, Announces $350.00 PT",2014-04-16 08:12:00-04:00,REGN,neutral
1076291.0,Top 40 Upcoming Earnings Releases  ,2014-04-11 16:08:00-04:00,REGN,positive
1076292.0,Biotechs Struggling To Find A Bottom,2014-04-08 10:24:00-04:00,REGN,negative
1076293.0,Regeneron Names Robert Ingram to Board,2014-04-04 16:00:00-04:00,REGN,neutral
1076294.0,Regeneron Announces Initiative for STEM Education in Hudson Valley,2014-04-03 16:00:00-04:00,REGN,neutral
1076295.0,"Sanofi, Regeneron Announce Primary Endpoint in Phase 2 Japanese Study of Alirocumab Met, PCSK0 Significantly Reduced LDL-C",2014-04-01 08:08:00-04:00,REGN,neutral
1076296.0,Regeneron Shares Flirting with Session Highs as Roth Boosts Price Target from $362 to $382,2014-03-31 13:49:00-04:00,REGN,positive
1076297.0,Market Wrap For March 27: Markets Lower Following Mixed Economic Data,2014-03-27 17:39:00-04:00,REGN,negative
1076298.0,Morgan Stanley's Top Biotech Pick is Biogen,2014-03-27 15:57:00-04:00,REGN,positive
1076299.0,"US Stock Futures Rise; GDP, Jobless Claims Data In Focus",2014-03-27 07:33:00-04:00,REGN,neutral
1076300.0,"Morgan Stanley Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Equal-weight, Announces $320.00 PT",2014-03-27 07:04:00-04:00,REGN,neutral
1076301.0,"Sanofi, Regeneron to Present Alirocumab Clinical Data at ACCs 63rd Annual Scientific Session ",2014-03-27 05:40:00-04:00,REGN,neutral
1076302.0,UPDATE: Citigroup Upgrades Regeneron Pharmaceuticals,2014-03-17 10:02:00-04:00,REGN,neutral
1076303.0,"Citigroup Upgrades Regeneron Pharmaceuticals, Inc. to Buy",2014-03-17 07:51:00-04:00,REGN,neutral
1076304.0,"UPDATE: Sanofi and Regeneron Unaware of Neurocognitive Adverse Event Signal Related to Alirocumab, Sanofi Says",2014-03-07 15:02:00-05:00,REGN,negative
1076305.0,Regeneron 10-K Filing from February 13 Mentions Adverse Events Related to PCSK9,2014-03-07 13:26:00-05:00,REGN,negative
1076306.0,Adam Feuerstein Tweet: '$REGN 10-K filed Feb. 13 contains exact same language used by $SNY in 20-F. No one seemed to notice.',2014-03-07 13:21:00-05:00,REGN,negative
1076307.0,"Regeneron Shares Resume, Now Down ~8.5%",2014-03-07 13:09:00-05:00,REGN,positive
1076308.0,UPDATE: Sanofi's 20-F Filing Was Out Just After 11AM EST,2014-03-07 13:07:00-05:00,REGN,neutral
1076309.0,"UPDATE: Bloomberg Reporting on Adverse Events Related to PCSK9, Says News Was Out in Sanofi's Form 20-F Filing Earlier",2014-03-07 13:06:00-05:00,REGN,negative
1076310.0,Downside in Regeneron Could Related to FDA Advisory on Adverse Events Related to PCSK9,2014-03-07 13:05:00-05:00,REGN,negative
1076311.0,"Regeneron Pharma Shares Halted on Ciruit Breaker, Now Down 10%",2014-03-07 13:04:00-05:00,REGN,positive
1076312.0,"Bayer, Regeneron Announce Regulatory Submission of EYLEA Injection for Treatment of DME in Japan ",2014-03-03 05:44:00-05:00,REGN,neutral
1076313.0,"UDPATE: Cramer's Momentum Monster Stocks: Priceline, Regeneron, Solar City, Stratasys, Tesla, Twitter, Under Armour, Workday, Yelp",2014-02-24 18:33:00-05:00,REGN,neutral
1076314.0,UPDATE: Regeneron Announces FDA Acceptance of EYLEAÂ® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion,2014-02-24 07:32:00-05:00,REGN,positive
1076315.0,Regeneron Reports FDA Acceptance of EYLEA,2014-02-24 07:31:00-05:00,REGN,positive
1076316.0,"Oppenheimer Downgrades Regeneron Pharmaceuticals, Inc. to Market Perform, Raises PT to $325.00",2014-02-13 08:51:00-05:00,REGN,neutral
1076317.0,"Bank of America Reinstates Buy on Regeneron Pharmaceuticals, Inc., Announces $387.00 PT",2014-02-12 07:17:00-05:00,REGN,neutral
1076318.0,Market Wrap For February 11: Yellen Re-assures Markets & Wakes Up The Sleeping Bulls,2014-02-11 16:47:00-05:00,REGN,neutral
1076319.0,Regeneron Pharmaceuticals Continue Higher Following a Mid-Day Report from Deutsche Bank,2014-02-11 16:24:00-05:00,REGN,neutral
1076320.0,"UPDATE: Deutsche Bank on Regeneron Said Key Takeaway from Q4 Call Was 'Tax Benefit from Ireland Manufacturing, Moving IPs for Antibodies Which Could Lower Tax Rate Starting 2017'",2014-02-11 14:26:00-05:00,REGN,positive
1076321.0,Deutsche Bank Lifts Target on Regeneron to New Street High of $410,2014-02-11 14:24:00-05:00,REGN,neutral
1076322.0,Top Trending Tickers On StockTwits For February 11,2014-02-11 11:10:00-05:00,REGN,positive
1076323.0,"Regeneron Said Expecting FY14 Eylea US Net Sales $1.7-1.8B, Capex $350-425M",2014-02-11 06:47:00-05:00,REGN,neutral
1076324.0,Regeneron Pharmaceuticals Reports Q4 Adjusted EPS of $2.24 vs $0.98 Est; Revenue of $610.0M vs $580.47M Est,2014-02-11 06:38:00-05:00,REGN,neutral
1076325.0,"Earnings Scheduled For February 11, 2014",2014-02-11 04:34:00-05:00,REGN,neutral
1076326.0,"UPDATE: Regeneron Reports Two-Year Results from Phase 3 VISTA Trail of Eylea, Says Showed Sustained Improvement in Vision",2014-02-10 07:36:00-05:00,REGN,positive
1076327.0,"Regeneron Reports Two-Year Results from Phase 3 VISTA Trail of Eylea, Says Showed Sustained Improvement in Vision",2014-02-10 07:31:00-05:00,REGN,positive
1076328.0,UPDATE: SEC Filing from Regeneron Shows Bayer Prohibited from Purchase 20+% Stake,2014-01-16 15:41:00-05:00,REGN,neutral
1076329.0,Form 8-K from Regeneron Pharma Shows Co. Says Bayer Agreed to a Standstill,2014-01-16 15:39:00-05:00,REGN,positive
1076330.0,Benzinga's Top Downgrades,2014-01-15 08:00:00-05:00,REGN,positive
1076331.0,"BMO Capital Downgrades Regeneron Pharmaceuticals, Inc. to Market Perform, Maintains $331.00 PT",2014-01-15 07:22:00-05:00,REGN,neutral
1076332.0,Regeneron Pharmaceuticals CEO Schleifer: 'We have a Great Relationship with Sanofi',2014-01-14 18:20:00-05:00,REGN,positive
1076333.0,Regeneron Pharmaceuticals CEO Schleifer: 'The Data from the Phase 3 Trial of Our Cholesterol Drug has been Positive So Far',2014-01-14 18:19:00-05:00,REGN,positive
1076334.0,Regeneron Pharmaceuticals CEO Schleifer: 'There has been an Epidemic of Allergic Diseases',2014-01-14 18:18:00-05:00,REGN,negative
1076335.0,Regeneron Pharmaceuticals CEO Schleifer: 'We Think Eylea has Opportunity to Grow',2014-01-14 18:17:00-05:00,REGN,positive
1076336.0,Jim Cramer Interviews CEO Dr. Leonard S. Schleifer of Regeneron Pharmaceuticals on Mad Money,2014-01-14 18:16:00-05:00,REGN,negative
1076337.0,"From Regeneron Presentation at JP Morgan Healthcare Conference: Reports Prelim. US Eylea Sales ~$400M, Sees FY14 Capital Spending $350-425M",2014-01-14 10:33:00-05:00,REGN,positive
1076338.0,UPDATE: Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration; Bayer Retains Exclusive Commercialization Rights Outisde US; Regeneron Retains Full US Rights,2014-01-13 16:11:00-05:00,REGN,positive
1076339.0,"Regeneron, Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration",2014-01-13 16:11:00-05:00,REGN,neutral
1076340.0,"Regeneron, Bayer Will Develop New Treatment Option for WetAMD, Regeneron Will Get Upfront Payment of $25.5M",2014-01-13 16:08:00-05:00,REGN,neutral
1076341.0,"Regeneron Announces FDA Acceptance of Eylea SBLA to Treat DME, Sets PDUFA Date as Aug. 18th, 2014",2013-12-18 07:34:00-05:00,REGN,positive
1076342.0,UPDATE: Piper Jaffray Initiates Coverage on Regeneron Pharmaceuticals as 2014 Biotech Sector Outlook Remains Strong,2013-11-27 11:30:00-05:00,REGN,positive
1076343.0,US Stock Futures Flat After Record Close,2013-11-22 07:09:00-05:00,REGN,neutral
1076344.0,EYLEA Injection Approved for Treatment of Macular Edema Following CRVO In Japan ,2013-11-22 05:53:00-05:00,REGN,positive
1076345.0,"Sanofi, Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial ",2013-11-22 01:13:00-05:00,REGN,positive
1076346.0,Downside Protection For Regeneron Pharmaceuticals,2013-11-15 13:34:00-05:00,REGN,negative
1076347.0,Downside Protection For Regeneron Pharmaceuticals,2013-11-15 13:34:00-05:00,REGN,negative
1076348.0,FDA Says Outcomes Trials Are Not Needed for PCSK9 Approval,2013-11-14 15:43:00-05:00,REGN,positive
1076349.0,Gilead Sciences Leads In Rising Short Interest Among Biotechs ,2013-11-12 16:41:00-05:00,REGN,positive
1076350.0,Regeneron CEO Schleifer: 'We are Getting Close to a Treatment for Allergic Diseases',2013-11-05 18:30:00-05:00,REGN,negative
1076351.0,Regeneron CEO Schleifer: 'There are Still Opportunities for Us to Grow Eylea in US',2013-11-05 18:29:00-05:00,REGN,positive
1076352.0,Regeneron CEO Schleifer: 'We have a Very Strong Partnership with Sanofi',2013-11-05 18:28:00-05:00,REGN,positive
1076353.0,Jim Cramer Interviews CEO Leonard S. Schleifer of Regeneron Pharmaceuticals on Mad Money,2013-11-05 18:27:00-05:00,REGN,negative
1076354.0,"Market Wrap: Stocks End Flat, but Tesla Shares Sag After Hours",2013-11-05 17:17:00-05:00,REGN,positive
1076355.0,"Deutsche Bank Maintains Overweight on Regeneron Pharmaceuticals, Inc., Raises PT to $376.00",2013-11-05 13:17:00-05:00,REGN,negative
1076356.0,"Deutsche Bank Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to $375.00",2013-11-05 11:57:00-05:00,REGN,neutral
1076357.0,Regeneron Pharma Files Automatic Mixed Securities Shelf,2013-11-05 08:27:00-05:00,REGN,positive
1076358.0,Regeneron Pharmaceuticals Reports Q3 Adjusted EPS of $2.40 Which May Not Compare $0.90 Est; Revenue of $597.0M Which May Not Compare $502.78M Est,2013-11-05 06:45:00-05:00,REGN,neutral
1076359.0,"Earnings Expectations For The Week Of November 4: Disney, Tesla, Groupon And More",2013-11-03 16:32:00-05:00,REGN,neutral
1076360.0,Benzinga Weekly Preview: Central Banks Back In The Spotlight,2013-11-01 16:19:00-04:00,REGN,neutral
1076361.0,"Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)",2013-10-25 15:36:00-04:00,REGN,positive
1076362.0,Regeneron Says Phase 3 Data on Eylea Shows 53% Gained At Least 15 Letters in Vision,2013-10-21 07:21:00-04:00,REGN,positive
1076363.0,UPDATE: Leerink Swann Downgrades Sanofi Based on Low Visibility,2013-10-18 12:14:00-04:00,REGN,negative
1076364.0,Sanofi Regeneron Report Phase 3 ODYSSEY MONO trial with Alirocumab Met Primary Efficacy Endpoint,2013-10-16 06:07:00-04:00,REGN,neutral
1076365.0,"Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)",2013-10-11 14:33:00-04:00,REGN,neutral
1076366.0,Bank of America Raises Target on Regeneron Pharma from $310 to $345,2013-10-01 08:44:00-04:00,REGN,neutral
1076367.0,UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Complete Phase 3 Eye Drug Data,2013-09-30 12:25:00-04:00,REGN,neutral
1076368.0,UPDATE: Oppenheimer Raises PT on Regeneron Pharmaceuticals Following Results of VIVID & VISTA Studies,2013-09-30 12:19:00-04:00,REGN,neutral
1076369.0,UPDATE: Piper Jaffray Raises PT on Regeneron Pharmaceuticals Following Presentation of EYLEA DME Data,2013-09-30 12:14:00-04:00,REGN,neutral
1076370.0,"Goldman Sachs Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to $355.00",2013-09-30 09:32:00-04:00,REGN,neutral
1076371.0,Cramer on CNBC Says 'Watch for Bounce' in Regeneron Pharma Shares,2013-09-30 09:32:00-04:00,REGN,positive
1076372.0,"Oppenheimer Maintains Outperform on Regeneron Pharmaceuticals, Inc., Raises PT to $310.00",2013-09-30 09:31:00-04:00,REGN,neutral
1076373.0,"Piper Jaffray Maintains Overweight on Regeneron Pharmaceuticals, Inc., Raises PT to $360.00",2013-09-30 09:29:00-04:00,REGN,negative
1076374.0,"BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)",2013-09-25 12:52:00-04:00,REGN,positive
1076375.0,"Traders in Regeneron Pharma Responding to Boosted Price Target from $298 to $329 at Goldman Sachs, Firm Maintains Buy; Stock Up 3% to $305.60",2013-09-18 10:53:00-04:00,REGN,positive
1076376.0,"Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)",2013-09-14 11:47:00-04:00,REGN,positive
1076377.0,"Lazard Capital Markets Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to $325.00",2013-09-13 09:25:00-04:00,REGN,neutral
1076378.0,"Regeneron Names Robert Landry as Senior VP, Finance, CFO",2013-09-10 08:15:00-04:00,REGN,neutral
1076379.0,"Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)",2013-08-27 13:29:00-04:00,REGN,positive
1076380.0,"Oppenheimer Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Outperform, Announces $300.00 PT",2013-08-21 16:27:00-04:00,REGN,neutral
1076381.0,"Oppenheimer Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Outperform, Announces $300.00 PT",2013-08-21 16:17:00-04:00,REGN,neutral
1076382.0,"Piper Jaffray Raises Target on Regeneron Pharma from $274 to $336, Maintains Overweight",2013-08-06 11:11:00-04:00,REGN,negative
1076383.0,Benzinga's Top Pre-Market Losers,2013-08-06 08:27:00-04:00,REGN,negative
1076384.0,"Regeneron, Bayer Report Positive Results from Phase 3 Trials of EYLEA Injection for Treatment of Diabetic Macular Edema ",2013-08-06 05:52:00-04:00,REGN,positive
1076385.0,"Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)",2013-07-26 10:46:00-04:00,REGN,positive
1076386.0,Regeneron Drug Receives Positive Recommendation From European Authorities,2013-07-26 09:01:00-04:00,REGN,positive
1076387.0,Biotech to Watch: Alnylam Pharmaceuticals Soars on Drug Data (ALNY),2013-07-14 20:39:00-04:00,REGN,neutral
1076388.0,"Lazard Capital Markets Upgrades Regeneron Pharmaceuticals, Inc. to Buy, Announces $298.00 PT",2013-07-12 07:29:00-04:00,REGN,neutral
1076389.0,"Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)",2013-07-11 12:47:00-04:00,REGN,positive
1076390.0,What to Expect From Tesla Shares After Joining QQQ (TSLA),2013-07-10 13:59:00-04:00,REGN,positive
1076391.0,RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea,2013-07-03 12:33:00-04:00,REGN,positive
1076392.0,"BMO Says Biotech Sector Could See Upside from M&A, Offers Multiple Attractive Targets",2013-07-02 12:29:00-04:00,REGN,positive
1076393.0,UPDATE: Piper Jaffray Upgrades Regeneron Pharmaceuticals to Overweight Following EYLEA Launch,2013-07-01 10:13:00-04:00,REGN,negative
1076394.0,Benzinga's Top Upgrades,2013-07-01 07:26:00-04:00,REGN,positive
1076395.0,"Piper Jaffray Upgrades Regeneron Pharmaceuticals, Inc. to Overweight, Maintains $274.00 PT",2013-07-01 06:40:00-04:00,REGN,negative
1076396.0,SLIDESHOW: Top 10 Performing S&P 500 Stocks of the Second Quarter,2013-06-28 11:50:00-04:00,REGN,positive
1076397.0,"Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)",2013-06-26 13:17:00-04:00,REGN,positive
1076398.0,"Jefferies Says Analysis on Elan Supports $19/Share Takeover Bid, Lifts Price Target to $19",2013-06-18 10:39:00-04:00,REGN,positive
1076399.0,"Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)",2013-06-12 13:29:00-04:00,REGN,positive
1076400.0,"Market Wrap for Thursday, June 6: Stocks Reverse Mid-Day; Rally to Close at Session Highs ",2013-06-06 16:33:00-04:00,REGN,neutral
1076401.0,Regeneron and Bayer Announce Positive Phase 3 Results for EYLEA Injection,2013-06-06 05:55:00-04:00,REGN,positive
1076402.0,"Short Interest in Vertex Rises, in Biogen Idec Falls",2013-05-29 13:19:00-04:00,REGN,positive
1076403.0,"Sanofi, Regeneron Says Phase 2a Trial of Dupilumab Demonstrated 87% Cut i Asthma Risk",2013-05-21 08:16:00-04:00,REGN,negative
1076404.0,"Form 8-K Showing Regeneron, Genentech Announced Deals on Worldwide Sales of Eylea",2013-05-20 17:11:00-04:00,REGN,neutral
1076405.0,"Sanofi, Regeneron Announce Patient Enrollment in Two Phase 3 Sarilumab Trials for Rheumatoid Arthritis",2013-05-15 05:55:00-04:00,REGN,neutral
1076406.0,"Short Interest in Vertex Rises, in Celgene Falls",2013-05-11 10:45:00-04:00,REGN,positive
1076407.0,UPDATE: Jefferies Raises PT on Regeneron Pharmaceuticals Following Top-Line Q1 Beat,2013-05-06 12:50:00-04:00,REGN,neutral
1076408.0,"Market Wrap for Friday, May 3: Stocks Jump on Strong Jobs Data",2013-05-03 16:28:00-04:00,REGN,positive
1076409.0,"Brean Capital Upgrades Regeneron Pharmaceuticals, Inc. to Buy, Announces $315.00 PT",2013-05-03 14:51:00-04:00,REGN,neutral
1076410.0,A Peek Into The Market Before The Trading Starts,2013-05-03 07:06:00-04:00,REGN,neutral
1076411.0,Regeneron Acquires Rights to Two Families of Novel Antibodies,2013-05-03 06:41:00-04:00,REGN,positive
1076412.0,Regeneron Pharmaceuticals Reports Q1 EPS Ex-Items of $1.78 vs $0.95 Est; Revenue of $439.66M vs $424.26M Est,2013-05-03 06:38:00-04:00,REGN,neutral
1076413.0,Regeneron Pharmaceuticals: The Stock That Only Goes Up?,2013-05-01 16:42:00-04:00,REGN,neutral
1076414.0,"Market Wrap for Wednesday, May 1: Stocks Fall as Employment Data Weakens in April ",2013-05-01 16:16:00-04:00,REGN,negative
1076415.0,"Allergan Says DARPin Data Do Not Support Phase 3 Trials, Will Delay Study -Bloomberg",2013-05-01 11:22:00-04:00,REGN,negative
1076416.0,Regeneron Circuit Breaker on Volatility,2013-05-01 11:07:00-04:00,REGN,neutral
1076417.0,UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Cardiologist/Lipidologist Survey,2013-05-01 09:35:00-04:00,REGN,neutral
1076418.0,"Goldman Sachs Maintains Conviction Buy on Regeneron Pharmaceuticals, Inc., Raises PT to $240.00",2013-05-01 06:15:00-04:00,REGN,neutral
1076419.0,"Stocks to Watch for April 30, 2013",2013-04-30 09:31:00-04:00,REGN,neutral
1076420.0,"Short Sellers Move into Celgene, Regeneron",2013-04-26 13:25:00-04:00,REGN,neutral
1076421.0,S&P Says Regeneron to Join S&P 500,2013-04-24 17:17:00-04:00,REGN,positive
1076422.0,"Bank of America Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PO to $220.00",2013-04-12 08:11:00-04:00,REGN,negative
1076423.0,"Short Sellers Move Out of Amgen, Celgene, Pharmacyclics",2013-04-10 13:30:00-04:00,REGN,neutral
1076424.0,Stocks Hitting 52-Week Highs ,2013-04-09 11:17:00-04:00,REGN,neutral
1076425.0,UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals on Strong Eylea Launch,2013-04-09 10:52:00-04:00,REGN,positive
1076426.0,"Goldman Sachs Maintains Buy on Regeneron Pharmaceuticals, Inc., Raises PT to $215.00",2013-04-09 08:04:00-04:00,REGN,neutral
1076427.0,"Regeneron Pharma to Expand Corporate HQ, Labs in Westchester County",2013-04-04 09:17:00-04:00,REGN,positive
1076428.0,"JMP Securities Initiates Coverage on Regeneron Pharmaceuticals, Inc. at Market Perform",2013-03-28 08:44:00-04:00,REGN,positive
1076429.0,"Short Sellers Dump Amgen, Focus on Celgene, Gilead Sciences",2013-03-28 08:18:00-04:00,REGN,negative
1076430.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)",2013-03-12 13:19:00-04:00,REGN,positive
1076431.0,Regeneron Pharma Announces Possible Added Royalty Stream Related to EU Approval for Ilaris,2013-03-04 09:02:00-05:00,REGN,positive
1076432.0,"Sanofi, Regeneron Report Positive Phase 1b Data for Dupilumab in Atopic Dermatitis ",2013-03-02 10:47:00-05:00,REGN,positive
1076433.0,"Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)",2013-02-28 15:13:00-05:00,REGN,positive
1076434.0,"Barclays Initiated Coverage on Regeneron Pharmaceuticals, Inc. at Overweight, Announced $194.00 PT",2013-02-28 10:07:00-05:00,REGN,negative
1076435.0,A Peek Into The Market Before The Trading Starts,2013-02-19 07:19:00-05:00,REGN,neutral
1076436.0,"Regeneron, Bayer Initiate Phase 3 Trial of EYLEA Injection for Treatment of Diabetic Macular Edema in Asia and Russia ",2013-02-19 05:51:00-05:00,REGN,neutral
1076437.0,"Earnings Scheduled For February 14, 2013",2013-02-14 00:32:00-05:00,REGN,neutral
1076438.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)",2013-02-12 13:29:00-05:00,REGN,positive
1076439.0,JP Morgan Cautious on Sanofi Buying Regeneron,2013-02-11 10:54:00-05:00,REGN,positive
1076440.0,Regeneron Pharma Shares Resume Trading Up ~8%,2013-02-11 10:05:00-05:00,REGN,positive
1076441.0,"Sanofi Says No Plan to Take Controlling Stake in Regeneron, Says Could Increase Stake Over Time - Bloomberg",2013-02-11 09:53:00-05:00,REGN,neutral
1076442.0,Regeneron Pharma Shares to Resume Trade at 10:05AM EST,2013-02-11 09:46:00-05:00,REGN,positive
1076443.0,UPDATE: Regeneron Pharm Announces Receipt of HSR Notice Sanofi to Buy Stock in Open Market,2013-02-11 09:38:00-05:00,REGN,neutral
1076444.0,Regeneron Announces Receipt of HSR Notice Sanofi Intends to buy Stock in Open Market,2013-02-11 09:37:00-05:00,REGN,neutral
1076445.0,Regeneron Halted News Pending,2013-02-11 09:20:00-05:00,REGN,neutral
1076446.0,"Jefferies Reiterates Buy Rating, $34 PT on Partnership with Alnylam Pharmaceuticals",2013-02-04 13:17:00-05:00,REGN,neutral
1076447.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2013-01-26 12:17:00-05:00,REGN,positive
1076448.0,"EMA Says Novartis, Regeneron Win Backing for Ilaris",2013-01-18 07:45:00-05:00,REGN,positive
1076449.0,"Brean Capital Downgrades Regeneron Pharmaceuticals, Inc. to Hold, Removes $180.00 PT",2013-01-17 08:11:00-05:00,REGN,neutral
1076450.0,UPDATE: Jefferies Downgrades Regeneron Pharmaceuticals to Hold on Limited Eylea Upside  ,2013-01-15 08:56:00-05:00,REGN,negative
1076451.0,"Jefferies Downgrades Regeneron Pharmaceuticals, Inc. to Hold, Maintains $179.00 PT",2013-01-15 06:40:00-05:00,REGN,neutral
1076452.0,"Regeneron CEO Schleifer: 'It's Hard to Figure Out What People Expect, But there was a Problem with Compounding Pharmacies'",2013-01-08 18:23:00-05:00,REGN,negative
1076453.0,"Regeneron CEO Schleifer: 'If We Put the Cash on Research, We'll Be in Good Shape'",2013-01-08 18:23:00-05:00,REGN,positive
1076454.0,Regeneron CEO Schleifer: 'Our Franchise is Going Well Despite the Fact We Weren't Able to Deliver on Everything Expected',2013-01-08 18:21:00-05:00,REGN,positive
1076455.0,Jim Cramer Interviews CEO Dr. Leonard S. Schleifer of Regeneron Pharmaceuticals on Mad Money,2013-01-08 18:18:00-05:00,REGN,negative
1076456.0,"Regeneron Pharmaceuticals, Inc. Reports Q4 Revenue of $276.0M vs $264.20M Est; Sees 2013 Eylea Sales Growth ~50%",2013-01-08 08:05:00-05:00,REGN,positive
1076457.0,"Benzinga's M&A Chatter for Friday January 4, 2013",2013-01-05 12:15:00-05:00,REGN,neutral
1076458.0,Regeneron Recommends Rejection of Mini-Tender Offer by TRC Capital,2013-01-04 16:39:00-05:00,REGN,negative
1076459.0,"Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)",2012-12-28 11:10:00-05:00,REGN,positive
1076460.0,These Three Prominent Stocks Have Doubled in 2012,2012-12-20 07:29:00-05:00,REGN,positive
1076461.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2012-12-12 12:57:00-05:00,REGN,positive
1076462.0,Regeneron's EYLEA Submitted for EU Marketing Authorization for Treatment of Macular Edema ,2012-12-06 06:17:00-05:00,REGN,neutral
1076463.0,Regeneron's EYLEA Injection Approved for Treatment of Wet Age-Related Macular Degeneration by EC,2012-11-27 06:05:00-05:00,REGN,positive
1076464.0,Watchlist For Next Week,2012-11-19 11:00:00-05:00,REGN,neutral
1076465.0,From Earlier:  CHMP Recommends Granting of Marketing Authorization for ZALTRAP,2012-11-16 10:11:00-05:00,REGN,positive
1076466.0,UPDATE: Credit Suisse Initiates Regeneron Pharmaceutical at Outperform  ,2012-11-13 13:39:00-05:00,REGN,positive
1076467.0,"Credit Suisse Initiates Coverage on Regeneron Pharmaceuticals at Outperform, Announces PT of $187",2012-11-12 16:28:00-05:00,REGN,positive
1076468.0,"Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)",2012-11-12 13:24:00-05:00,REGN,positive
1076469.0,"Sanofi, Regeneron Begin Enrollment in CV Outcomes Trial with PCSK9 Antibody for Hypercholesterolemia",2012-11-05 08:15:00-05:00,REGN,neutral
1076470.0,"Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)",2012-10-25 14:09:00-04:00,REGN,positive
1076471.0,"Stocks To Watch For October 25, 2012",2012-10-25 09:15:00-04:00,REGN,neutral
1076472.0,"Deutsche Bank Maintains Regeneron Pharmaceuticals at Buy, Raises PT from $165 to $190",2012-10-25 08:11:00-04:00,REGN,neutral
1076473.0,Rating Breakdown: Best & Worst ETFs & Mutual Funds by Sector,2012-10-24 17:44:00-04:00,REGN,neutral
1076474.0,"Goldman Sachs Maintains Regeneron Pharmaceuticals at Buy, Raises PT from $170 to $175",2012-10-24 17:12:00-04:00,REGN,neutral
1076475.0,"Deutsche Bank Maintains Regeneron Pharmaceuticals at Buy, Raises PT from $165 to $190",2012-10-24 15:25:00-04:00,REGN,neutral
1076476.0,"Citi Maintains Regeneron Pharmaceuticals at Neutral, Raises PT from $151 to $182",2012-10-24 15:23:00-04:00,REGN,neutral
1076477.0,"Jefferies & Company Maintains Regeneron Pharmaceuticals at Buy, Raises PT from $161 to $179",2012-10-24 15:20:00-04:00,REGN,neutral
1076478.0,Citi Raises PT on Regeneron Pharmaceuticals from $151 to $182,2012-10-24 15:15:00-04:00,REGN,neutral
1076479.0,From Earlier: Regeneron Pharmaceuticals Reports Q3 EPS $1.89 vs $0.95 Est; Revenues $427.7M vs $349.17M Est,2012-10-24 13:53:00-04:00,REGN,neutral
1076480.0,Leerink Swann Raises PT on Regeneron Pharmaceuticals from $150 to $182,2012-10-22 08:21:00-04:00,REGN,neutral
1076481.0,Regeneron Announces Publication of EYLEA (aflibercept) Injection Phase 3,2012-10-18 16:13:00-04:00,REGN,neutral
1076482.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)",2012-10-15 06:59:00-04:00,REGN,positive
1076483.0,Regeneron Pharmaceuticals Spikes Higher,2012-10-10 15:02:00-04:00,REGN,neutral
1076484.0,Regeneron's EYLEA Injection Approved for Treatment of Wet Age-Related Macular Degeneration in Japan ,2012-09-28 06:01:00-04:00,REGN,positive
1076485.0,"Short Interest in Biotech Firms Resumes (BIIB, GILD, ILMN, REGN)",2012-09-26 13:22:00-04:00,REGN,positive
1076486.0,UPDATE: Goldman Sachs Raises PT to $170 on Regeneron Pharmaceuticals on Eylea EU Approval  ,2012-09-24 14:17:00-04:00,REGN,positive
1076487.0,UPDATE: Bank of America Raises PO to $172 on Regeneron Pharmaceuticals on EU Approval  ,2012-09-24 13:50:00-04:00,REGN,negative
1076488.0,"Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from $168 to $172",2012-09-24 08:19:00-04:00,REGN,negative
1076489.0,"Piper Jaffray Maintains Regeneron Pharmaceuticals at Neutral, Raises PT from $128 to $140",2012-09-24 08:17:00-04:00,REGN,neutral
1076490.0,Regeneron Announces FDA Approval of EYLEA,2012-09-21 14:08:00-04:00,REGN,positive
1076491.0,Regeneron Pharma Says Eylea Injection Recommend for Approval by CHMP,2012-09-21 09:23:00-04:00,REGN,positive
1076492.0,"Goldman Sachs Maintains Regeneron Pharmaceuticals at Buy, Raises PT from $160 to $168",2012-09-17 07:21:00-04:00,REGN,neutral
1076493.0,"Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from $164 to $168",2012-08-28 16:13:00-04:00,REGN,negative
1076494.0,"Regeneron Spikes to 52-Week High, $147.00",2012-08-28 13:20:00-04:00,REGN,neutral
1076495.0,"Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from $164 to $168",2012-08-28 07:01:00-04:00,REGN,negative
1076496.0,"Benzinga's M&A Chatter for Thursday August 23, 2012",2012-08-23 17:01:00-04:00,REGN,neutral
1076497.0,Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter,2012-08-23 14:21:00-04:00,REGN,neutral
1076498.0,Regeneron Pharmaceuticals Hits 52-Week High on Takeover Rumors,2012-08-23 11:15:00-04:00,REGN,neutral
1076499.0,Hearing Unconfirmed Takeover Chatter in Regeneron,2012-08-23 10:52:00-04:00,REGN,negative
1076500.0,Regeneron Pharmaceuticals Spikes Higher,2012-08-23 10:50:00-04:00,REGN,neutral
1076501.0,"Bank of America Adds Questcor to US 1 List, Removes Regeneron Pharma",2012-08-21 06:25:00-04:00,REGN,neutral
1076502.0,Regeneron CEO Schleifer: 'Eylea Only Treatments for Macular Degeneration Approved by FDA to be Used Every Other Month',2012-08-13 18:22:00-04:00,REGN,positive
1076503.0,Regeneron CEO Schleifer: 'Eylea Could be One of the Best Launches in the History of the Biopharmaceutical Industry,2012-08-13 18:20:00-04:00,REGN,positive
1076504.0,Regeneron CEO Schleifer: 'Eylea Only Approved in US; Expect to Launch Our First Countries Outside of US in Q4',2012-08-13 18:19:00-04:00,REGN,positive
1076505.0,Jim Cramer Interviews CEO Leonard S. Schleifer of Regeneron Pharmaceuticals on Mad Money,2012-08-13 18:15:00-04:00,REGN,negative
1076506.0,"PREVIEW: Jim Cramer to Interview CEO's of Regeneron, Charles River on Mad Money",2012-08-13 18:11:00-04:00,REGN,negative
1076507.0,Short Sellers Shy Away from Biotech Firms,2012-08-13 06:18:00-04:00,REGN,negative
1076508.0," Regeneron, Sanofi Win FDA Approval for Colon Cancer Drug Zaltrap",2012-08-03 11:49:00-04:00,REGN,positive
1076509.0,"Social Media Outlook for Wednesday July 25 (RVBD, REGN, IGT, NFLX) ",2012-07-25 14:12:00-04:00,REGN,neutral
1076510.0,"Piper Jaffray Maintains Regeneron Pharmaceuticals at Neutral, Raises PT from $113 to $128",2012-07-25 13:57:00-04:00,REGN,neutral
1076511.0,Regeneron Plunges From Open After Earnings; Stock Still Higher,2012-07-25 13:49:00-04:00,REGN,neutral
1076512.0,BMO Capital Markets Upgrades Regeneron Pharmaceuticals from Market Perform to Outperform,2012-07-25 13:04:00-04:00,REGN,neutral
1076513.0,Regeneron Pharmaceuticals Reports Q2 EPS $0.90 vs $0.27 Est; Revenues $304.4M vs $257.05M Est,2012-07-25 06:32:00-04:00,REGN,neutral
1076514.0,"Financial Breakfast: Morning News Summary for July 20, 2012",2012-07-20 07:17:00-04:00,REGN,neutral
1076515.0,Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody ,2012-07-20 06:34:00-04:00,REGN,positive
1076516.0,Biotechs With Upcoming PDUFA Dates,2012-07-18 15:09:00-04:00,REGN,neutral
1076517.0,"S&P: Not All Mid-Cap ETFs Created Equal (MDY, VO)",2012-07-05 14:37:00-04:00,REGN,positive
1076518.0,"Trading the Trend: Regeneron, Alexion, TripAdvisor, Expedia All Pushing Higher ",2012-07-02 13:17:00-04:00,REGN,neutral
1076519.0,Ultimate Stock Watch List for The Supreme Court's Health Care Ruling,2012-06-28 09:51:00-04:00,REGN,positive
1076520.0,Regeneron Plunging; May be Related to Drug Data From Ophthotech,2012-06-13 10:23:00-04:00,REGN,neutral
1076521.0,Jefferies Maintains Buy on Regeneron After Positive Data,2012-06-13 09:43:00-04:00,REGN,positive
1076522.0,JP Morgan Comments on Wet AMD Data for Regeneron,2012-06-13 09:41:00-04:00,REGN,positive
1076523.0,UPDATE: Bank of America Raises Regeneron Pharmaceuticals' PO,2012-05-29 09:02:00-04:00,REGN,negative
1076524.0,"Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from $154 to $158",2012-05-29 06:39:00-04:00,REGN,negative
1076525.0,"Goldman Sachs Maintains Regeneron Pharmaceuticals at Buy, Lowers PT from $157 to $155",2012-05-09 15:15:00-04:00,REGN,negative
1076526.0,Regeneron Reports That It Will Attend JP Morgan Biotech Conference,2012-05-09 09:31:00-04:00,REGN,positive
1076527.0,UPDATE: Jefferies Lowers Regeneron Pharmaceuticals' PT ,2012-05-09 07:18:00-04:00,REGN,negative
1076528.0,"Jefferies & Company Maintains Regeneron Pharmaceuticals at Buy, Lowers PT from $163 to $161",2012-05-09 06:10:00-04:00,REGN,negative
1076529.0,FDA Panel Votes 11 to 0 to Reject Regeneron's Arcalyst for Gout Flares,2012-05-08 15:28:00-04:00,REGN,negative
1076530.0,FDA Panel Votes 3 Yes 8 No on Question of Regeneron Arcalyst Safety,2012-05-08 15:25:00-04:00,REGN,positive
1076531.0,"Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from $150 to $154",2012-05-08 06:37:00-04:00,REGN,negative
1076532.0,"Jefferies & Company Maintains Regeneron Pharmaceuticals at Buy, Raises PT from $127 to $163",2012-04-27 07:08:00-04:00,REGN,neutral
1076533.0,"Piper Jaffray Maintains Regeneron Pharmaceuticals at Neutral, Raises PT from $89 to $113",2012-04-26 11:46:00-04:00,REGN,neutral
1076534.0,Regeneron Pharmaceuticals Rises 13% Pre-Market on Solid Earnings Beat,2012-04-26 07:28:00-04:00,REGN,positive
1076535.0,Regeneron Pharmaceuticals Reports Q1 EPS $0.37 May Not Compare vs $-0.24 Est; Revenues $231.8M vs $172.62M Est,2012-04-26 06:37:00-04:00,REGN,neutral
1076536.0,UPDATE: Bank of America Raises Regeneron Pharmaceuticals' PO,2012-04-23 08:12:00-04:00,REGN,negative
1076537.0,"Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from $135 to $146",2012-04-23 05:58:00-04:00,REGN,negative
1076538.0,"ETFs For Momentum Stocks (FBT, PNQI, HDGE)",2012-04-10 13:07:00-04:00,REGN,neutral
1076539.0,Top Momentum Names to Ride the Rally! ,2012-04-05 14:54:00-04:00,REGN,positive
1076540.0,From Earlier: Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP ,2012-04-05 07:37:00-04:00,REGN,neutral
1076541.0,Stocks Close Out Stellar Quarter on High Note; A Look at Top Performers,2012-03-30 15:56:00-04:00,REGN,positive
1076542.0,"Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from $130 to $135",2012-03-27 08:41:00-04:00,REGN,negative
1076543.0,UPDATE: Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody ,2012-03-26 11:32:00-04:00,REGN,neutral
1076544.0,J.P. Morgan's Thoughts on Regeneron Pharmaceuticals,2012-03-26 07:30:00-04:00,REGN,neutral
1076545.0,"Painkillers Win FDA Panel Backing to Continue Development; Pfizer, JNJ, Regeneron Pain Drugs Should Resume Halted Studies -Bloomberg",2012-03-12 15:59:00-04:00,REGN,positive
1076546.0,Bank of America Adds Regeneron Pharmaceuticals to US 1 List,2012-03-12 06:29:00-04:00,REGN,neutral
1076547.0,Regeneron and Bayer Announce Approval of EYLEA Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia  ,2012-03-08 07:59:00-05:00,REGN,positive
1076548.0,Regeneron Pharmaceuticals Spiking Lower on Negative Comments from Summer Street Research,2012-02-21 13:53:00-05:00,REGN,negative
1076549.0,Deutsche Bank Comments on Avastin Fake-Out,2012-02-15 10:35:00-05:00,REGN,neutral
1076550.0,UPDATE: Deutsche Bank Raises Target on Regeneron Pharma to $140,2012-02-14 09:51:00-05:00,REGN,neutral
1076551.0,UPDATE: Bank of America Raises Regeneron Pharmaceuticals PT,2012-02-14 08:50:00-05:00,REGN,neutral
1076552.0,"Bank of America Maintains Regeneron Pharmaceuticals at Buy, Raises PO from $105 to $130",2012-02-14 06:42:00-05:00,REGN,negative
1076553.0,Regeneron Analyst: More Patients Will Switch From Lucentis to Avastin in 2012.  Company Could Sell $299 Million of Avastin This Year.,2012-02-13 14:15:00-05:00,REGN,neutral
1076554.0,UPDATE: Piper Jaffray Raises Price Target on Regeneron Pharmaceuticals to $89,2012-02-13 11:49:00-05:00,REGN,neutral
1076555.0,"Piper Jaffray Maintains Regeneron Pharmaceuticals at Neutral, Lowers PT from $81 to $89",2012-02-13 10:44:00-05:00,REGN,negative
1076556.0,"Piper Jaffray Maintains Regeneron Pharmaceuticals at Neutral, Lowers PT from $89 to $81",2012-02-13 10:43:00-05:00,REGN,negative
1076557.0,Regeneron Pharmaceuticals Hits 52-Week High of $112.79,2012-02-13 09:31:00-05:00,REGN,neutral
1076558.0,Regeneron Pharmaceuticals up 10.7% Pre-Market on Smaller Than Expected Q4 Loss ,2012-02-13 09:11:00-05:00,REGN,negative
1076559.0,Earnings Roundup,2012-02-13 08:29:00-05:00,REGN,neutral
1076560.0,Benzinga's Top Pre-Market Gainers,2012-02-13 08:09:00-05:00,REGN,positive
1076561.0,Regeneron Pharmaceuticals Rises 16% on Lower-than-Expected Losses,2012-02-13 07:54:00-05:00,REGN,negative
1076562.0,"Financial Breakfast: Morning News Summary for February 13, 2012",2012-02-13 07:23:00-05:00,REGN,neutral
1076563.0,Regeneron Reports Q4 EPS $(0.37) vs$(0.60) Est; Revenues $123.00M vs $131.50M Est,2012-02-13 07:02:00-05:00,REGN,neutral
1076564.0,Regeneron Pharmaceuticals Hits 52-Week High of $102.88,2012-02-09 09:32:00-05:00,REGN,neutral
1076565.0,Regeneron Pharmaceuticals Hits 52-Week High of $101.99,2012-02-08 09:36:00-05:00,REGN,neutral
1076566.0,Regeneron Pharmaceuticals Hits 52-Week High of $101.81,2012-02-07 09:31:00-05:00,REGN,neutral
1076567.0,Regeneron Pharmaceuticals Hits 52-Week High of $97.60,2012-02-06 09:55:00-05:00,REGN,neutral
1076568.0,UPDATE: Piper Jaffray Downgrades Regeneron Pharmaceuticals to Neutral ,2012-02-06 08:05:00-05:00,REGN,neutral
1076569.0,Benzinga's Top Downgrades,2012-02-06 07:44:00-05:00,REGN,positive
1076570.0,"Financial Breakfast: Morning News Summary for February 06, 2012",2012-02-06 07:27:00-05:00,REGN,neutral
1076571.0,UPDATE: Jefferies Raises PT to $1111 on Regeneron Pharmaceuticals,2012-02-06 07:11:00-05:00,REGN,neutral
1076572.0,Piper Jaffray Downgrades Regeneron Pharmaceuticals to Neutral,2012-02-06 05:57:00-05:00,REGN,neutral
1076573.0,Regeneron Pharmaceuticals Hits 52-Week High of $95.91,2012-02-03 09:33:00-05:00,REGN,neutral
1076574.0,Regeneron Pharmaceuticals Hits 52-Week High of $93.12,2012-02-02 09:41:00-05:00,REGN,neutral
1076575.0,Regeneron Pharmaceuticals Hits 52-Week High of $91.78,2012-02-01 10:25:00-05:00,REGN,neutral
1076576.0,Regeneron Pharmaceuticals Hits 52-Week High of $86.80,2012-01-30 09:30:00-05:00,REGN,neutral
1076577.0,Bank of America Upgrades Regeneron Pharmaceuticals to Buy from Neutral,2012-01-30 07:45:00-05:00,REGN,neutral
1076578.0,Regeneron Pharmaceuticals Hits 52-Week High of $83.50,2012-01-27 10:14:00-05:00,REGN,neutral
1076579.0,Regeneron Pharmaceuticals Hits 52-Week High of $80.79,2012-01-25 10:18:00-05:00,REGN,neutral
1076580.0,Regeneron Pharmaceuticals Hits 52-Week High of $79.98,2012-01-19 09:54:00-05:00,REGN,neutral
1076581.0,Roth Capital Downgrades Regeneron Pharma to Neutral,2012-01-17 08:12:00-05:00,REGN,neutral
1076582.0,Regeneron Pharmaceuticals Hits 52-Week High of $79.91,2012-01-12 11:40:00-05:00,REGN,neutral
1076583.0,"Benzinga's M&A Chatter for Tuesday January 10, 2012",2012-01-10 18:43:00-05:00,REGN,neutral
1076584.0,Regeneron CEO Schleifer: 'We're Excited About the Prospects We've been Working on with Sanofi',2012-01-10 18:25:00-05:00,REGN,positive
1076585.0,Regeneron CEO Schleifer: 'Our Bird in the Hand is Eylea',2012-01-10 18:23:00-05:00,REGN,positive
1076586.0,Regeneron CEO Schleifer: 'We Try to Develop Products Both Patients and Doctors Will Like',2012-01-10 18:23:00-05:00,REGN,positive
1076587.0,Jim Cramer Interviews CEO Dr. Leonard S. Schleifer of Regeneron Pharmaceuticals on Mad Money,2012-01-10 18:17:00-05:00,REGN,negative
1076588.0,PREVIEW: Jim Cramer to Interview CEO of Regeneron Pharmaceuticals on Mad Money,2012-01-10 18:11:00-05:00,REGN,negative
1076589.0,"UPDATE: Deutsche Bank Maintains Buy, Raises PT to $80 on Regeneron",2012-01-10 10:19:00-05:00,REGN,neutral
1076590.0,"Jefferies Maintains Buy, $75 PT on Regeneron",2012-01-10 07:30:00-05:00,REGN,neutral
1076591.0,Just What The Doctor Ordered: 4 ETFs For Biotech M&A,2012-01-09 15:49:00-05:00,REGN,neutral
1076592.0,"End-of-Day Market Summary for January 6, 2012",2012-01-06 16:24:00-05:00,REGN,neutral
1076593.0,UPDATE: Jefferies & Company Upgrades Regeneron Pharmaceuticals to Buy,2012-01-06 14:18:00-05:00,REGN,neutral
1076594.0,Benzinga's Volume Gainers,2012-01-06 13:22:00-05:00,REGN,neutral
1076595.0,Jefferies Upgrades Regeneron Pharmaceuticals to Buy,2012-01-06 06:31:00-05:00,REGN,neutral
1076596.0,"Piper Jaffray Reiterates Overweight, $83 PT On Regeneron ",2012-01-03 11:19:00-05:00,REGN,negative
1076597.0,A Peek Into The Market Before The Trading Starts,2012-01-03 07:33:00-05:00,REGN,neutral
1076598.0,Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA injection ,2012-01-03 07:00:00-05:00,REGN,negative
1076599.0,Regeneron to Host Conference Call on January 3 at 8:30am EST to Discuss Ongoing Patent Litigation,2012-01-02 19:41:00-05:00,REGN,negative
1076600.0,"Regeneron Informed by Sanofi that on December 19, 2011, Sanofi Voluntarily Withdrew Biologics License Application Submitted to the US FDA for Marketing Approval of ZALTRAP",2011-12-21 16:33:00-05:00,REGN,positive
1076601.0,"Regeneron Says Sanofi Withdrew, Plans to Resubmit Zaltrap BLA",2011-12-21 16:25:00-05:00,REGN,neutral
1076602.0,Regeneron Pharmaceuticals Spiking Lower on Heavy Volume,2011-12-16 16:00:00-05:00,REGN,negative
1076603.0,"Jefferies Reiterates Hold, $66 PT On Regeneron",2011-12-05 12:47:00-05:00,REGN,neutral
1076604.0,Brean Murray Lowers PT on Regeneron Pharma to $67,2011-12-05 09:29:00-05:00,REGN,negative
1076605.0,"Financial Breakfast: Morning News Summary for November 28, 2011",2011-11-28 07:39:00-05:00,REGN,neutral
1076606.0,Regeneron and Bayer Initiate Phase 3 Clinical Program for the Treatment of Wet Age-Related Macular Degeneration in China  ,2011-11-28 06:58:00-05:00,REGN,neutral
1076607.0,Regeneron Receives FDA Approval; Begins to Eye Bright Future,2011-11-22 12:18:00-05:00,REGN,positive
1076609.0,"End-of-Day Market Summary for November 21, 2011",2011-11-21 16:16:00-05:00,REGN,neutral
1076610.0,Regeneron CEO: Bayer and Regeneron will Split Eylea Profits Outside US,2011-11-21 09:50:00-05:00,REGN,positive
1076611.0,Regeneron CEO Talking on CNBC,2011-11-21 09:49:00-05:00,REGN,neutral
1076612.0,Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors,2011-11-21 09:03:00-05:00,REGN,neutral
1076613.0,"Jefferies Maintains Hold, $66 PT on Regeneron Pharma",2011-11-21 08:29:00-05:00,REGN,neutral
1076614.0,UPDATE: Bank of America Downgrades Rating to Neutral on Regeneron Pharmaceuticals ,2011-11-21 07:53:00-05:00,REGN,neutral
1076615.0,"Financial Breakfast: Morning News Summary for November 21, 2011",2011-11-21 07:34:00-05:00,REGN,neutral
1076616.0,UPDATE: Piper Jaffray Raises PT to $83 on Regeneron Pharmaceuticals ,2011-11-21 07:09:00-05:00,REGN,neutral
1076617.0,"Bank of America Upgrades Regeneron Pharma to Neutral, PO Raised to $64",2011-11-21 07:03:00-05:00,REGN,negative
1076618.0,Piper Jaffray Raises PT on Regeneron Pharmaceuticals to $83,2011-11-21 06:23:00-05:00,REGN,neutral
1076619.0,Regeneron Announces FDA Approval of EYLEA Injection for Treatment of Wet Age-Related Macular Degeneration,2011-11-18 18:05:00-05:00,REGN,positive
1076620.0,Regeneron Pharmaceuticals Halted; Announces FDA Approval of EYLEA,2011-11-18 17:59:00-05:00,REGN,positive
1076621.0,"Bank of America Maintains Underperform Rating, $62 PT on Regeneron Pharmaceuticals ",2011-11-15 07:55:00-05:00,REGN,neutral
1076622.0,Stifel Nicolaus Maintains Hold on Regeneron Pharmaceuticals  ,2011-11-14 09:45:00-05:00,REGN,neutral
1076623.0,Deutsche Bank Maintains Buy Rating and $67 PT on Regeneron Pharma ,2011-11-14 09:26:00-05:00,REGN,neutral
1076624.0,Deutsche Bank Maintains Buy Rating and $67 PT on Regeneron Pharma ,2011-11-14 09:26:00-05:00,REGN,neutral
1076625.0,Hearing Roth Capital Upgrades Regeneron Pharmaceuticals from Hold to Buy,2011-11-10 09:58:00-05:00,REGN,neutral
1076626.0,Deutsche Bank Maintains Buy Rating and $67 PT on Regeneron Pharma ,2011-11-07 10:34:00-05:00,REGN,neutral
1076627.0,FDA Inspectors Find Manufacturing Issues at Roche Avastin Plant,2011-11-04 14:05:00-04:00,REGN,neutral
1076628.0,FDA Inspectors Found Manufacturing Issues at Roche Avastin Plant -Bloomberg,2011-11-04 13:58:00-04:00,REGN,neutral
1076629.0,Regeneron Pharmaceuticals Announces Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting  ,2011-10-27 08:05:00-04:00,REGN,positive
1076630.0,Regeneron Pharmaceuticals Reports Q3 EPS $(0.68) vs $(0.76) Est; Revenues $102.8M vs $115.60M Est	,2011-10-27 07:05:00-04:00,REGN,neutral
1076631.0,Hearing Negtive Comments on Regeneron by Deal Reporter  ,2011-10-18 11:01:00-04:00,REGN,neutral
1076632.0,"Regeneron Pharmaceuticals Announces Pricing of Offering of $400M Convertible Senior Notes due October 1, 2016 ",2011-10-18 10:01:00-04:00,REGN,neutral
1076633.0,Regeneron Pharmaceuticals Announces Proposed Offering of $400M Convertible Senior Notes due 2016,2011-10-17 16:07:00-04:00,REGN,neutral
1076634.0,Deutsche Bank Maintains Buy Rating and $67 PT on Regeneron Pharmaceuticals,2011-10-13 09:56:00-04:00,REGN,neutral
1076635.0,UPDATE: Less Costly Avastin May Be Rewarded by U.S. Govt for Wet AMD -Bloomberg,2011-10-12 11:06:00-04:00,REGN,positive
1076636.0,Regeneron Spiking Lower,2011-10-12 11:05:00-04:00,REGN,negative
1076637.0,Regeneron Shares Falling On Competitor Concerns,2011-10-05 14:39:00-04:00,REGN,positive
1076638.0,"Regeneron Shares Drop, Novartis Lowers Price of Lucentis by 30%",2011-10-05 14:37:00-04:00,REGN,negative
1076639.0,J.P. Morgan Initiates Coverage on Regeneron Pharmaceuticals,2011-10-04 07:55:00-04:00,REGN,neutral
1076640.0,"JP Morgan Initiates Regeneron Pharmaceuticals at Neutral, $60 PT",2011-10-04 06:26:00-04:00,REGN,positive
1076641.0,Piper Jaffray Overweight on Regeneron Pharmaceuticals ,2011-09-26 08:18:00-04:00,REGN,negative
1076642.0,Piper Jaffray Raises PT on Regeneron Pharmaceuticals to $73,2011-09-26 06:13:00-04:00,REGN,neutral
1076643.0,Regeneron Announces ZALTRAPÂ® Clinical Presentation at European Multidisciplinary Cancer Congress ,2011-09-23 07:02:00-04:00,REGN,negative
1076644.0,Afternoon Gainers; HP Up Over 8%,2011-09-21 15:34:00-04:00,REGN,neutral
1076645.0,Regeneron Pharmaceuticals Soars On Avastin Announcement,2011-09-21 14:47:00-04:00,REGN,neutral
1076646.0,Option Alert: Regeneron October 80 Call Rises 600% on News,2011-09-21 14:22:00-04:00,REGN,positive
1076647.0,Regeneron Pharmaceuticals Resumes Trading,2011-09-21 14:13:00-04:00,REGN,neutral
1076648.0,"Regeneron Pharmaceuticals Halted Again, Circuit Breaker",2011-09-21 14:08:00-04:00,REGN,neutral
1076649.0,Regeneron Pharmaceuticals Resumes Trading,2011-09-21 14:08:00-04:00,REGN,neutral
1076650.0,VA Drops Roche's Avastin for Eye Disease Citing Infection Risks,2011-09-21 14:03:00-04:00,REGN,negative
1076651.0,"Regeneron Pharmaceuticals Halted, Single-Stock Circuit Breaker",2011-09-21 14:02:00-04:00,REGN,neutral
1076652.0,Regeneron Pharmaceuticals Spiking Higher on Heavy Volume,2011-09-21 14:01:00-04:00,REGN,neutral
1076653.0,Jefferies Initiates Coverage on Regeneron Pharmaceuticals with Hold Rating,2011-09-20 07:59:00-04:00,REGN,neutral
1076654.0,"Jefferies Initiates Regeneron Pharmaceuticals at Hold, $66 PT",2011-09-20 06:14:00-04:00,REGN,neutral
1076655.0,Midday Gainers; Pandora up Nearly 7%,2011-09-19 12:47:00-04:00,REGN,neutral
1076656.0,Midday Movers; Deutsche Bank Down 8%,2011-09-09 12:58:00-04:00,REGN,neutral
1076657.0,Bank of America Merrill Lynch Downgrades Regeneron,2011-09-09 09:37:00-04:00,REGN,neutral
1076658.0,"Bank of America Downgrades Regeneron Pharmaceuticals To Underperform, Raises PO To $62",2011-09-09 07:40:00-04:00,REGN,negative
1076659.0,Hearing Leerink Swann and Bank of America Merrill Lynch Downgraded Regeneron,2011-09-09 07:14:00-04:00,REGN,neutral
1076660.0,Breaking the Trend: Stocks Hitting 52-Week Highs Despite Today's Selloff ,2011-09-08 15:11:00-04:00,REGN,neutral
1076661.0,"Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary ",2011-09-06 07:01:00-04:00,REGN,neutral
1076662.0,Regeneron Pharmaceuticals Rises 14% on Positive Seeking Alpha Blog Post Yesterday,2011-09-02 11:37:00-04:00,REGN,positive
1076663.0,UPDATE: Citi Downgrades Regeneron To Hold,2011-08-26 07:59:00-04:00,REGN,neutral
1076664.0,Benzinga's Top Downgrades,2011-08-26 07:49:00-04:00,REGN,positive
1076665.0,"Citigroup Downgrades Regeneron Pharmaceuticals To Hold, Lowers PT To $60",2011-08-26 06:15:00-04:00,REGN,negative
1076666.0,Regeneron Blindsided By PDFUA Delay,2011-08-18 11:51:00-04:00,REGN,negative
1076667.0,Bank of America Merrill Lynch Maintains Neutral on Regeneron Pharmaceuticals,2011-08-18 08:38:00-04:00,REGN,neutral
1076668.0,Regeneron Announces Review of Biologics License Application for EYLEA; Says Review Extended by 3 Months by FDA,2011-08-16 17:12:00-04:00,REGN,neutral
1076669.0,Piper Jaffray Reiterates Overweight Rating On Regeneron Pharmaceuticals,2011-08-15 07:33:00-04:00,REGN,negative
1076672.0,Monday's Put/Call Ratio Leaders,2011-07-25 12:15:00-04:00,REGN,neutral
1076673.0,Regeneron Pharma Spiking Lower on Heavy Volume,2011-07-21 15:10:00-04:00,REGN,negative
1076674.0,Fifteen Health Care ETFs Trading Near 52-Week Highs,2011-07-21 13:57:00-04:00,REGN,positive
1076675.0,Biotech/Pharma Stocks Investor News Alert,2011-07-20 11:57:00-04:00,REGN,positive
1076676.0,Deutsche Bank Comments on Regeneron Pharmaceuticals,2011-07-19 10:14:00-04:00,REGN,neutral
1076677.0,Twelve Health Care ETFs Trading Near 52-Week Highs,2011-07-13 07:38:00-04:00,REGN,positive
1076678.0,Piper Jaffray Reiterates Overweight and PT of $62 on Regeneron Pharmaceuticals ,2011-07-13 06:11:00-04:00,REGN,negative
1076679.0,Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis,2011-07-12 16:07:00-04:00,REGN,positive
1076680.0,Catalysts Abound For Regeneron Pharmaceuticals ,2011-07-07 14:57:00-04:00,REGN,neutral
1076681.0,Phase 3 Trial of ZALTRAP in Advanced Prostate Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee,2011-07-07 07:05:00-04:00,REGN,negative
1076682.0,Money Flowing Into Regeneron Pharmaceuticals ,2011-06-28 13:39:00-04:00,REGN,neutral
1076683.0,Piper Jaffray Reiterates Overweight Rating On Regeneron,2011-06-20 07:51:00-04:00,REGN,negative
1076684.0,"Regeneron Showing Volatile Movement After Trading Resumption, Trading Lower After Winning Panel's Backing",2011-06-17 14:44:00-04:00,REGN,positive
1076685.0,Regeneron Pharmaceuticals Up Slightly Despite FDA Approval,2011-06-17 14:26:00-04:00,REGN,negative
1076686.0,PREVIEW: Regeneron to Resume Trading at 2.20 pm EST,2011-06-17 14:07:00-04:00,REGN,neutral
1076687.0,Regeneron Announces EYLEA Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory Committee ,2011-06-17 14:05:00-04:00,REGN,positive
1076688.0,FDA Advisory Panel Backs Regeneron's Eye Treatment 10-0,2011-06-17 13:26:00-04:00,REGN,negative
1076689.0,Regeneron Halted Ahead Of FDA,2011-06-17 09:01:00-04:00,REGN,neutral
1076690.0,Trading in Regeneron Common Stock Halted for FDA Review,2011-06-17 07:06:00-04:00,REGN,neutral
1076691.0,Top Percentage Gainers and Losers as of 2pm 06/15/11,2011-06-15 14:01:00-04:00,REGN,negative
1076692.0,Benzinga's Volume Movers,2011-06-15 10:31:00-04:00,REGN,neutral
1076693.0,UPDATE: Regeneron's Drug was not Superior to the Roche Drug at Any Dose Level,2011-06-15 08:12:00-04:00,REGN,negative
1076694.0,UPDATE: Regeneron Eye Drug Meets FDA's Effectiveness Goals; Raises No Major Safety Concerns,2011-06-15 08:10:00-04:00,REGN,positive
1076695.0,Regeneron Pharma Eye Drug Faces FDA Panel Review Friday -Dow Jones,2011-06-14 14:40:00-04:00,REGN,neutral
1076696.0,Piper Jaffray Reiterates Overweight on Regeneron Pharmaceuticals,2011-06-13 07:33:00-04:00,REGN,negative
1076697.0,Bank of America Merrill Lynch Maintains Buy on Regeneron Pharmaceuticals,2011-06-10 08:10:00-04:00,REGN,neutral
1076698.0,Puts Purchased on Regeneron Pharmaceuticals,2011-06-09 15:27:00-04:00,REGN,neutral
1076699.0,Regeneron Pharmaceuticals Spiking,2011-05-31 10:51:00-04:00,REGN,neutral
1076700.0,Regeneron Pharmaceuticals Announces FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration ,2011-05-23 12:14:00-04:00,REGN,neutral
1076701.0,Regeneron's Aflibercept Eye Solution To Face FDA Advisory Panel -Bloomberg,2011-05-23 08:50:00-04:00,REGN,positive
1076702.0,"CEOWORLD TOP 5 higher priced Biotechnology stocks picks- BIIB, CBST, MYGN, REGN and ITMN",2011-05-02 08:56:00-04:00,REGN,positive
1076703.0,Piper Jaffray Reiterates Overeweight on Regeneron Pharmaceuticals (REGN),2011-05-02 07:30:00-04:00,REGN,neutral
1076704.0,Short-Term Traders Should Check Out Regeneron (REGN),2011-04-28 11:53:00-04:00,REGN,neutral
1076705.0,"Stocks we are watching on 4/28- AMZN, LVLT, NFLX, BIDU, ORCL, YRCW, AMD, GS, POT, FCX, SNDK, IRE, AIB, CIGX, CTIC, AKAM, WFMI",2011-04-28 09:09:00-04:00,REGN,neutral
1076706.0,Brean Murray Raises REGN Target From $67 To $78,2011-04-28 08:27:00-04:00,REGN,neutral
1076707.0,"CEOWORLD Top 10 most active stocks on 28 April- CEG, SBUX, NTRI, AKAM, REGN, CTXS, EQIX, ALL, BIDU, LOOP",2011-04-28 03:59:00-04:00,REGN,positive
1076708.0,"Top Percentage Gainers and Losers as of 2pm 4/27/11 (RLOC, REGN, SIMG, SHOR, MOBI, MIPS, SFN, SCEI, BRCM, MRCY, GOOG)",2011-04-27 14:00:00-04:00,REGN,negative
1076709.0,Regeneron Pharmaceuticals Soars 33% (REGN),2011-04-27 13:34:00-04:00,REGN,neutral
1076710.0,Piper Jaffray Raises PT To $62 On REGN,2011-04-27 07:37:00-04:00,REGN,neutral
1076711.0,Piper Jaffray Raises PT On Regeneron Pharmaceuticals To $62,2011-04-27 06:51:00-04:00,REGN,neutral
1076712.0,Regeneron Pharmaceuticals Jumps 14% After Halt (REGN),2011-04-26 16:39:00-04:00,REGN,neutral
1076713.0,Sanofi-aventis and Regeneron Report Positive Phase III Results With ZALTRAP in Second-line Metastatic Colorectal Cancer  ,2011-04-26 16:14:00-04:00,REGN,negative
1076714.0,"Sanofi-aventis and Regeneron Report Positive Phase III Results With ZALTRAPâ¢ (SNY, REGN)",2011-04-26 16:09:00-04:00,REGN,positive
1076715.0,"Options Brief: Regeneron Pharmaceuticals, Inc. (REGN)",2011-04-21 11:53:00-04:00,REGN,neutral
1076716.0,Regeneron Pharmaceuticals Announces FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration  ,2011-04-18 07:33:00-04:00,REGN,positive
1076717.0,UPDATE: Deutsche Bank Initiates Regeneron Pharma at Buy (REGN),2011-04-13 07:32:00-04:00,REGN,neutral
1076718.0,"Deutsche Bank Initiates Regeneron Pharma At Buy, $67 PT",2011-04-13 06:51:00-04:00,REGN,neutral
1076719.0,Piper Jaffray Overweight On Regeneron Pharmaceuticals  (REGN),2011-04-08 07:31:00-04:00,REGN,negative
1076720.0,Roth Capital Downs REGN To Neutral,2011-04-07 06:46:00-04:00,REGN,neutral
1076721.0,Calls Purchased on Regeneron Pharmaceuticals (REGN),2011-03-24 13:27:00-04:00,REGN,neutral
1076722.0,Piper Jaffray Trims Regeneron Pharmaceuticals PT To $48 (REGN),2011-03-11 09:10:00-05:00,REGN,neutral
1076723.0,Regeneron Pharms Reports Top-Line Phase III Results (REGN),2011-03-10 16:08:00-05:00,REGN,neutral
1076724.0,RBC Capital Ups REGN To Outperform,2011-02-24 07:28:00-05:00,REGN,neutral
1076725.0,Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment,2011-02-22 08:20:00-05:00,REGN,neutral
1076726.0,"Benzinga's Volume Movers (KVHI, REGN, ARTC, AAWW)",2011-02-14 10:33:00-05:00,REGN,neutral
1076727.0,"NASDAQ Stocks Hitting 52-Week Highs (MWIV, REGN, ZOLT, KAMN)",2011-02-14 10:21:00-05:00,REGN,neutral
1076728.0,Piper Jaffray Overweight On Regeneron Pharmaceuticals  (REGN),2011-02-14 07:30:00-05:00,REGN,negative
1076729.0,Piper Jaffray Raises PT On Regeneron Pharmaceuticals To $46,2011-02-14 06:54:00-05:00,REGN,neutral
1076730.0,"Piper Jaffray Reiterates OW Rating, $40 PT On REGN",2011-02-07 08:09:00-05:00,REGN,neutral
1076731.0,REGN's Pipeline Advances - Analyst Blog,2011-01-18 11:31:00-05:00,REGN,neutral
1076732.0,REGN's Pipeline Advances - Analyst Blog,2011-01-18 11:00:00-05:00,REGN,neutral
1076733.0,Ardea's Promising Gout Candidate  - Analyst Blog,2011-01-07 13:03:00-05:00,REGN,positive
1076734.0,Ardea's Promising Gout Candidate  - Analyst Blog,2011-01-07 12:30:00-05:00,REGN,positive
1076735.0,"Piper Jaffray's Favorite Antibody Plays (SGEN, MITI, REGN)",2011-01-05 07:50:00-05:00,REGN,positive
1076736.0,Jolt for Regeneron's Pipeline - Analyst Blog,2010-12-28 09:03:00-05:00,REGN,neutral
1076737.0,Jolt for Regeneron's Pipeline - Analyst Blog,2010-12-28 08:45:00-05:00,REGN,neutral
1076738.0,Sanofi Expands Oncology Pipeline - Analyst Blog,2010-12-20 14:00:00-05:00,REGN,positive
1076739.0,Sanofi Expands Oncology Pipeline - Analyst Blog,2010-12-20 13:36:00-05:00,REGN,positive
1076740.0,Neutral on Regeneron - Analyst Blog,2010-11-29 15:00:00-05:00,REGN,neutral
1076741.0,Neutral on Regeneron - Analyst Blog,2010-11-29 09:37:00-05:00,REGN,neutral
1076742.0,Regeneron Pipeline Progresses - Analyst Blog,2010-11-23 10:51:00-05:00,REGN,neutral
1076743.0,"RBC Capital Mkts. Increases Price Target (REGN, NOC, HPQ)",2010-11-23 10:32:00-05:00,REGN,neutral
1076744.0,Regeneron Pipeline Progresses - Analyst Blog,2010-11-23 05:10:00-05:00,REGN,neutral
1076745.0,"Benzinga's Volume Movers (REGN, GMCR, CTRN, CRUS)",2010-11-22 11:00:00-05:00,REGN,neutral
1076746.0,Regeneron Pharmaceuticals Up 15% (REGN),2010-11-22 10:20:00-05:00,REGN,neutral
1076747.0,Loss at REGN Wider than Expected - Analyst Blog,2010-11-04 15:03:00-04:00,REGN,negative
1076748.0,Calls Purchased on Regeneron Pharmaceuticals (REGN),2010-11-02 14:20:00-04:00,REGN,neutral
1076749.0,Regeneron Announces Closing of Underwritten Offering of Common Stock; Raises $175.1M ,2010-10-13 09:35:00-04:00,REGN,neutral
1076750.0,Regeneron Increases Size of Public Offering of Common Stock,2010-10-08 08:29:00-04:00,REGN,neutral
1076751.0,"Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares ",2010-10-06 16:22:00-04:00,REGN,positive
1076752.0,Buy REGN Ahead Of VEGF Trap-Eye Data In December,2010-09-22 09:42:00-04:00,REGN,neutral
1076753.0,Good News for Regeneron - Analyst Blog,2010-09-09 13:12:00-04:00,REGN,positive
1076754.0,Piper Jaffray Sees Sharp Upside In Regeneron  (REGN),2010-09-09 07:24:00-04:00,REGN,neutral
1076755.0,"2H:10 Milestones In Drug Discovery (ARNA, VRTX, REGN, EXEL)",2010-08-18 11:28:00-04:00,REGN,neutral
1076756.0,Ardea remains Neutral  - Analyst Blog,2010-08-17 16:38:00-04:00,REGN,neutral
1076757.0,Q2 Loss Widens at Ardea - Analyst Blog,2010-08-09 12:09:00-04:00,REGN,negative
1076758.0,REGN's Loss Narrower than Expected - Analyst Blog,2010-07-30 17:10:00-04:00,REGN,negative
1076759.0,Put Volume Grows on Regeneron Pharma (REGN),2010-06-21 11:40:00-04:00,REGN,neutral
1076760.0,Regeneron (REGN) Closes 8.70% Higher,2010-05-12 17:08:00-04:00,REGN,neutral
1076761.0,"Market Update - IBM (NYSE: IBM), Wal-Mart (NYSE: WMT), Sybase (NYSE: SY), Regeneron (NASDAQ: REGN)",2010-05-12 16:51:00-04:00,REGN,neutral
1076762.0,PowerShares Small Cap Sector ETFs Hit the Tape,2010-04-08 03:02:00-04:00,REGN,neutral
1076763.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,REGN,positive
